Margetuximab MacroGenics, Inc.
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020
CLINICAL TRIAL PROTO COL : CP-MGAH22 -04
PROTOCOL AMENDMENT 4  
Study Title: A Phase 3, Randomized Study of Margetuximab Plus 
Chemotherapy vs Trastuzumab Plus Chemotherapy in the 
Treatment of Patients with HER2+ Metastatic Breast 
Cancer Who Have Received Prior Anti -HER2 Therapi[INVESTIGATOR_718657]: CP-MGAH22 -04
Study Phase: [ADDRESS_980512] Name: [CONTACT_718773]:
EudraCT Number: 2015 -000380 -13
Indication: Metastatic or Locally Advanced HER2 -positive Breast 
Cancer
Coordinating Principal 
Investigator: [INVESTIGATOR_718658]: MacroGenics, Inc.
[ADDRESS_980513]
Rockville, MD [ZIP_CODE]
[LOCATION_003]
[PHONE_14971]
Sponsor â€™s Medical 
Monitor:Refer to Study Contact [CONTACT_718706]. It contains proprietary information of MacroGenics, Inc., that 
can only be used for the purpose of reviewing or performing this study. Any use, viewing or 
disclosure of such information that is not authorized in writing by [CONTACT_55360].  
Confidential Page 1 of 142
[STUDY_ID_REMOVED] 
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
  
  
Confidential Page 2 of 142

Margetuximab MacroGenics, Inc.
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020
Confidential Page 3 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 4 of 142

0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

TABLE  OF CONTENTS  
 6<1236,6      
 %$&.*5281',1)250$7, 21   
 +(50HWDVWDWLF%UHDV W&DQFHU&XUUHQW7KHUDS\   
 5DWLRQDOHIRU7U HDWPHQWZLWK+(5 WDUJHWLQJ$JHQWV$IWHU3ULRU
5HFHLSWRI+(5 WDUJHWLQJ$JHQWVLQ0%&7KHUDS\   
  
  
 0DUJHWX[LPDE%DFNJURXQG    
  0DUJHWX[LPDE&OLQLFDO([SHULHQFH    
  0DUJHWX[LPDE3KDUPD FRNLQHWLFVDQG'RVH6HOHFWLRQ   
 678'<385326($1'2% -(&7,9(6    
 3ULPDU\2EMHFWLYH     
 6HFRQGDU\2EMHFWLYH     
 7HUWLDU\2EMHFWLYHV     
 ([SORUDWRU\2EMHFWLYH     
 678'<'(6,*1     
 2YHUDOO6WXG\'HVLJQDQG3ODQ    
  6WXG\'HVLJQ     
  ,QIXVLRQ6XE 6WXG\   
  7UHDWPHQWRI3DWLHQWV    
 &KHPRWKHUDS\     
  6WXG\'UXJV     
  'RVH'HOD\V     
  'LVHDVH$VVHVVPHQWV     
  5XOHVIRU&RQWLQXDWLRQRI6WXG\7UHDWPHQW   
 5DWLRQDOHIRU6WXG\'HVLJQ     
 6WXG\'XUDWLRQ     
  3DWLHQW$FFUXDO     
  'HILQLWLRQRI(QGRI6WXG\    
 6(/(&7,21$1':,7+'5 $:$/2)3$7,(176    
 ,QFOXVLRQ&ULWHULD     
 ([FOXVLRQ&ULWHULD     
 (QWU\&ULWHULDIRUWKH,QIXVLRQ6XE 6WXG\   
 :LWKGUDZDORI3DWLHQWIURPWKH6WXG\RU6WXG\'UXJ   
  *XLGHOLQHVIRU3HUPD QHQW'LVFRQWLQXDWLRQ   
  3URFHGXUHVIRU3DWLHQWV/RVWWR)ROORZ XS  
Confidential Page 6 of 142
0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

 678'<75($70(176   
 'HVFULSWLRQRI7UHDWPHQWV   
  6WXG\'UXJV   
  0DUJHWX[LPDE   
  'RVH5DWHRU6FKHGXOH0RGL ILFDWLRQVIRU7R[LFLW\   
  7UDVWX]XPDE   
  'RVH0RGLILFDWLRQIRU7R[LFLW\   
  %DFNERQH&KHPRWKHUDS\   
 6WXG\'UXJVDQG6XSSOLHV   
  0DUJHWX[LPDE   
  7UDVWX]XPDE   
  %DFNERQH&KHPRWKHUDSLHV   
 'UXJ3UHSDUDWLRQDQG $GPLQLVWUDWLRQ   
  *HQHUDO3UHFDXWLRQV   
  0DUJHWX[LPDE3UHSDUDWLRQ   
  6WXG\'UXJDQG&KHPRWKHUDS\$GPLQLVWUDWLRQ   
  3UHPHGLFDWLRQVDQG3URSK\OD[LVIRU&KHPRWKHUDS\   
  3UHPHGLFDWLRQVIRU0DUJHWX[LPDE   
  3UHPHGLFDWLRQVIRU7UDVWX]XPDE   
  $GGLWLRQDO,QVWUXFWLRQVIRU+DQGOLQJ   
 'LVSHQVLQJ6WXG\'UXJ   
 6HOHFWLRQDQG7LPLQJRI 'RVHIRU(DFK3DWLHQW   
  6HOHFWLRQDQG7LPLQJRI,QIXVLRQ6XE6WXG\3DWLHQWV   
 3RWHQWLDO$GYHUVH(YHQWVDQG6XSSRUWLYH&DUH0HDVXUHV   
  6WXG\'UXJV0DUJHWX[LPDEDQG7UDVWX]XPDE   
  ,QIXVLRQ5HODWHG5HDFWLRQV   
  *UDGLQJRI,QIXVLRQ5HDFWLRQV   
  0DQDJHPHQWRI2EVHUYH G0DUJHWX[LPDERU
7UDVWX]XPDE,QIXVLRQ5HDFWLRQV   
 0HWKRGRI$VVLJQLQJ3DWLHQWVW R7UHDWPHQW*URXSV   
  $VVLJQPHQWVLQWKH,QIXVLRQ6XE6WXG\   
 %OLQGLQJ   
 &RQFRPLWDQW7KHUDS\   
  5HVWULFWLRQV   
  3ULRU7KHUDS\   
  )OXLGDQG)RRG,QWDNH   
  3DWLHQW$FWLYLW\5HVWULFWLRQV   
  7UHDWPHQW&RPSOLDQFH   
Confidential Page 7 of 142
0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

  3DFNDJLQJDQG/DEHOLQJ   
  6WRUDJHDQG$FFRXQWDELOLW\   
  ,QYHVWLJDWLRQDO3URGXFW'LVSRVLWLRQDW(QGRI6WXG\   
 678'<352&('85(6   
 ,QIRUPHG&RQVHQW   
 0HGLFDO+LVWRU\   
 3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV   
 3K\VLFDO([DPLQDWLRQ   
 9LWDO6LJQV   
 &OLQLFDO/DERUDWRU\7HVWV   
 6DPSOHVIRU+(57HVWLQJ   
 &DUGLDF(YDOXDWLRQV   
  /HDG(OHFWURFDUGLRJUDPV   
  0XOWLJDWHG$FTXLVLWLRQ9HQWULFXORJUDSK\6FDQQLQJDQG
(FKRFDUGLRJUDSK\   
 $GYHUVH(YHQWV   
  &ULWHULDIRU(YDOXDWLRQ   
  'HILQLWLRQV   
  $GYHUVH(YHQW   
  $GYHUVH'UXJ5HDFWLRQ   
  $GYHUVH(YHQWRI6SHFLDO,QWHUHVW   
  7UHDWPHQW(PHUJHQW$GYHUVH(YHQW   
  3URGXFW4XDOLW\,VVXH   
  6HULRXV$GYHUVH(YHQWV   
  ,PPHGLDWHO\5HSRUWDEOH(YHQW,5(   
  $GYHUVH(YHQWVRI6SHFLDO,QWHUHVW   
  3URGXFW4XDOLW\,VVXHZLWK&OLQLFDO&RQVHTXHQFHV   
  3HUIRUPLQJ$GYHUVH(YHQW$VVHVVPHQWV   
  $VVHVVPHQWRI6HULRXVQHVV   
  $VVHVVPHQWRI6HYHULW\   
  $VVHVVPHQWRI&DXVDOLW\   
  $VVHVVPHQWRI([SHFWHGQHVV   
  5HSRUWLQJRI$GYHUVH(YHQWVWRWKH6SRQVRU   
  &KDQJHVLQ&OLQLFDO/DERUDWRU\3DUDPHWHUV   
  1RWLILFDWLRQWRWKH6SRQVRURI(YH QWV5HTXLULQJ,PPHGLDWH
5HSRUWLQJ   
  (PHUJHQF\8QEOLQGLQJ   
  (IILFDF\3KDUPDFRNLQHWL F3KDUPDFRG\QDPLF$VVHVVPHQWV   
Confidential Page 8 of 142
0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

  (IILFDF\$VVHVVPHQWV   
  5DGLRORJLF(YDOXDWLRQ   
  'LJLWDO,PDJLQJRI6NLQ/HVLRQV   
  2YHUDOO6XUYLYDO   
  ,PPXQRJHQLFLW\   
  3KDUPDFRNLQHWLFV   
  %LRPDUNHUV   
  +HDOWK5HODWHG4XDOLW\RI/LIH   
  6DPSOH5HWHQWLRQDQG)XUWKHU7HVWLQJ   
  $SSURSULDWHQHVVRI0HDVXUHPHQWV   
 678'<$&7,9,7,(6   
 6FUHHQLQJ3HULRG   
  8SWR:HHNV3ULRUWR5DQGRPL]DWLRQ   
  8SWR7ZR:HHNV3ULRUWR5DQGRPL]DWLRQ   
 5HJLVWUDWLRQDQG5DQGRPL]DWLRQ   
  5HJLVWUDWLRQIRUWKH,QIXVLRQ6XE6WXG\   
 &\FOH   
  &\FOH'D\   
  3ULRUWR)LUVW'RVHRI6WXG\7UHDWPHQWRQ&\FOH'D\
   
  'XULQJDQG)ROORZLQJ$GPLQLVWUDWLRQRI6WXG\
7UHDWPHQW   
  &\FOH'D\   
 6WXG\(YDOXDWLRQVIRU(YHQ&\FOHVHJ&\FOHV   
  (YHQ&\FOH7UHDWPHQW9LVLWV'D\   
  3ULRUWR$GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  $GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  )ROORZLQJ$GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  (YHQ&\FOH7UHDWPHQW9LVLWV'D\DVQHHGHG   
 6WXG\(YDOXDWLRQVIRU2GG&\FOHV!HJ&\FOHV   
  2GG&\FOH7UHDWPHQW9LVLWV'D\   
  3ULRUWR$GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  $GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  )ROORZLQJ$GPLQLVWUDWLRQRI6WXG\7UHDWPHQWV   
  2GG&\FOH7UHDWPHQW9LVLWV'D\DVQHHGHG   
 (QGRI7UHDWPHQW9LVLW   
 3RVW7UHDWPHQW)ROORZXSDQG2EVHUYDWLRQRI6XUYLYDO   
 3/$11('67$7,67,&$/0(7+2'6   
Confidential Page 9 of 142
0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

 *HQHUDO&RQVLGHUDWLRQV   
 ,QGHSHQGHQW'DWD6DIHW\0RQLWRULQJ&RPPLWWHH   
 'HWHUPLQDWLRQRI6DPSOH6L]H   
  $QDO\VLV3RSXODWLRQV   
 'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV   
 6DIHW\(QGSRLQWVDQG$QDO\VHV   
  $GYHUVH(YHQWV   
  /DERUDWRU\9DOXHV   
  2WKHU6DIHW\(QGSRLQWV   
 (IILFDF\(QGSRLQWVDQG$QDO\VHV   
  3ULPDU\(QGSRLQWV   
  3ULPDU\(QGSRLQWIRUWKH,QIXVLRQ6XE6WXG\   
  6HFRQGDU\(QGSRLQWV   
  6HFRQGDU\(QGSRLQWIRU,QIXVLRQ6XEVWXG\   
  7HUWLDU\(QGSRLQWV   
  ([SORUDWRU\$QDO\VHV   
 3KDUPDFRNLQHWLFDQG([SRVXUH5HVSRQVH$QDO\VHV   
 ,PPXQRJHQLFLW\$QDO\VHV   
 7LPLQJRI$QDO\VHV   
  ,QWHULP$QDO\VHV   
  ,QWHULP$QDO\VHVIRU26   
  ,QWHULP)XWLOLW\$QDO\VLVIRU3)6   
  )LQDO$QDO\VLV   
 48$/,7<&[ZIP_CODE]/$1'$6685$1&(   
  0RQLWRULQJ$XGLWLQJDQG,QVSHFWLRQV   
  'DWD(QWU\DQG&RPSXWHUL]HG6\VWHPV   
 $'0,1,675$7,9(&216,'(5$7,216   
  ,QVWLWXWLRQDO5HYLHZ%RDUGRU, QGHSHQGHQW(WKLFV&RPPLWWHH
$SSURYDO   
  (WKLFDO&RQGXFWRIWKH6WXG\   
  3DWLHQW,QIRUPDWLRQDQG&RQVHQW   
  3DWLHQW&RQILGHQWLDOLW\   
  &DVH5HSRUW)RUPVDQG6WXG\5HFRUGV   
  $FFHVVWR6RXUFH'RFXPHQWDWLRQ   
  5HWHQWLRQRI'DWD   
  )LQDQFLDO'LVFORVXUH   
  3XEOLFDWLRQDQG'LVFORVXUH3ROLF\   
  'LVFRQWLQXDWLRQRIWKH6WXG\RU6WXG\6LWHV   
Confidential Page 10 of 142
0DUJHWX[LPDE 0DFUR*HQLFV,QF
&OLQLFDO7ULDO3URWRFRO&30*$+ $PHQGPHQW-XQH

  'LVFRQWLQXDWLRQRI6WXG\6LWHV    
  'LVFRQWLQXDWLRQRIWKH6WXG\    
  ,GHQWLILFDWLRQRIWKH&RRUGLQDWLQJ3ULQFLSDO,QYHVWLJDWRU   
  
   
   
   
  
 5()(5(1&(/,67     

LIST OF TABLES   
 
 
 
 
7DEOH  0DUJHWX[LPDE3KDUPD FRNLQHWLFVDW6WHDG\6WDWH Â±PJNJ
PJNJPJNJÂ±&30*$+   
7DEOH 2YHUYLHZRI6WXG\7UHDWPHQWV    
7DEOH  3ODQQHG,QWHULP$QDO\VHV    

LIST OF FIGURES   
)LJXUH6WXG\'HVLJQIRU,QIXVLRQ5DWH5HGXFWLRQRI0DUJHWX[L PDE  

LIST OF APPENDICES   
$33(1',;  6&+('8/(2)(9(176  
$33(1',;  35,1&,3$/,19(67,*$7 25Â¶6$*5((0(17  
$33(1',;  &(1625,1*58/(6)25 35,0$5<3)6$1$/<6,6  
$33(1',;  ($67(51&223(5$7,9( 21&2/2*<*5283
(&2*3(5)250$1&(6 7$786  
$33(1',;  1&&1)$&7%5($67 6<[ZIP_CODE],1'(; )%6, 
$33(1',;  (4'/ 
$33(1',;  /$%25$725<7(67,1*% /22'92/80(6  
$33(1',;  5(&,67*8,'(/,1( 6 

Confidential Page 11 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 SPONSOR SIGNATURES   
Study Title:  A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. 
Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ 
Metastatic Breast Cancer Who Have Received  Prior Anti -HER2 Therapi[INVESTIGATOR_718659]:  CP-MGAH22 -04 
  
  
 
This clinical study protocol has been approved by [CONTACT_1034]:  
Signed:  See Appended Electronic Signature [CONTACT_718774]:   
  
Vice -President, Clinical Research  
MacroGenics, Inc.  
 
   
Signed:  See Appended Electronic Signature [CONTACT_718774]:   
  
Senior Director, Biostatistics  
MacroGenics, Inc.  
 
   
 
 
Confidential Page 12 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980514]  
ALB  Albumin  
ALK -P Alkaline phosphatase  
ALT  Alanine aminotransferase (SGPT)  
aPTT  Activated partial thromboplastin time  
ASCO  American Society of Clinical Oncology  
AST  Aspartate aminotransferase (SGOT)  
AUC  Area under the concentration -time curve  
BID Twice daily  
BSA  Body surface area  
BUN  Blood urea nitrogen  
Â°C Degrees Celsius  
Cmax Maximum serum concentration  
Ctrough  Trough serum concentration  
Ca Calcium  
CAP  College of American Pathologists  
CBC  Complete blood count  
CBR  Clinical benefit rate  
CDR  Complementarity -determining region  
Ch4D5  Chimeric 4D5  
Confidential Page 13 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980515] Hematocrit  
Confidential Page 14 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 HEENT  Head, eyes, ears, nose, and throat  
HER2+  Human epi[INVESTIGATOR_5168] [ADDRESS_980516] ratio  
IB Investigatorâ€™s Brochure  
ICH International Conference on Harmonisation  
ICF Informed Consent Form  
IEC Independent Ethics Committee  
IHC Immunohistochemistry  
IL Interleukin  
Ig Immunoglobulin  
IND Investigational New Drug  
IRB Institutional Review Board  
IRE Immediately Reportable Event  
ISH In-situ hybridization  
IUD Intrauterine device  
IV Intravenous  
IxRS  Interactive Response System  
K Potassium  
Kg Kilogram  
LC Light chain  
LDH  Lactate dehydrogenase  
LVEF  Left ventricle ejection fraction  
MBC  Metastatic breast cancer  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
mL Milliliter  
Confidential Page 15 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980517] Cancer Symptom 
Index - 16 
NSAID  Non-steroidal anti -inflammatory drug  
NYHA  [LOCATION_001] Heart Association  
ORR  Objective response rate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cell  
PD Progressive disease  
PE Physical examination  
PES Polyethersulfone  
PFS Progression free survival  
PI [INVESTIGATOR_718660]  
Q3W  Every 3 weeks  
QW Every week  
Confidential Page 16 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980518]  Upper limit of normal  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
Vss Volume of distribution at steady state  
WBC  White blood cell  
Confidential Page 17 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 1 SYNOPSIS   
Sponsor:  MacroGenics, Inc.  IND Number:  
Name [CONTACT_2756]: Margetuximab  
Study Title:  
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in 
the Treatment of Patients with HER2+ Metastatic Breast Can cer Who Have Received Prior Anti -HER2 
Therapi[INVESTIGATOR_718661]:  
CP-MGAH22 -04 
Investigator(s)/Centers:  
This study will be executed at approximately 200 centers in approximately 25 countries.  
Study Phase:  3 
Primary Objectives  
The primary objective of this study is to evaluate the efficacy, as measured by [CONTACT_3988] -free survival (PFS) 
assessed by [CONTACT_718707] (OS), of margetuximab plus chemotherapy compared 
with trastuzumab plus chemothera py in patients with advanced HER2+ breast cancer who have received at 
least 2 prior lines of anti -HER2 directed therapy in the metastatic setting, or in case of having received 
(neo)adjuvant pertuzumab, at least [ADDRESS_980519] one, and no more than three, lines of therapy overall in the metastatic setting.  
Infusion Sub -Study:  The primary objective of the infusion sub -study is to determine the safety and 
tolerability of m argetuximab administered at a reduced infusion time in Cycle 2 and beyond. The incidence of 
Grade 3 or greater infusion -related reactions (IRRs) by [CONTACT_42334] 2 is the outcome measure.  
Secondary Objectives  
â€¢ To evaluate PFS, as assessed by [CONTACT_2792], of margetuximab plus chemotherapy vs. trastuzumab 
plus chemotherapy in these patients.  
â€¢ To evaluate by [CONTACT_193384], the objective response rate (ORR) of margetuximab plus 
chemotherapy vs. trastuzumab plus chemotherapy in these patients . 
Infusion Sub -Study:  To evaluate the incidence of all Grade infusion -related reactions in all sub -study 
patients.  
Tertiary Objectives  
â€¢ To evaluate health -related quality of life (HRQoL), as assessed using the Network -Functional 
Assessment of Cancer Therap y-Breast Cancer Symptom Index (NFBSI) -16 and EQ -5D-5L, associated 
with margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in these patients.  
â€¢ To characterize the safety profile of margetuximab plus chemotherapy vs. trastuzumab plus 
chemothera py in these patients.  
â€¢ To evaluate the clinical benefit rate (CBR) of margetuximab plus chemotherapy vs. trastuzumab plus 
chemotherapy in these patients.  
â€¢ To evaluate ORR, as assessed by [CONTACT_2792], of margetuximab plus chemotherapy vs. 
trastuzumab  plus chemotherapy in these patients.  
â€¢ To evaluate the duration of response (DoR) of margetuximab plus chemotherapy vs. trastuzumab plus 
chemotherapy in these patients.  
â€¢ To characterize the population pharmacokinetics (PPK) and exposure -response (E -R) relat ionships of 
margetuximab in these patients.  
â€¢ To evaluate anti -drug antibodies (ADA) directed against margetuximab and its effects on 
pharmacokinetics (PK), efficacy, and safety in these patients.  
 
Confidential Page 18 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980520] been approved in the [LOCATION_002] (US) to specifically treat patients after two prior lines of treatment, 
although both lapatinib and trastuzumab are often used in this setting. The purpose of this study is to evaluate 
the activity of margetuximab in combination with standard of care chemotherapi[INVESTIGATOR_718662]2+ breast cancer who have received at least 2 prior lines of anti -HER2 directed therapy in 
the metastatic setting, or in case of having received (neo)adjuvant pertuzumab, at least [ADDRESS_980521] of margetuximab 
with placebo, and therefore an active comparator was chosen. Trastuzumab is  commonly used in this setting, 
and the comparison will directly evaluate whether enhanced antibody dependent cell -mediated cytotoxicity 
(ADCC) produces superior clinical efficacy. Although not approved in this setting, trastuzumab is an 
acceptable compara tor because continued treatment with trastuzumab after failure while on trastuzumab has 
demonstrated clinical benefit. In addition, trastuzumab has a generally favorable toxicity profile compared 
with lapatinib, and is commonly used in clinical practice  (4, 15). 
The decision to allow physicianâ€™s choice of chemotherapy from among a selected list is based on the 
well-described finding (7) that, in the treatment of advanced breast cancer, sequential single agent 
chemotherapi[INVESTIGATOR_718663], and that , other than eribulin â€“ which showed a modest 
survival benefit - no one agent has been clearly shown to be superior to another in the salvage setting. 
Common practice is to choose a therapy based on individual patient needs and combine that with trastuzuma b. 
Rather than dictate the therapy, investigators will choose the patientâ€™s combination chemotherapy from a 
predetermined list, allowing for a tailored approach to each individual patientâ€™s status (also similar to the 
control arm in the eribulin pi[INVESTIGATOR_45899] (6). To minimize bias, the selected chemotherapy will be chosen and 
documented prior to patient randomization.  
Infusion Sub -Study : This protocol will include a sub -study that reduces infusion time from 120 to 
30 minutes. Reduced infusion times will decrease the burden on patients receiving margetuximab.   
Study Design  
Overview  
This is a Phase 3, randomized, open -label, comparator -controlled study comparing margetuximab to 
trastuzumab, each in combination with chemotherapy, for the treatment of patients with advanced HER2+ 
breast cancer who have received at least 2 prior lines of anti -HER2 directed therapy in the metastatic setting, 
or in case of having received (neo)adjuvant pertuzumab, at leas t [ADDRESS_980522] recent therapy. E ligible patients 
will be assigned to chemotherapy of the investigatorâ€™s choice to be chosen from capecitabine, eribulin, 
gemcitabine, or vinorelbine. The selected chemotherapy must be allowed for use per local regulations. Upon 
meeting all entry criteria, patients enrolled in the study will be randomized 1:[ADDRESS_980523]  by [CONTACT_718708]. Following completion of (or discontinuation from) treatment, patients will be followed for survival.  
The study will include a non -randomized sub -study cohort of approximately 78 subjects with HER2+ 
metas tatic breast cancer to receive either single agent margetuximab or margetuximab in combination with the 
Investigator's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). This infusion sub -
study will enroll patients meeting all cr iteria for the randomized study with the exception of the requirements 
for prior therapy; the infusion sub -study will require patients to have received at least [ADDRESS_980524] cancer, as well as prior trastuzumab, pertuzumab , and ado -trastuzumab emtansine (T -
DM1).   
Confidential Page 19 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Treatment Groups  
Patients in the randomized portion of the study, will receive either margetuximab or trastuzumab in 
combination with the preselected chemotherapy of the investigatorâ€™s choice. Patient randomizati on will be 
stratified by [CONTACT_612032] (â‰¤2, >2), number of lines of therapy in the metastatic setting (â‰¤2, >2), 
and choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).  
Patients in the Infusion Sub -Study will receive m argetuximab alone or in combination with protocol -specified 
physician choice chemotherapy.  
Study Population  
This study will enroll patients with advanced HER2+ breast cancer who have received at least 2 prior lines of 
anti-HER2 directed therapy in the metastatic setting, or in case of having received (neo)adjuvant pertuzumab, 
at least [ADDRESS_980525] 4 prior 
lines of therapy (includ ing trastuzumab, pertuzumab and T -DM1) for metastatic HER2+ breast cancer, so that 
there is no direct overlap with the primary study population for the randomized component of this trial.  
Inclusion/Exclusion Criteria  
Inclusion Criteria  
To be included in t his study, patients must:  
General  
1. Be able to provide informed consent and documentation of informed consent prior to initiation of any 
study -related tests or procedures that are not part of standard -of-care for the patientâ€™s disease. Patients 
must also be willing and able to comply with st udy procedures, including the acquisition of specified 
research specimens and completion of HRQoL assessments.  
2. Be â‰¥ [ADDRESS_980526] histologically proven, metastatic or locally advanced, relapsed/refractory HER2+ ( 3+ by [CONTACT_718709]-amplified as per American Society of Clinical Oncology [ASCO] and the College of American 
Pathologists [CAP] Guidelines) breast cancer based on the most recently available tumor biopsy collected 
from the patient. HER2 status must be docume nted from a reference laboratory that conforms to standards 
set for accreditation by [CONTACT_718710]. Confirmatory IHC testing is not 
required for study entry. Tumors may be estrogen receptor (ER)/progesterone receptor (PgR) po sitive or 
negative.  
4. Have received at least 2 prior lines of anti -HER2 directed therapy in the metastatic setting, or in case of 
having received (neo)adjuvant pertuzumab, at least [ADDRESS_980527] received prior treatment with pertuzumab in the 
(neo)adjuvant or metastatic setting. Prior radiotherapy, hormonal therapi[INVESTIGATOR_014], and other anti -HER2 
therapi[INVESTIGATOR_33938].  
5. Have received treatment with at least one, and no mor e than three, lines of therapy overall in the 
metastatic setting. Hormonal therapi[INVESTIGATOR_718664]. Prior neo -adjuvant or adjuvant therapy that resulted in relapse 
within [ADDRESS_980528] recent line of therapy. Dose 
interruptions, delays, pauses during previous therapy,  or changes in therapy to manage toxicity will not 
constitute a new line of therapy provided disease progression did not occur.  
6. Resolution of all chemotherapy or radiation -related toxicities to â‰¤ Grade 1 (with exception of â‰¤  Grade  2 
alopecia, stable se nsory neuropathy, or stable electrolyte disturbances that are managed by 
[CONTACT_718711]).  
7. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ( Appendix 4 ). 
8. Have life expectancy â‰¥ [ADDRESS_980529] 
and/or MRI.  
Laboratory Features  
Confidential Page 20 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980530] acceptable laboratory parameters as follows:  
a. Platelet count â‰¥ 100 Ã— 103/ÂµL without having received a transfusion or growth factor support within 
4 weeks prior to randomization.  
b. Hemoglobin â‰¥ 9.0 g/dL without having received a transfusion or growth factor support within 4 weeks 
prior to randomization.  
c. Absolute neutrophil count â‰¥ 1.5 Ã— 103/ÂµL in the absence of any gr owth factor support given within 
4 weeks prior to randomization.  
d. Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) â‰¤ 3.0 Ã— the upper limit of normal 
(ULN), except patients with liver metastases, who may enroll with ALT/AST â‰¤ 5.0 Ã— ULN.  
e. Total bilirubin â‰¤ 1.5 Ã— ULN, except patients with Gilbertâ€™s syndrome, who may enroll if the 
conjugated bilirubin is within laboratory normal limits.  
f. Creatinine < 1.5 mg/dL, or a calculated or measured creatinine clearance > 50 mL/min.  
Reproductive Feat ures 
11.  Female patients of childbearing potential (not surgically sterilized and between menarche and [ADDRESS_980531] 
menopause) must have a negative result from a serum pregnancy test performed within [ADDRESS_980532] dose of study drug (either 
margetuximab or trastuzumab). Highly effective methods of contraception include:  
â€¢ Combined (estrogen and progestogen containing) hormonal contraception associated with the 
inhibition of ovulation  
o Oral  
o Intravaginal  
o Transdermal  
â€¢ Progestogen -only hormonal contraception associated with inhibition of ovulation  
o Oral  
o Injectable  
o Implantable  
o Intrauterine device (IUD)  
o Intrauterine hormone -releasing system (IUS)  
â€¢ Bilateral tubal occlusion  
â€¢ Vasectomized partner  
â€¢ Sexual abstinence  
 
12. Male patients should also have their partners who are women of childbearing potential use a highly 
effective method of contraception (as shown above) from the time of informed consent through [ADDRESS_980533] dose of study drug (either margetuximab or trastuzumab).  
 
Exclusion Criteria:  
Patients who meet any of the following criteria will be excluded from the study:  
1. Patients with known, untreated brain metastasis.  
â€¢ Patients with signs or symptoms of brain metastasis must have a CT or MRI performed within 4 
weeks prior to randomization to specifically exclude the presence of radiographically detectable 
brain metastases.  
â€¢ Patients with known, treated brain metastases m ust have a baseline CT or MRI within [ADDRESS_980534] been 
Confidential Page 21 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 on a s table dose of steroids (â‰¤ 10 mg/day of prednisone or equivalent) for at least 4 weeks prior to 
randomization with no symptoms.  
2. History of uncontrolled seizures within 6 months of randomization.  
3. History of prior allogeneic bone marrow, stem -cell, or solid organ transplantation.  
4. Treatment with any local or systemic anti -neoplastic therapy (including hormonal therapi[INVESTIGATOR_718665]) or any investigational therapy within 2 weeks prior to randomization. Bisphosphonates and 
receptor activator of n uclear factor kappa B ligand (RANKL) inhibitors are allowed provided treatment 
starts prior to randomization.  
5. Treatment with corticosteroids (i.e., > 10 mg prednisone per day or equivalent) or other immune 
suppressive drugs within 2 weeks prior to rando mization. Steroids for topi[INVESTIGATOR_44785], inhalational use, nasal 
spray, or ophthalmic solution are allowed.  
6. History of clinically significant cardiovascular disease including but not limited to:  
a. Myocardial infarction or unstable angina within 6 months pri or to randomization.  
b. Stroke or transient ischemic attack within 6 months prior to randomization.  
c. Clinically significant cardiac arrhythmias.  
d. Uncontrolled (persistent) hypertension defined as systolic blood pressure (SBP) >180 mmHg or 
diastolic bl ood pressure (DBP) >100 mmHg.  
e. Congestive heart failure ([LOCATION_001] Heart Association [NYHA] class II -IV). 
f. Pericarditis or clinically significant pericardial effusion.  
g. Myocarditis.  
h. Left ventricle ejection fraction (LVEF) < 50% by [CONTACT_718712] -gated acquisition 
(MUGA) scan.  
7. Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to 
maintain adequate oxygenation.  
8. Evidence of active viral, bacterial, or systemic fungal infection requiring paren teral treatment within 
[ADDRESS_980535] for hepatitis B surface antigen , hepatitis 
B core antigen, or hepatitis C polymerase chain reaction (PCR).  
11. Second primary malignancy that has not been in remission for at least 2 years from the anticipated start of 
study treatment. Exceptions of treated malignancies that do not req uire a 2 -year remission include: non -
melanoma skin cancer; cervical carcinoma in situ; squamous intraepi[INVESTIGATOR_112716]; localized prostate 
cancer (Gleason score < 6); resected melanoma in situ or ductal carcinoma in situ. Patients with second 
primary breas t cancers within 2 years are eligible provided that both primary tumors were HER2+ (3+ by 
[CONTACT_718713]).  
12. History of trauma or major surgery within 4 weeks prior to randomization.  
13. Any serious underlying medical or psychiatric condition that would impair the ability of the patient to 
receive or tolerate the planned treatment at the investigational site.  
14. Known hypersensitivity to recombinant proteins, polysorbate 80, benzyl alcohol, or any excipi[INVESTIGATOR_718666], trastuzumab or other study treatments. Previous 
infusion reactions to trastuzumab or other monoclonal antibodies will not preclude enrollment provided 
no contraindication to trastuzumab therapy remains.  
15. Any condition that would be a contrain dication to receiving trastuzumab as described in the approved 
local label or a condition that would prevent treatment with the physicianâ€™s choice of chemotherapy.  
16. Vaccination with any live virus vaccine within [ADDRESS_980536] feeding.  
20. Prior participation in a margetuximab clinical study.  
Confidential Page 22 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 21. Any investigative site personnel directly affiliated with this study.  
22. Employees of MacroGenics, Inc.  
23. Prisoners or other individuals who are involuntari ly detained.  
24. Any issue or condition that in the opi[INVESTIGATOR_313182]â€™s 
participation in the study or confound the results of the study.  
Entry Criteria for the Infusion Sub -Study : 
1. Patients will meet all entry criteria for the randomized portion of the study with the exception of inclusion 
criteria #4 and #5.  
2. Patients must have received at least [ADDRESS_980537] cancer (capecitabine, eribulin, gemcitabine, or vinorelbine) to be 
administered in combination with the study drug (margetuximab or trastuzumab). The chemotherapy selected 
must be allowed for use per local regulations (see  Section  6.1.2  for additional information). Chemotherapy 
will be started on Day  [ADDRESS_980538] a response of stable disease or better.  
Study treatments (study drugs and chemotherapi[INVESTIGATOR_014]) to be administered during this study are summarized in the 
following table.  
 
Agent  Starting Dose  Schedu le Mode of 
Administration  
Chemotherapya    
     Capecitabine  1000 mg/m2 BID BID for 14 days in a 21 -day cycle  Oral 
     Eribulinb 1.4 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
     Gemcitabine  1000 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
     Vinorelbine  25-30 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
Study Drugs     
     Trastuzumab  8 mg/kg loading dose then 
6 mg/kg  Every 21 days  IV 
     Margetuximab  15 mg/kg  Every 21 days  IV 
BID = twice daily; IV = intravenous  
a. The chemotherapy selected must be allowed for use per local regulations (see  Section 6.1.2 ). 
Chemotherapi[INVESTIGATOR_718667] -indicated sta rting doses, schedule, and route of 
administration, however dose adjustments to improve tolerability and manage toxicities are 
permitted.  
b. Dose of eribulin noted here is based on use as eribulin mesylate; if free base eribulin is used, 
equivalent dose of 1 .23 mg/m2 is permitted.  
Doses may be modified as recommended in the appropriate local labels and as described in  Section 6. 
  
Confidential Page 23 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Duration of Treatment a nd Study Duration  
Patients will be treated with margetuximab or trastuzumab, both in combination with chemotherapy, in 
3-week (21 -day) cycles. Patients will be evaluated every 2 cycles (at 6 -week intervals) for radiologic and 
clinical disease progression u sing RECIST 1.1. Treatment decisions will be made locally based on 
investigator interpretation of available studies, but central review assessments of radiologic scans will be used 
for the primary endpoint of PFS. Study treatment will continue until eviden ce of disease progression, 
unacceptable toxicity, withdrawal of consent, physician recommendation to discontinue therapy, or death. The 
anticipated median PFS for the trastuzumab arm is approximately 4 months. The anticipated median PFS for 
the margetuxima b arm is approximately 6 months. There is no requirement to discontinue treatment after a 
prescribed number of cycles. There is no crossover in this study.  
Approximately 530 patients, randomized 1:[ADDRESS_980539]. It is anticipated that  accrual will take 24 months and that total follow up will take an additional 
16 months, for a total study duration of approximately 40 months.  
Infusion Sub -Study  
About 9 patients will receive a 120 -minute margetuximab infusion in Cycle 1, in order to hav e 6 patients 
receive a 60 -minute infusion in Cycle 2 and beyond (Stage A1). Any extra patients beyond [ADDRESS_980540] 6 patients receive a 30 -minute infusion at Cycle 2 and beyond (Stage A2). Patients 
enrolled into Stage A1 and A2 will be assigned to receive the  reduced infusions until [ADDRESS_980541]-progression margetuximab may be considered on a case -by-case basis within the infusion substudy only, 
with agreement of the Sponsor.  
Deta ils of the study design and stoppi[INVESTIGATOR_415232] 6.7.1 . 
Treatment Schedule (Procedure)  
See Schedule of Events ( Appendix 1 ) 
Criteria for Evaluation  
Safety Assessments  
â€¢ Safety assessment will be based on the evaluation of AEs from the time of initiation of any study therapy 
through the End of Treatment visit (or [ADDRESS_980542] dose of study drug, whichever occurs later) 
and will be determined based on signs, symptoms, physical examination findings and/or laboratory test 
results from enrolled patients as appropriate.  
â€¢ All AEs (related to the protocol or not) will be collected from the time the patient receives the first dose 
of any study medication.  
â€¢ AEs reported between the time the patient signed the informed consent and the administration of the first 
dose of any study medication will be captured as concurre nt medical history unless due to a protocol -
related procedure.  
â€¢ AE and SAE recording will continue until the End of Treatment visit is performed (or [ADDRESS_980543] dose of study drug, whichever is later).  
â€¢ SAEs considered related to study drug may be  reported at any time, even after the patientâ€™s final visit.  
Confidential Page 24 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Progression of the underlying neoplasm resulting in hospi[INVESTIGATOR_30059] (e.g., patient hospi[INVESTIGATOR_80529], 
or dies from disease progression only, without any other SAE) will be documented as a n anti -tumor 
activity outcome and not as an SAE. If an SAE occurs in a patient and it is unclear whether the event is 
related to progressive disease, the SAE should be reported.  
Efficacy Assessments  
Tumor assessments will be obtained at Screening using CT and/or MRI scans at time intervals as specified in 
Appendix 1  (Schedule of Events). Assessment of skin lesions may be made by [CONTACT_718714] a reference 
ruler or by [CONTACT_718715] 1.1. Treatment will continue until disease 
progression, withdrawal from the study, or death. At each on -treatment tumor assessment time point, 
radiologic assessment of tumor status will be made using RECIST 1.1 criteria. Investigators will assess tumor 
response(s) for determination of suitability for continued therapy and the secondary endpoint of Investigator -
Assessed PFS. All patients who have complete response (CR), partial response (PR), stable disease (SD), or 
non-evaluable as their local radiological assessment are eligible for further therapy. Non -radiological evidence 
of disease progression should be cle arly documented in the electronic case report form (eCRF).  With Protocol 
Amendment 4, central review of radiographic images is discontinued, but investigator -assessed PFS and ORR 
will continue to be measured.    
All patients will have a bone scan performed  at baseline and then as clinically indicated during the study for 
the assessment of bone metastasis. Patients with a history of treated brain metastasis who are otherwise 
eligible must have a baseline brain CT or MRI within [ADDRESS_980544] to follow up, or the end of study  
Pharmacokinetic Assessments  
With Protocol Amendment 4, PK sample collection will be discontinued  for patients who are still receiving 
study treatment .  
Immunogenicity Assessments  
With Protocol Amendment 4, collection of samples for anti -drug antibody (ADA) assay will be decreased in 
frequency from once every 6 weeks (every 2 treat ment cycles) to once every 12 weeks (every 4 treatment 
cycles), consistent with radiographic evaluation. ADA samples will continue to be collected at end of 
treatment and during follow -up.  
The generation of ADA directed against margetuximab will be assaye d using ELISA. Samples positive for 
ADA will be evaluated for neutralizing activity.  
Analysis Populations:  
Three analysis populations are defined:  
â€¢ Intent -to-Treat Population  â€“ all patients randomized. Patients will be analyzed according to the 
treatment (margetuximab or trastuzumab) assigned during randomization. This population will be used to 
summarize baseline data and evaluate PFS, OS, and HRQoL.  
â€¢ Response Evaluable Popula tion â€“ all patients who are randomized who have measurable disease at 
baseline. This population will be used to evaluate ORR and CBR.  
â€¢ Safety Population  â€“ all patients who are randomized and receive any amount of any study treatment. 
Patients will be analy zed according to the actual treatment received rather than the treatment group to 
which they were randomized. This population will be used for safety, PK, pharmacodynamics (PD), and 
immunogenicity analyses.  
Confidential Page 25 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Statistical Methods:  
Sample Size Determination  
There are [ADDRESS_980545] a 2 -month improvement in median PFS from 4 months to 6 months (HR=0.67) in pati ents treated with 
margetuximab plus chemotherapy, a total of 257 PFS events are required to provide 90% power at a 2 -sided 
alpha=0.05. The analysis of the primary PFS endpoint will occur when about [ADDRESS_980546] been ra ndomized, whichever occurs later.  
The sample size is calculated to ensure 80% power for the analysis of OS. The median OS for patients treated 
with trastuzumab plus chemotherapy is estimated to be [ADDRESS_980547] an increase 
to a median OS of 16 months in patients treated with margetuximab plus chemotherapy (hazard ratio 
[HR]=0.75). To detect a 4 -month improvement in OS from 12 months to 16 months, a total of 385 events are 
required to provide 80% power at a 2 -sided alpha=0.05. I t is anticipated that about 530 patients will be 
accrued to achieve this number of events. Patients will be enrolled over 24 months, and estimated to remain 
on study for an average of 16 months, for a total anticipated study duration of approximately 40 mo nths.  
The sample size of approximately 78 patients is planned for the infusion sub -study, consisting of 18  patients 
for Stage A and about 60 patients for Stage B. The sample size of 60 patients for Stage B of the infusion sub -
study is derived to provide a dequate assessment of the primary safety endpoint.  
Efficacy Analyses  
Definition of Efficacy Endpoints  
Progression -free survival â€“ defined as the time from randomization date to the date of first documented 
disease progression or death from any cause, which ever occurs first. For patients who are not known to be 
dead or progressed at time of data cut -off for PFS analysis, the PFS will be censored at the last tumor 
assessment.    
Overall survival â€“ defined as the time from randomization to the date of death (f rom any cause). For patients 
who are not known to be dead at the time of data cut -off for OS analysis, the OS will be censored at the time 
they are last known to be alive.  
Objective response rate â€“ the proportion of patients in the response evaluable popul ation achieving a best 
response of CR or PR when such responses are confirmed at least [ADDRESS_980548] -baseline radiographic assessment will be 
considered as non -respo nders.  
Duration of response â€“ defined as the time from initial response to date of first documented disease 
progression or death from any cause, whichever occurs first. DoR will be analyzed for responding patients 
only. For responding patients who are not known to be dead or progressed at the time of data cut -off for DoR 
analysis, the DoR will be censored at the last tumor assessment.  
Clinical benefit rate - the proportion of patients in the response evaluable population achieving a best response 
of CR, PR,  or SD of duration >6 months.  
HRQoL â€“ Patients will be administered the EQ -5D-5L and NFBSI -[ADDRESS_980549] occurred. Analysis of OS 
will be conducted at th e time of PFS analysis and subsequently when 70% of the OS events and a final OS 
analysis when about [ADDRESS_980550] occurred.  
For both PFS and OS, Kaplan -Meier methods will be used to generate survival curves and estimate the 
median OS and PFS along with corresponding 95% confidence intervals (CIs) for each treatment group. A 
log-rank test stratified by [CONTACT_718716] -to-event 
endpoints between the two treatment groups. In addition, the hazard ratios and 95% CIs for PFS and OS will 
be assessed using stratified Cox proportional hazards models with treatment as the only covariate.  
Confidential Page 26 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980551] significant p -value<0.05, then both hypotheses are rejected. Otherwise, this endpoint is 
retained and t he second p -value is tested at p<0.025. If a p -value<0.025 (0.05/2) is obtained, this hypothesis is 
rejected. Otherwise, both hypotheses are retained.  
Investigator -assessed PFS will be analyzed using the same methods as described above for the primary 
endpoint of PFS.  
Independent review assessed ORR will be compared between groups using a Mantel -Haenszel statistic 
stratified by [CONTACT_718717].  
Analysis of Tertiary Endpoints  
No multiplicity adjustment will be used for tertiary endp oints.  
Duration of response, where response is assessed by [CONTACT_718718], 
respectively, will be analyzed using Kaplan -Meier methods and compared between two treatment groups 
using a stratified log -rank test.  
Investigator ass essed ORR will also be compared between two treatment groups using a Mantel -Haenszel 
statistic stratified by [CONTACT_718717].  
Clinical benefit where response is assessed by [CONTACT_718718], respectively , 
will also be compared between two treatment groups using a Mantel -Haenszel statistic stratified by [CONTACT_718719].  
Change in tumor size over time will be summarized and the best percentage change from baseline will be 
presented by [CONTACT_15224]. Change calculations will be based on target lesions only.  
Direct reports from patients will be obtained using the NFBSI -16 and EQ -5D-5L Questionnaires (10, 16). 
Responses Data will be collected at baseline, Day 1 of each Odd cycle, and at the End of Treatment visit. The 
primary patient -reported outcome (PRO) endpoint for analysis will be the NFBSI -16 total score , with 
secondary analysis of the subscales that add to the total (disease related symptoms, treatment side effects, and 
function/well -being. Analyses using mixed model repeated measures using the baseline score and protocol 
defined stratification factors a re planned as covariates. Subscale scores will be tabulated and summarized for 
additional analyses. Data from the EQ -5D-5L scale will be summarized by [CONTACT_15449]. To minimize missing 
data, sites will be instructed and patients educated on the importance o f recording the direct patient experience 
in order to appreciate the positive and negative aspects of treating advanced breast cancer, and they will 
specifically be trained on best practices for patient enrollment, adherence to endpoint data collection 
requirements, and methods to ensure complete data capture and management. Every effort will be made to 
collect survey data at all defined visits including at early withdrawal. Reasons for missing data will be 
summarized.  
Pharmacokinetic Analysis:  Serum conce ntrations of margetuximab will be summarized by [CONTACT_718720]. Any population PK modeling will be performed by [CONTACT_170789]. An analysis plan will be created prior to analysis.  
Summary statistics will  be tabulated for serum PK parameters by [CONTACT_718721]. Geometric means and 
percent coefficients of variation will be reported for C max, AUC tau, AUC inf, and C trough; arithmetic means and 
standard deviations will be reported for T half, CL, and V ss; and medians, minimum, and maximum will be 
reported for T max. 
Exposure -Response Analyses:  E-R analyses will be conducted separately using key efficacy and safety 
parameters of interest. An analysis plan will be created prior to analysis.  
Immunogenicity Analysis : The proportion of patients who are negative for ADA at baseline and become 
positive in this assay, the proportion of patients who are negative at baseline and remain negative, and those 
patients who have positive ADA at baseline that increases or decreas es in titer over the course of treatment 
will be summarized. Neutralizing activity will be determined for samples with positive ADA. The effects of 
ADA on key PK, efficacy, and safety parameters will be investigated.  
Safety Analyses: AEs will be coded to t he Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary. Only treatment -emergent AEs, as defined in  Section 7.9.2 , will be summarized i n tables. Events 
prior to treatment (e.g., due to study -related procedure) will be listed in an appendix to the final study report.  
Confidential Page 27 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Summaries of laboratory values will display descriptive statistics for numerically quantified labs. Summaries 
will be group ed by [CONTACT_16416] (e.g., hematology, blood chemistry, and urinalysis) and will be displayed 
by [CONTACT_451429].  
In cases where an abnormality resulted in a repeat laboratory test, the repeat value will be used for the 
summaries. A list of repeated labs including original values and repeat values will be included.  
Graphs of mean values over time may also be generated.  
Electrocardiograms (ECGs) will be collected and analyzed for evidence of cardiac toxicity, especially 
prolongation o f QT interval. Vital signs will be summarized with descriptive statistics at each visit and time 
point where they are collected. LVEF will be evaluated by [CONTACT_718722].  
Infusion Sub -Study : Summary statistics will be calculated to describe incidence of infusion -related reactions 
by [CONTACT_718723].  
 
Confidential Page 28 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 2 BACKGROUND INFORMATI ON  
2.1 HER2+ Metastatic Breast Cancer Current Therapy   
Among women, invasive adenocarcinoma of the breast is the most common non -
dermatological cancer and the second leading cause of death in the [LOCATION_002] (US). While 
early detection and treatment have reduced the death rate associated with breast cancer, for 
women diagnosed with metastatic breast cancer (MBC) in the US, the overall prognosis 
remains poor , with an estimate d 40,300 deaths due to this disease in 2014 (23). In the 
European Union (EU), mortality associated with breast cancer was estimated to affect 
92,000  individuals in 2012 (15). Metastatic breast cancer can be identified either as the initial 
presentation of the disease, or after recurrence following previous treatment for local disease. 
Prior to the era of targeted therapi[INVESTIGATOR_014], patients with HER2+ tumors had more aggressive 
tumors that foretold a shorter survival. The introduction of trastuzumab into clinical practice 
in 1998 and subsequent therapeutic developments dramatically altered the natural h istory of 
HER2+ MBC (14). Direct targeting of the HER2 oncoprotein lengthened survival in patients 
with HER2+ MBC to the point that now patients with HE R2+ disease have a much more 
favorable prognosis than prior to the introduction of trastuzumab.  
In the US and elsewhere, several agents are approved for the treatment of HER2+ breast 
cancer. For patients who require systemic therapy as part of definitive s urgical resection, 
either neo -adjuvant therapy with trastuzumab - and increasingly - pertuzumab (13), or 
adjuvant therapy with trastuzumab (21), both in combination with cytotoxic chemotherapy, is 
the treatment of choice. Treatment at the time of recurrence is determined in part by [CONTACT_718724] -free interval. Patients whose disease recurs late after adjuvant 
treatment are often treated with the same or similar anti -HER2 regimen (trastuzumab 
Â± pertuzumab) (2, 24)used in the neo -adjuvant or adjuvant setting. Patients whose disease 
recurs shortly after initial neoadjuvant/adjuvant therapy (within 6  months) will often proceed 
to a second -line regimen, usually ado -trastuzumab emtansine (T -DM1) monotherapy (25) or 
other  anti-HER2 agents in combination with chemotherapy. The progression of therapi[INVESTIGATOR_718668], with trastuzumab (Â±  pertuzumab) used in combination with 
chemotherapy in first -line (2) and T -DM1 monotherapy or other anti -HER2 therapi[INVESTIGATOR_718669] -line. Of note, T -DM1 approv ed only for 
use in patients who have previously received trastuzumab, and the benefit of this agent as 
first-line therapy, either alone or in combination with pertuzumab, has not yet been 
demonstrated. Trastuzumab is also approved for use as a monotherapy in patients who have 
received previous chemotherapy (11), although its use is limited in this indication (14). 
Lapatinib, a small molecule tyrosine kinase inhibitor of both HER1 (EGFR) and HER2, has 
been approved in the US for use in combination with capecitabine in patients who have 
previously received an anthracycline, a taxane and  trastuzumab (12) and additionally in 
Europe in combination with trastuzumab (3). In theory, this allows for lapatinib use 
immediately after T -DM1: however, in practice, lapatinib is more often used in a later line of 
therapy for patients with HER2+ tumors. Given the effectiveness of neoad juvant, adjuvant, 
and first -line therapi[INVESTIGATOR_44980]+ d isease, more patients are surviving and suitable for later -
line therapy. However, recurrence of disease is common, and additional treatments are 
needed.   
Confidential Page 29 of 142
Margetuximab MacroGenics, Inc.
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020
2.2 Rationale for Treatment with HER2 -targeting Agents After Prior 
Receipt of HER2 -targeting Agents in MBC  Therapy  
There is mounting evidence that continued therapy with anti -HER2 antibodies provides 
additional benefit beyond early therapy. A small study by [CONTACT_703411]. (26) 
established  early on that continued HER2 blockade provides benefit beyond first -line 
therapy. In this study, patients who experienced disease progression on trastuzumab and 
docetaxel were randomized to continue trastuzumab with a different chemotherapy or 
chemotherap y alone. Despi[INVESTIGATOR_718670], there was a clear demonstration of 
prolonged progression free survival (PFS) among patients who continued on trastuzumab. T -
DM1 was approved based on a prolongation of PFS compared with lapatinib in patients who  
had previously received trastuzumab (25). In the recently reported trial of T -DM1 in patients 
who had previously received trastuzumab and lapatinib (17), patients who received T -DM1 
had prolonged PFS and overall survival (OS) compared with those who received phy sicians â€™ 
choice chemotherapy. Interestingly, in the physicians â€™ choice group, approximately 80% of 
patients received trastuzumab along with chemotherapy. Patients who demonstrated an 
objective response to trastuzumab after two prior anti -HER2 therapi[INVESTIGATOR_718671] a 
prolonged response with the median length of response not reached at the time of the data 
cutoff for publication. Together, these data suggest that patients who have experienced 
progression during treatment with HER2 -targeted agents can st ill benefit from additional 
anti-HER2 therapy with the same or different agents, suggesting that the optimal treatment 
paradigm in later lines remains unsettled. 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
  
 
 
 
 
 
 
Confidential Page 30 of 142

Margetuximab MacroGenics, Inc.
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidential Page 31 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
Confidential Page 32 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
   
  
  
  
 
 
   
 
   
   
    
  
 
 
  
  
  
  
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Confidential Page 33 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
    
 
 
 
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
  
 
  
  
 
 
 
   
2.3 Margetuximab Background   
Margetuximab (20) was derived from 4D5, the murine precursor to the humanized 
therapeutic antibody, trastuzumab . Chimeric 4D5 (ch4D5) was generated by [CONTACT_718725] (LC) and heavy chain (HC) complementarity -determining region (CDR) 
and framework sequences of 4D5 to a human immunoglobulin (Ig) G1 backbone. 
Margetuximab  was generated from ch4D5 by [CONTACT_718726] N -glycosylation site in the 
LC variable region (modification of one amino acid residue) and by [CONTACT_718727] (modification of five amino acid residues). Margetuximab binds the HER2 
oncoprotein with  affinity similar to that of trastuzumab, and preserves the direct anti -
proliferative properties of trastuzumab. The optimized Fc domain of margetuximab, however, 
confers enhanced binding to the activating low -affinity Fc receptor, CD16A. In particular, 
binding to the low -affinity allele of CD16A (CD16A -158F) is enhanced in a proportionally 
greater fashion than binding to the high -affinity allele (CD16A -158V). In addition, the 
Confidential Page 34 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980552] HER2 -expressing tumor cell lines in in vitro 
antibody -dependent cell -mediated cytotoxicity (ADCC) assays and in human tumor 
xenograft models in human CD16A+ transgenic mice. Since most patients carry the 
low-affinity allele of CD16A, the enhanced binding properties of margetuximab a re expected 
to confer benefit to the whole patient population and not disproportionately to the high -
binding homozygous carriers (V/V genotype). Homozygous high -binding (V/V) carriers 
make up less than 20% of Caucasian, African American, and Asian populati ons, and the 
remainder is composed of low affinity F/F and intermediate affinity F/V carriers.  
Based on the greater activity of margetuximab compared with trastuzumab in preclinical 
animal models with low affinity CD16A+ transgenic mice, and the demonstra tion of 
prolonged PFS for patients with metastatic breast cancer treated with  trastuzumab in high 
affinity vs. low affinity carriers (18), it is hypothesized that margetuximab will have superior 
efficacy compared with trastuzumab when either is used to treat patients with metastatic 
breast cancer who have received  two prior lines of anti -HER2 therapy.  
2.3.1 Margetuximab Clinical Experience   
Margetuximab is being evaluated for HER2+ metastatic breast cancer in two clinical studies, 
CP-MGAH22 -01 and CP -MGAH22 -02. 
Study CP -MGAH22 -01 is a Phase 1, open -label, single -arm, multicenter dose -escalation 
study to define the toxicity profile, maximum tolerated dose (MTD), immunogenicity, 
pharmacokinetic (PK), and potential anti -tumor activity of margetuxim ab in patients with 
refractory HER2+ breast cancers and patients with other carcinomas that overexpress HER2 
for whom no standard therapy is available. Two regimens of margetuximab (administered via 
intravenous [IV] infusion) are being investigated in this  study: weekly dosing 
(0.1 â€“ 6.0 mg/kg) and every 3 -week dosing (10.0, 15.0, and 18.0 mg/kg). Patients with  stable 
disease or evidence of disease regression are eligible for continued treatment with 
margetuximab.  
Study CP -MGAH22 -[ADDRESS_980553] cancer whose tumors express HER2 at a 2+ level 
by [CONTACT_9064] (IHC) and lack evidence of HER2  gene amplification by 
[CONTACT_187044] (FISH) or expre ss HER2 at a 1+ level by [CONTACT_718728] a 
value of >10.5 by [CONTACT_718729]Â® testing. The study employs a Simon -two stage optimum design 
in which an initial cohort of 21 patients will be evaluated. The original margetuximab dose 
and schedule evaluated was 6.0 mg/kg via IV infusion weekly on Days 1, 8, and 15 of a 
28-day cycle. The study protocol has been amended to evaluate margetuximab at a dose and 
schedule of 15  mg/kg via IV infusion every 3 weeks for all subsequent patients.  
To date, the safety profile of marget uximab in the Phase 1 and 2 studies is generally 
consistent with that observed for trastuzumab in the same setting. Of note, cardiac toxicity, in 
Confidential Page 35 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 the form of reduction in left -ventricular ejection fraction (LVEF) and/or frank congestive 
heart failure (CHF) , has not been observed to date. No significant decrease (defined as an 
absolute drop of 15% or to below 50%) in LVEF has been observed in patients receiving 
margetuximab in the monotherapy studies. Several patients have received multiple cycles of 
margetu ximab in these studies with no apparent cardiotoxicity. Thus, margetuximab appears 
to be well -tolerated when administered either at a dose of up to 6.0  mg/kg given every week 
for 3 weeks in a 4 -week cycle schedule, or when administered up to a dose of 18.0  mg/kg via 
every 3 -week dosing.  
Although not designed as an efficacy study, the Phase 1 study did demonstrate preliminary 
antitumor activity of margetuximab when used as a monotherapy in the treatment of patients 
with HER2+ tumors who had experienced multi ple treatment failures with previous 
therapi[INVESTIGATOR_014]. In particular, 4 of 21 patients with HER2+ MBC have experienced a partial 
response (PR) by [CONTACT_13407]. Three of these [ADDRESS_980554] been obser ved in the Phase 2 study of patients with MBC 
who express HER2 at the 2+ level by [CONTACT_718730] a HERMarkÂ® score of â‰¥10.5.  
Detailed clinical data for these ongoing studies are provided in the margetuximab 
Investigator â€™s Brochure (IB).  
2.3.2 Margetuximab Phar macokinetics and Dose Selection   
Clinical PK were evaluated in the Phase 1 study. A two -compartment model with parallel 
linear and Michaelis -Menten elimination adequately described the observed (interim) data. 
Model parameters were generally in agreement with those commonly expected for a 
monoclonal antibody. Single dose exposure was predicted to be approximately dose 
proportional at doses >3 mg/kg when dosed weekly for 3 weeks in 4 -week cycles and 
â‰¥15 mg/kg when dosed every 3 weeks. The terminal half -life (T half) was estimated at 
12.7 days. Interestingly, the individual estimates of clearance (CL) and central volume were 
slightly lower in patients with breast cancer compared with oth er tumor types, although the 
inter-patient variability was greater than the difference observed between groups.  
Confidential Page 36 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Table 3 Margetuximab Pharmacokinetics at Steady State â€“ 6 mg/kg,  
15 mg/kg, 18 mg/kg â€“ CP-MGAH22 -01  
Parameter  
  (unit)   Margetuximab Dose and Schedule  
6 mg/kg QWa 
N=19  15 mg/kg Q3Wb 
N=6 18 mg/kg Q3Wb 
N=6 
Ctrough  
  (Âµg/mL)  Mean  
(SD)  73.0  
(38.2)  69.9  
(42.9)  86.1  
(47.9)  
 Median  
(95% CI)  66.9 
(20.5 - 169) 61 
(15.8 - 180) 77.6 
(20.8 - 207) 
Cmax 
  (Âµg/mL)  Mean  
(SD)  217  
(58.1)  360  
(93.9)  429  
(103)  
 Median  
(SD)  211 
(125 - 355) 345 
(222 - 590) 417 
(263 - 660) 
AUC  
  (Âµg/mL*h)  Mean  
(SD)  [ZIP_CODE]  
([ZIP_CODE])  [ZIP_CODE]  
([ZIP_CODE])  [ZIP_CODE]  
([ZIP_CODE])  
 Median  
(95% CI) [ZIP_CODE]  
([ZIP_CODE] - [ZIP_CODE])  [ZIP_CODE]  
([ZIP_CODE] - 139000)  [ZIP_CODE]  
([ZIP_CODE] - 160000)  
a Dosed once weekly (QW) for 3 weeks in 4 -week (28 -day) cycles  
b Dosed once every 3 weeks in 3 -week (21 -day) cycles.  
 
Steady state exposure estimates are shown in Table 3 for margetuximab when dosed at 
6.0 mg/kg weekly for 3 of every 4 weeks (n=19), 15.0 mg/kg every 3 weeks (n=6), and 
18.0 mg/kg every 3  weeks (n=6)  in Study CP -MGAH22 -01. At steady state, these doses and 
regimens are estimated to have very similar exposure. Serum trough concentrations (C trough) 
for all three doses are nearly identical, are at or above those reported for trastuzumab in 
patients with b reast cancer (11), and are above that required for inhibition of HER2 signaling 
as demonstrated for trastuzumab in published reports (5). Similarly, area under the 
concentration -time curve (AUC) values are also very similar , with the 15.0  mg/kg slightly 
lower than either 6.0 mg/kg or 18.0 mg/kg. C max differs among the three doses, as would be 
expected with higher maximal concentrations seen in the 15.0 mg/kg and 18.0 mg/kg doses 
compared with 6 mg/kg.  
At the time of data cutoff (5 January 2015),  of the 69 patients treated in ongoing studies 
CP-MGAH22 -01 and CP -MGAH22 -02, 48 had been treated at 6.0 mg/kg weekly for 3 of 
every 4 weeks (n=33), 15.0 mg/kg every 3 weeks (n=9), or 18.0 mg/kg every 3 weeks (n=6). 
Based on exposure data from CP -MGAH22 -01, these patients can be considered as a single 
cohort of 48 patients that provides clinical experience supporting the selection of the 
15.0 mg/kg dose of margetuximab for the current Phase 3 study, despi[INVESTIGATOR_718672]/kg 
doses administered.  
There are no obvious differences in the safety profiles of each margetuximab dose evaluated 
to date suggesting a dose -toxicity relationship. (Details of the number and kind of adverse 
events [AEs] reported both in aggregate and by [CONTACT_718731]). In p articular, of 
the [ADDRESS_980555] studied margetuximab doses of 6.0 mg/kg, 15.0 mg/kg, 
Confidential Page 37 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 and 18.0 mg/kg to date, no events of congestive heart failure were recorded, and no decreases 
in LVEF of â‰¥ 15%, or to < 50% were observed The frequency , type, and severity of AEs 
observed in these dose groups did not differ from the overall study populations and although 
the C max differs for these three dose groups in a dose -related manner, no obvious difference in 
the safety profile was observed between  patients treated at 6.0 mg/kg (the lowest C max), 15.0 
mg/kg, and 18.0 mg/kg (the highest C max). Given the similarity of margetuximab to 
trastuzumab, this result is to be expected as no safety differential has been reported between 
the weekly dose of trast uzumab of 2 mg/kg and the every 3 -week dose of 6  mg/kg. In the 
Phase [ADDRESS_980556] 26 weeks, and of these, 5 patients received doses â‰¥10.0 mg/kg. No 
increase in AEs was not ed with prolonged exposure, and none of these patients were 
discontinued from treatment because of toxicity.  
Patients participating in the present study will be randomized to either margetuximab or 
trastuzumab, both to be administered in combination with a chemotherapy of the 
investigator â€™s choice to be chosen from a specified list.  
The margetuximab dose and schedule selected, 15.0 mg/kg given every 3  weeks, is based on 
the observed safety and efficacy profile of margetuximab at all doses tested to date a nd the 
predictable PK characteristics in the ongoing Phase 1 study. As noted, the majority of clinical 
experience with margetuximab has been gained in patients treated at 6.0  mg/kg dosed weekly 
for 3 of 4 weeks and 15.0 mg/kg and 18.0 mg/kg given every [ADDRESS_980557] demonstrated anti -tumor activity when 
given as monotherapy, trastuzumab has greater activity when combined with cytotoxic 
chemotherapi[INVESTIGATOR_718673]. NCCN and European S ociety for Medical 
Oncology (ESMO) guidelines recommend the combination of trastuzumab with numerous 
different chemotherapy regimens, though none are preferred for the treatment of MBC 
following two prior lines of therapy (4, 19). In HER2 - MBC, only eribulin has shown a very 
modest  survival benefit when compared with other commonly used therapi[INVESTIGATOR_718674] (6). Trastuzumab and margetuximab share the same a ntigen recognition 
domain, and the preliminary safety profile of margetuximab appears similar to trastuzumab. 
Trastuzumab has been combined with capecitabine (22), eribulin  (27), gemcitabine (28), and 
vinorelbine (1) in the first and later line settings. These agents in combination with 
trastuzumab have not been compared with each other in a single study in the same setting, so 
it is not  possible to determine if one combination is superior to another, but all have exhibited 
acceptable safety profiles when used in combination. Because none of these chemotherapy 
agents has been shown to be superior in the later line setting, it is reasonabl e to allow a 
choice of any of the four chemotherapi[INVESTIGATOR_718675]. The choice of chemotherapy must be allowed for use per local regulations.  
Based on the superior ADCC activity of margetuximab compared with trastuzumab in 
preclinical in vivo and in vitro models, the preclinical data demonstrating superior antitumor 
Confidential Page 38 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980558] previously received anti -HER2 therapy participating in the ongoing Phase 1 study 
(see margetuximab IB for detailed data), the combination of margetuximab plus 
chemotherapy is expected to provide enhanced efficacy and comparable safety  over 
trastuzumab plus chemotherapy in patients with MBC requiring additional therapy after at 
least two previous anti -HER2 containing regimens.  
Confidential Page 39 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 3 STUDY PURPOSE AND OB JECTIVES   
This is a Phase 3, randomized, open -label, comparator -controlled study of margetuximab 
plus chemotherapy versus trastuzumab plus chemotherapy in patients with advanced HER2+ 
breast cancer who have received at least 2 prior lines of anti -HER2 directed therapy in  the 
metastatic setting, or in case of having received (neo)adjuvant pertuzumab, at least [ADDRESS_980559] 
one, and no more than three, lines of therapy overall in the meta static setting.  
3.1 Primary Objective   
The primary objective of this study is to evaluate the efficacy, as measured by [CONTACT_3988] -
free survival (PFS) assessed by [CONTACT_718732] d overall survival (OS), of 
margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in patients 
with advanced HER2+ breast cancer who have received at least 2 prior lines of anti -HER2 
directed therapy in the metastatic setting, or in cas e of having received (neo)adjuvant 
pertuzumab, at least [ADDRESS_980560] one, and no more than three, lines of therapy overall in the 
metastatic setting.   
Infusion Sub-Study : The primary objective of the infusion sub -study is to determine the 
safety and tolerability of margetuximab administered at a reduced infusion time in Cycle 2 
and beyond. The incidence of Grade 3 or greater infusion -related reactions (IRRs) by t he end 
of Cycle 2 is the outcome measure.  
3.2 Secondary Objective   
Secondary objectives of this study are:  
â€¢ To evaluate PFS, as assessed by [CONTACT_2792], of margetuximab plus 
chem otherapy  vs. trastuzumab plus chemotherapy in these patients.  
â€¢ To evaluate by [CONTACT_193384], the objective response rate (ORR) of 
margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in these 
patients.  
Infusion sub -study : Incidence of all Grade infusion -related reactions in all sub -study 
patients . 
3.3 Tertiary Objectives   
Tertiary objectives are:  
â€¢ To evaluate health -related quality of life (HRQoL), as assessed using the 
Network -Functional Assessment of Cancer Therapy -Breast Cancer Symptom 
Index (NFBSI) -16 and EQ -5D-5L, associated with margetuximab plus 
chemotherapy vs. trastuzumab plus chemotherapy in these patients.  
Confidential Page 40 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ To characterize the safety profile of margetuximab plus chemotherapy vs. 
trastuzumab plus chemotherapy in these patients.  
â€¢ To evaluate the clinical benefit rate (CBR) of margetuximab plus chemotherapy 
vs. trastuzumab plus chemotherapy in these patients.  
â€¢ To evaluate ORR, as assessed by [CONTACT_2792], of ma rgetuximab plus 
chemotherapy vs. trastuzumab plus chemotherapy in these patients.  
â€¢ To evaluate the duration of response (DoR) of margetuximab plus chemotherapy 
vs. trastuzumab plus chemotherapy in these patients.  
â€¢ To characterize the population PK (PPK) and  exposure -response (E -R) 
relationships of margetuximab in these patients.  
â€¢ To evaluate anti -drug antibodies (ADA) directed against margetuximab and its 
effects on PK, efficacy, and safety in these patients.  
 
3.[ADDRESS_980561] of allelic variation in CD16A, 
CD32A, and CD32B on the efficacy of margetuximab in all patients receiving study 
treatments.  
Confidential Page 41 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 4 STUDY DESIGN   
4.1 Overall Study Design and Plan   
4.1.1 Study Design   
This is a Phase 3, randomized, open -label, comparator -controlled study comparing 
margetuximab to trastuzumab, each in combination with chemotherapy, for the treatment of 
patients with advanced HER2+ breast cancer who have receive d at least 2 prior lines of 
anti-HER2 directed therapy in the metastatic setting, or in case of having received 
(neo)adjuvant pertuzumab, at least [ADDRESS_980562] recent therapy. Eligible patients will be assigned to chemotherapy of the investigator â€™s 
choice to be chosen from capecitabine, eribulin, gemcitabine, or vinorelbine. The selected 
chemotherapy must be allowed for use per local regulations; see Section 6.1.2  for additional 
information. Upon meeting all entry criteria, patients enrolled in the study will be 
randomized 1:[ADDRESS_980563] by [CONTACT_718733]. 
Following completion of (or discontinuation from) treatment, patients will be followed for 
survival.  
[IP_ADDRESS]  Infusion Sub -Study   
The sub -study will start with a run -in group to evaluate the safety and tolerability of reduced 
infusion times. About 9 patients will receive a 120 -minute margetuximab infusion (as a 
single agent, or in combination wit h protocol -specified chemotherapy) in Cycle  1, in order to 
have 6 patients receive a 60-minute infusion in Cycle 2 and beyond (Stage A1). If no 
stoppi[INVESTIGATOR_26501], an additional cohort of about [ADDRESS_980564] 6 patients receive a 30 -
minute infusion at Cycle 2 and beyond (Stage A2). Patients enrolled into Stage A1 and A2 
will be assigned to receive the reduced infusions until [ADDRESS_980565] received reduced 
infusion times. Any extra patients beyond 6 in run -in groups A1 or A2 will continue 120 -
minute infusions until the Stage B regimen is confirmed. In the absence of Grade 3 or higher 
IRRs, patients in Stage A may reduce infusion duration to the Stage B regimen.   
Safety events observed in Stage A1 and A2 will be used to inform infusion reduction 
schemes for a subsequent group of about 60 patients enrolled to Stage B, who will receive 
margetuximab over a 120 -minute infusion in Cycle 1, followed by [CONTACT_5640] a 60 -minute or  30-
minute infusion in Cycles 2 and beyond. Details of the study design and stoppi[INVESTIGATOR_718676] 6.7.1 , and  Figure 1.   
Confidential Page 42 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 The backbone chemotherapi[INVESTIGATOR_718677] 6.1.2 . 
[IP_ADDRESS]  Study Drugs   
Following enrollment and selection of chemotherapy, patients will be randomized 1:1 to 
receive either margetuximab or trastuzumab. Randomization will be stratified by [CONTACT_718734] (â‰¤2, >2), number of lines of therapy overall in the metastatic  setting (â‰¤2, >2), 
and choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). Patients 
will receive either margetuximab or trastuzumab on Day 1 of a 3 -week cycle. Chemotherapy 
will be administered according to the schedule of the cho sen agent beginning on Day 1 and 
will be given prior to margetuximab or trastuzumab on days when both study drug and 
chemotherapy are to be administered.  
The study drugs (margetuximab and trastuzumab) to be administered during this study are 
described in Section  6.1.1 .  
4.1.3 Dose Delays   
For patients who experience toxicity due to bac kbone chemotherapy and the investigator 
deems it necessary to hold the chemotherapy treatment, treatment with study drug should 
continue without delay. Chemotherapy treatment should be reinstituted at the next scheduled 
dose for that chemotherapeutic agent , once toxicity has improved or resolved. Any toxicity 
that leads to delay in study drug treatment, reinstitution of the study drug at the next 
scheduled dose of the study drug is recommended.  Delays of up to 28 days are allowed, after 
which patients are d iscontinued from treatment. For patients who specifically experience a 
drug-related decrease in cardiac function, guidance on dose delays is provided in Sections  
[IP_ADDRESS].1  and [IP_ADDRESS].1 . 
4.1.4 Disease Assessments   
Patients will be e valuated at regular intervals for disease status as described in 
Section  [IP_ADDRESS]  and Appendix 1  (Schedule of Events). Computed tomography (CT) and/or 
magnetic resonance imaging (MRI) scans will be performed prior to treatment (baseline) and 
every [ADDRESS_980566] to fo llow-up, withdrawal of informed consent, death, or the end of study. 
Bone scans will be performed on all patients at baseline and then as clinically indicated for 
the assessment of bone metastasis. Disease response will be determined both locally and by 
[CONTACT_718735] (RECIST) 1.1. With 
Protocol Amendment 4, central review of radiographic images will be discontinued. 
Investigator -assessed PFS and ORR will continue to be assessed according to the protocol 
schedule.  
Confidential Page 44 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Patient treatment decisions will be based on local (investigator) reviews of available 
assessments. Central reviews will be blinded to study treatment (margetuximab or 
trastuzumab) and will be used only for the primary endpoint analysis of PFS.  
4.1.5 Rules for Continuation of Study Treatment   
Patients who tolerate the combination therapy may continue on study until disease 
progression or as otherwise determined by [CONTACT_20616] r. Patients who are intolerant of the 
chosen backbone chemotherapy, but do not exhibit signs of disease progression should 
continue on margetuximab or trastuzumab alone. At the investigator â€™s discretion, patients 
who have received at least [ADDRESS_980567]-progression margetuximab may be considered on a case -by-case basis, with agreement 
of the Sponsor â€™s medical monitor, f or infusion sub -study patients only.  
See Section 5.4.[ADDRESS_980568] of care chemotherapi[INVESTIGATOR_718678]2+ breast 
cancer who have received at least 2 prior lines of anti -HER2 directed therapy in the 
metastatic setting, or in case of having received (neo)adjuvant pertuzumab, at least [ADDRESS_980569] of margetuximab with placebo, and 
therefore an active comparator was chosen. Trastuzumab is commonly used in this setting, 
and the comparison will directly evaluate whether a molecule that has been engineered to 
enhance ADCC produc es superior clinical efficacy. Although not approved in this setting, 
trastuzumab is an acceptable comparator because continued treatment with trastuzumab after 
failure while on trastuzumab has demonstrated clinical benefit. In addition, trastuzumab has a 
generally favorable toxicity profile compared with lapatinib, and is commonly used in 
clinical practice (4, 19). 
The decision to allow physician â€™s choice of chemotherapy from among a selected list is 
based on the well -described finding (7) that, in the treatment of advanced breast cancer, 
sequential single agent chemotherapi[INVESTIGATOR_718663], and that, other 
than eribulin - which showed a modest survival benefi t - no one agent has been clearly shown 
to be superior to another in the salvage setting. Common practice is to choose a therapy 
based on individual patient needs and combine that with trastuzumab. Rather than dictate the 
therapy, investigators will choose  the patient â€™s combination chemotherapy from a 
Confidential Page 45 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980570], allowing for a tailored approach to each individual patient â€™s status (also 
similar to the control arm in the eribulin pi[INVESTIGATOR_2397] (6)). To minimize bias, the selected 
chemotherapy will be chosen and documented prior to patient randomization . 
See Section 2.2.1 , which details the rationale of modifying eligibility criteria as of 
Amendment  2 to enroll patients with metastatic HER2+ breast cancer who have received at 
least 2  prior lines of anti -HER2 directed therapy in the metastatic setting, or in case of having 
received (neo)adjuvant pertuzumab, at least [ADDRESS_980571] been random ized, whichever occurs 
later.  
4.3.1 Patient Accrual   
After obtaining informed consent and conducting pre -study eligibility assessments, eligible 
patients will be enrolled and randomized in a 1:[ADDRESS_980572].  
Infusion Sub -Study : Up to about [ADDRESS_980573] be sourced by [CONTACT_1704]/treating physician and will no t be the 
responsibility of the study Sponsor, unless required by [CONTACT_5737]/site regulations.  
Confidential Page 46 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980574] meet  all of these criteria to be eligible for study participation; no 
exceptions to these criteria will be granted by [CONTACT_1034].  
5.[ADDRESS_980575]:  
General  
1. Be able to provide informed consent and documentation of informed consent 
prior  to initiation of any study -related tests or procedures that are not part of 
standard -of-care for the patient â€™s disease. Patients must also be willing and ab le 
to comply with study procedures, including the acquisition of specified research 
specimens and completion of HRQoL assessments.  
2. Be â‰¥ [ADDRESS_980576] histologically proven metastatic or locally advanced relapsed/refrac tory 
HER2+ (3+ by [CONTACT_718736] -amplified as per American Society of Clinical 
Oncology [ASCO] and the College of American Pathologists [CAP] Guidelines) 
breast cancer based on the most recently available tumor biopsy collected from the 
patient. HER2 status mu st be documented from a reference laboratory that 
conforms to standards set for accreditation by [CONTACT_718737]. Confirmatory IHC testing is not required for study entry. Tumors may be 
estrogen receptor (ER)/progesterone recep tor (PgR) positive or negative.  
4. Have received at least 2 prior lines of anti -HER2 directed therapy in the metastatic 
setting, or in case of having received (neo)adjuvant pertuzumab, at least [ADDRESS_980577] received prior treatment with pertuzumab in the (neo)adjuvant or 
metastatic setting. Prior radiotherapy, hormonal therapi[INVESTIGATOR_014], and other anti -HER2 
therapi[INVESTIGATOR_33938].  
5. Have received treatment for at least one, and n o more than three, lines of therapy 
overall in the metastatic setting. Hormonal therapi[INVESTIGATOR_718679]. Prior 
neo-adjuvant or adjuvant therapy that resulted in rel apse within [ADDRESS_980578] recent line of 
therapy. Dose interruptions, delays, pauses during previous therapy , or changes in 
therapy to manage toxicity will not constitute a new line of therapy provided 
disease progression did not occur.  
Confidential Page 47 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 6. Resolution of all chemotherapy or radiation -related toxicities to â‰¤ Grade 1 (with 
exception of â‰¤ Grade 2 alopecia, stable sens ory neuropathy, or stable electrolyte 
disturbances that are managed by [CONTACT_718711]).  
7.  Have Eastern Cooperative Oncology Group ( ECOG) performance status of 0 or 1 
(Appendix 4 ). 
8. Have life expectancy â‰¥ [ADDRESS_980579] and/or MRI.  
 
Laboratory Features  
10. Have acceptable laboratory parameters as follows:   
a. Platelet count ï‚³ 100 Ã— 103/ÂµL without having received a transfusion or 
growth factor support within 4 weeks prior to randomization.  
b. Hemoglobin ï‚³ 9.0 g/dL without having received a transfusion or growth 
factor support within 4 weeks prior to randomization.  
c. Absolute neutrophil count ï‚³ 1.5 Ã— 103/ÂµL in the absence of any growth 
factor support given within 4 weeks prior to randomization.  
d. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)  ï‚£ 3.0 Ã—  
the upper limit of normal (ULN), except patients with liver metastases, 
who may enroll with ALT/AST ï‚£ 5.0 Ã— ULN.  
e. Total bilirubin ï‚£ 1.5 Ã— UL N, except patients with Gilbert â€™s syndrome, who 
may enroll if the conjugated bilirubin is within laboratory normal limits.  
f. Creatinine < 1.5 mg/dL, or a calculated or measured creatinine clearance 
> 50 mL/min.  
Reproductive Features  
11. Female patients of childb earing potential (not surgically sterilized and between 
menarche and [ADDRESS_980580] menopause) must have a negative result from a serum 
pregnancy test performed within [ADDRESS_980581] dose of study drug (e ither margetuximab or trastuzumab). Highly effective 
methods of contraception include:  
â€¢ Combined (estrogen and progestogen containing) hormonal contraception 
associated with the inhibition of ovulation  
o Oral 
o Intravaginal  
Confidential Page 48 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Transdermal  
â€¢ Progestogen -only hormona l contraception associated with inhibition of ovulation  
o Oral 
o Injectable  
o Implantable  
â€¢ Intrauterine device (IUD)  
â€¢ Intrauterine hormone -releasing system (IUS)  
â€¢ Bilateral tubal occlusion  
â€¢ Vasectomized partner  
â€¢ Sexual abstinence  
 
12. Male patients should also have their partners who are women of childbearing 
potential use a highly effective method of contraception (as shown above) from the 
time of informed consent through [ADDRESS_980582] dose of study drug (either 
margetuximab or t rastuzumab).  
5.2 Exclusion Criteria   
Patients who meet any of the following criteria will be excluded from the study:  
1. Patients with known, untreated brain metastasis.  
â€¢ Patients with si gns or symptoms of brain metastasis must have a CT or MRI 
performed within 4 weeks prior to randomization to specifically exclude the 
presence of radiographically detectable brain metastases.  
â€¢ Patients with known, treated brain metastases must have a basel ine CT or MRI 
within [ADDRESS_980583] been on a stable dose of 
steroids (â‰¤ 10 mg/day of prednisone or equivalent) for at least 4 weeks prior to 
randomization with no symptoms.  
2. History of uncontrolled seizures within 6 months of randomization.  
3. History of prior allogeneic bone marrow, stem -cell, or solid organ transplanta tion.  
4. Treatment with any local or systemic anti -neoplastic therapy (including hormonal 
therapi[INVESTIGATOR_530009]) or any investigational therapy within 2 weeks prior to 
randomization. Bisphosphonates and receptor activator of nuclear factor kappa B 
ligand (RANKL) inhibitors are allowed provided treatment starts prior to 
randomization.  
Confidential Page 49 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 5. Treatment with corticosteroids (i.e., > 10 mg prednisone per day or equivalent) or 
other immune suppressive drugs within 2 weeks prior to randomization. Steroids 
for topi[INVESTIGATOR_19529] l use, inhalational use, nasal spray, or ophthalmic solution are allowed.  
6. History of clinically significant cardiovascular disease including but not limited to:  
a. Myocardial infarction or unstable angina within 6 months prior to 
randomization.  
b. Stroke or tr ansient ischemic attack within 6 months prior to randomization.  
c. Clinically significant cardiac arrhythmias.  
d. Uncontrolled (persistent) hypertension defined as systolic blood pressure 
(SBP) >180 mmHg or diastolic blood pressure (DBP) >100 mmHg.  
e. Congestive he art failure ([LOCATION_001] Heart Association [NYHA] class II -IV). 
f. Pericarditis or clinically significant pericardial effusion.  
g. Myocarditis.  
h. LVEF < 50% by [CONTACT_327711] -gated acquisition (MUGA) scan.  
7. Clinically significant pulmonary compromise, includi ng a requirement for 
supplemental oxygen use to maintain adequate oxygenation.  
8. Evidence of active viral, bacterial, or systemic fungal infection requiring 
parenteral treatment within [ADDRESS_980584] for hepatitis B 
surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction 
(PCR).  
11. Second primary malignancy that has not been in remission for at least 2 years from 
the anticipated start of study treatment. Exceptions of treated malignancies that do 
not require a 2 -year remission include: non -melanoma skin cancer; cervical 
carcinoma in situ; squamous intraepi[INVESTIGATOR_718680]; localized prostate cancer 
(Gleason score < 6); resected melanoma in situ or ductal carcinoma in situ. 
Patients with second primary breast cancers within 2 years are eligible provided 
that both primary tumors were HER2+ (3+ by [CONTACT_718738] -situ hy bridization [ISH] 
amplified).  
12. History of trauma or major surgery within 4 weeks prior to randomization.  
13. Any serious underlying medical or psychiatric condition that would impair the 
ability of the patient to receive or tolerate the planned treatment at the  
investigational site.  
14. Known hypersensitivity to recombinant proteins, polysorbate 80, benzyl alcohol, 
or any excipi[INVESTIGATOR_718681], trastuzumab 
or other study treatments. Previous infusion reactions to trastuzumab or  other 
monoclonal antibodies will not preclude enrollment provided no contraindication 
to trastuzumab therapy remains.  
Confidential Page 50 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 15. Any condition that would be a contraindication to receiving trastuzumab as 
described in the approved local label or a condition that woul d prevent treatment 
with the physician â€™s choice of chemotherapy.  
16. Vaccination with any live virus vaccine within [ADDRESS_980585] feeding.  
20. Prior participation in a margetuximab clinical study.  
21. Any investigative site per sonnel directly affiliated with this study.  
22. Employees of MacroGenics, Inc.  
23. Prisoners or other individuals who are involuntarily detained.  
24. Any issue or condition that in the opi[INVESTIGATOR_718682] â€™s participation in the study or confound the results of the study.  
5.3 Entry Criteria for the Infusion Sub -Study   
1. Patients will meet all entry criteria for the randomized portion of the study with the 
exception of inclusion criteria #4 and #5.  
2. Patients must have received at least [ADDRESS_980586] received prior trastuzumab, pertuzumab, and T -DM1. 
5.4 Withdrawal of Patient from the Study or Study Drug   
5.4.1 Guidelines for Permanent Discontinuation   
Patients should be permanently withdrawn from all study treatment for any of the following 
situations. Patients who are withdrawn from the study will not be replaced.  
â€¢ Following patient enrollment and treatment, a violation of enrollment criteria or 
other significan t protocol violation is discovered of such nature that continued 
treatment would not be in the best interest of the patient.  
Confidential Page 51 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Patient develops an uncontrolled intercurrent illness unrelated to cancer that 
renders continuing treatment unsafe or regular study  visits impossible.  
â€¢ Patient experiences an AE or serious adverse event (SAE) that necessitates 
discontinuation of study drug (i.e., margetuximab or trastuzumab).  
â€¢ The Sponsor or Regulatory Agency terminates the study, or investigator 
terminates participation in the study.  
â€¢ The patient requests to be discontinued from the study, i.e., withdraws consent.  
â€¢ The patient is noncompliant with study drugs, chemotherapy, othe r study 
medication, or protocol -required evaluations.  
â€¢ Patient is withdrawn at investigator â€™s discretion.  
â€¢ The patient exhibits progression of disease by [CONTACT_393] 1.1 criteria.  
â€¢ The patient becomes pregnant during the study. Upon confirmation of the 
pregnancy,  the patient must discontinue treatment with study drug immediately.  
â€¢ Treatment delay of study drug greater than 28 days (except due to drug -related 
cardiac toxicity (see Section 4.1.3 )). 
â€¢ Patient death  
The Sponsor or its designee must be notified within 24 hours of discontinuations meeting 
criteria for an Immediately Reportable Event (IRE) ( Section [IP_ADDRESS] ) using the procedures 
outlined in Section 7.9.7 . For all permanent discontinuations, patients will continue to be 
followed as appropriate and consistent with protocol guidelines but should receive no further 
study treatment. All patients should be followed for survival â€“ the only exception would be 
withdrawal, by [CONTACT_102], of consent.  
5.4.[ADDRESS_980587] -Treatment Follow -up phase, 
evaluations should resume according to the protocol.  
Confidential Page 52 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 6 STUDY TREATMENTS   
6.1 Description of Treatment(s)   
An overview of study treatments to be administered during this study is presented in Table  4. 
On days when both the study drug and chemotherapy are to be administered, the 
chemotherapy will be administered first.  
Table  4 Overview of Study Treatments   
Agent  Starting Dose  Schedule  Mode of 
Administration  
Chemotherapya    
     Capecitabine  1000 mg/m2 BID BID for 14 days in a 21 -day cycle  Oral 
     Eribulinb 1.4 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
     Gemcitabine  1000 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
     Vinorelbine  25-30 mg/m2 Day 1 and 8 of a 21 -day cycle  IV 
Study Drugs     
     Trastuzumab  8 mg/kg loading dose then 
6 mg/kg  Every 21 days  IV 
     Margetuximab  15 mg/kg  Every 21  days IV 
BID = twice daily; IV = intravenous  
a The chemotherapy selected must be allowed for use per local regulations (see Section 6.1.2 ). 
Chemotherapi[INVESTIGATOR_718667] -indicated starting doses, schedule, and route of 
administration, however dose adjustments to improve tolerability and manage toxicities are permitted.  
b Dose of eribulin noted here is based on use as eribulin mesylate; if free base eribulin is used, equivalent 
dose of 1.23 mg/m2 is permitted.  
 
All changes in study drug infusions, including interruptions and their duration, as well as 
reductions  in rate and duration, must be recorded. Chemotherapi[INVESTIGATOR_718683], frequency, and route indicated per protocol.  
6.1.1 Study Drugs   
[IP_ADDRESS]  Margetuximab   
Margetuximab will be administered on Day 1 of a 3 -week cycle at a dose of 15 mg/kg via IV 
infusion over [ADDRESS_980588].  
Confidential Page 53 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 [IP_ADDRESS].1  Dose Rate or Schedule Modifications for Toxicity   
The rate of margetuximab in fusion or dose schedule may be modified for infusion -related 
reactions or cardiac toxicities, respectively, that are determined to be associated with 
margetuximab based on the following parameters:  
â€¢ Infusion -related reactions:  follow guidelines described i n Section [IP_ADDRESS]  
â€¢ Decreased cardiac function â€“ withhold margetuximab for at least 4 weeks if either 
of the following criteria are met:  
o â‰¥ 16% absolute decrease in LVEF from pre -treatment values, or  
o LVEF below institutional normal limits (or 50% if no limits are available) 
and â‰¥ 10% absolute decrease in LVEF from pretreatment values  
LVEF will be monitored at regular intervals during the st udy. If a decrease in cardiac function 
is suspected, LVEF should be determined using the same method as used prior to treatment.  
Margetuximab may be resumed if, within 8 weeks, the LVEF returns to within normal limits 
and the absolute decrease from baselin e is â‰¤ 15%.  
Margetuximab should be permanently discontinued if a decline in LVEF persists for 
>8 weeks or if dosing is interrupted for more than 3 occasions due to cardiomyopathy.  
Please refer to the Investigator â€™s Brochure for information on special warni ngs and 
precautions for use, interaction with other medicinal products and other forms of interaction, 
and undesirable effects associated with margetuximab.  
[IP_ADDRESS]  Trastuzumab   
Trastuzumab  will be administered via IV infusion on Day 1 of a 21 -day cycle at a dose of 
8 mg/kg for the first dose (over 90 minutes) and 6 mg/kg for all subsequent doses (over 30  to 
90 minutes). On days when both chemotherapy and trastuzumab are to be administered, the 
chemotherapy will be administered first.  
Contraindications  
In addition to inclusion exclusion criteria incorporated into this protocol, the following are 
contraindications specific to the administration of trastuzumab:  
â€¢ Hypersensitivity to trastuzumab, murine proteins, or to any of the excipi[INVESTIGATOR_840].  
â€¢ Severe dyspnea at rest due to complications of advanced malignancy or requiring 
supplemental oxygen therapy.  
Confidential Page 54 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 [IP_ADDRESS].1  Dose Modification for Toxicity   
Dose reduction  
No reductions in the dose of trastuzumab should be made. Patients may continue therapy 
during periods of reversible, chemotherapy -induced myelosuppression but they should be 
monitored carefully for complications of neutropenia during t his time.  
The trastuzumab package insert should be consulted for any dose modifications or 
adjustments. Trastuzumab dosing will be modified for infusion reactions and 
cardiomyopathy.  
For infusion reactions, the guidelines described in Section [IP_ADDRESS]  should be followed.  
Trastuzumab should be withheld for at least 4 weeks if a decrease in cardiac function as 
follows is observed:  
â€¢ â‰¥ 16% absolute decrease in LVEF from pre -treatment values, or  
â€¢ LVEF below institutional normal limits and â‰¥ 10% absolute decrease in LVEF 
from pretreatment values  
If LVEF has not improved, or declined further, or symptomatic congestive heart failure 
(CHF) has devel oped, discontinuation of trastuzumab should be strongly considered, unless 
the benefits for the individual patient are deemed to outweigh the risks. All such patients 
should be referred for assessment by a cardiologist and followed up.  
LVEF will be monitor ed at regular intervals during the study. If a decrease in cardiac function 
is suspected, LVEF should be determined using the same method as used prior to treatment.  
Trastuzumab may be resumed if, within 8 weeks, the LVEF returns to within normal limits 
and the absolute decrease from baseline is â‰¤ 15%.  
Trastuzumab should be permanently discontinued if a decline in LVEF persists for > 8 weeks 
or if dosing is interrupted for more than 3 occasions due to cardiomyopathy.  
6.1.2 Backbone Chemotherapy   
The choice of backbone chemotherapy will be made by [CONTACT_718739]. The choice of therapy should be made based on the patient â€™s co-morbidities 
and the physician â€™s best judgment about the most appropriate chemotherapy for a given 
patient. Chemotherapi[INVESTIGATOR_718667] -indicated starting doses, schedule, and 
route of administration (see Table  4); however, dose adjustments to improve tolerability and 
manage toxicities are permitted. Allowable chemotherapeutic agents include capecitabine, 
eribulin, gemcitabine, and vinorelbine (except in Italy where sites can choose from 
capecitabine and vinorelbine only per local requirements). The chemotherapy selected must 
be allowed for use per local regulations and will be supplied locally  unless an alternate 
source for the selected agent is needed . Changes in ba ckbone chemotherapy will not be 
Confidential Page 55 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 allowed following patient randomization (see Section [IP_ADDRESS] ). Substitution of generic 
equivalents for branded products is acceptable if such products have been approved by [CONTACT_718740]. Substi tution of different 
doses due to differences in formulation is allowed provided that the amount of active drug 
substance is equivalent. The use of therapi[INVESTIGATOR_718684], either alone or in combination with either of  the [ADDRESS_980589] â€™s respective package insert.  
If used in the infusion sub -study, backbone chemotherapy will be administered according to 
the same protocol -specified direction for the randomized cohorts.  
6.2 Study Drugs and Supplies   
6.2.1 Margetuximab   
Margetuximab is a sterile, clear -to-slightly -opalescent, colorless -to-pale-yellow or 
pale-brown, preservative -free solution for IV administration. Margetuximab will be supplied 
at a protein concen tration of 25 mg/mL in a single -use vial containing 250 mg/10 mL. 
Margetuximab is packaged in US Pharmacopeia (USP) and Ph. Eur. Conforming Type I 
borosilicate, 10 mL clear glass vials with FluroTecÂ® coated 4432/[ADDRESS_980590] is formulated in a buffer 
containing 1.1 mg/mL sodium phosphate monobasic, monohydrate, 0.58 mg/mL sodium 
phosphate dibasic, heptahydrate, 2.9 mg/mL sodium chloride, 11 mg/mL L -arginine 
hydrochloride, 30 mg/mL  sucrose, and 0.1 mg/mL Polysorbate 80, pH 6.1. Requests for 
additional study drug should be made to MacroGenics, Inc., via Interactive Response System 
(IxRS) at least 2 weeks in advance.  
6.2.2 Trastuzumab   
Trastuzumab (marketed as HERCEPTINÂ® by [CONTACT_8229], Inc., A Member of the [COMPANY_002] 
Group, [ADDRESS_980591], South San Francisco, CA [ZIP_CODE] -4990; Made in Switzerland by F. 
Hoffmann -La [COMPANY_002] Ltd, Basel) is available as follows:  
â€¢ 440 mg vial is supplied  in a multi -use vial containing 440 mg trastuzumab as a 
lyophilized sterile powder, under vacuum. Each carton contains one vial 
trastuzumab and one vial (20  mL) of Bacteriostatic Water for Injection, USP, 
containing 1.1% benzyl alcohol as a preservative. T hough supplied as a multi -use 
vial, each vial may only be used once.  
â€¢ 150 mg vial is supplied in a single -dose vial containing 150 mg trastuzumab as a 
white lyophilized powder for preparation of a concentrated solution for infusion. 
Each carton contains on e vial trastuzumab 150 mg.  
Confidential Page 56 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 6.2.3 Backbone Chemotherapi[INVESTIGATOR_718685].  
6.3 Drug Preparation an d Administration   
6.3.1 General Precautions   
The calculated dose for chemotherapy and margetuximab or trastuzuma b will be 
administered based on the patient â€™s actual weight at Cycle 1 Day 1 (baseline). Significant 
(â‰¥ 10%) change in body weight from baseline should prompt recalculation of dose. For body 
surface area (BSA) determination, a change in weight of â‰¥10% will prompt recalculation of 
BSA and dose according to institutional standards.  
Backbone chemotherapi[INVESTIGATOR_718686] â€™s respective package insert.  
Infusion or allergic reactions may occur with the infusion of monoclonal antibodies and other 
protein -based therapeutics. Precautions for anaphylaxis should be observed during 
margetuximab and trastuzumab administration. Supportive measures may include, bu t are not 
limited to: epi[INVESTIGATOR_238], antihistamines, corticosteroids, IV fluids, vasopressors, oxygen, 
bronchodilators, diphenhydramine, and acetaminophen. Please refer to Section [IP_ADDRESS]  for 
specific guidelines regarding the management of infusion reactions. Supportive care 
measures consistent with optimal patient care will be provided throughout the study 
according to institutional standards.  
6.3.2 Margetuxima b Preparation   
Recommended safety measures for handling and preparation include masks, protective 
clothing, gloves, and vertical laminar airflow safety cabinet.  
Before administratio n, parenteral drug products should be inspected visually. Some visible, 
translucent, proteinaceous, margetuximab particles may be present. However, if foreign 
particulate matter or discoloration is observed, the drug should not be administered. The 
desired  amount of margetuximab should be withdrawn from the vial(s) and diluted in a 
250 mL polyolefin (e.g., polypropylene) or olefin copolymer (e.g., ethylene and propylene 
copolymer) (hereafter referred to collectively as â€œolefin polymer/copolymer â€), or polyvi nyl 
chloride (PVC) infusion bag containing 0.9% Sodium Chloride Injection, USP at a final 
concentration of 2.4 to 7.2 mg/mL. The bag should be appropriately labeled and gently 
inverted to mix the solution. THE BAG MUST NOT BE SHAKEN; excessive agitation ma y 
cause aggregate formation. A low protein binding polyethersulfone (PES) 0.[ADDRESS_980592] s be used for IV administration of margetuximab.  
Confidential Page 57 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Since margetuximab does not contain preservatives, once diluted in normal saline, 
administration should begin immediately after preparation but can be stored at 2Â° to 8Â°C for 
up to 6 hours after preparation.  
Margetuximab should not be administered as an IV push or bolus.  Margetuximab should not 
be mixed or diluted with other drugs. Vials are single unit -dose containers. Any partially used 
vials or diluted dosing solutions should be discarded using appropriate drug disposal 
procedures.  
6.3.3 Study Drug and Chemotherapy Administration   
Margetuximab will be administered as a 120 -minute (2 -hour) IV infusion after chemotherapy 
administration for patients in the randomized cohorts. Margetuximab may be administered 
after completion of chemotherapy administration. Two consecutive doses should be a 
minimum [ADDRESS_980593] dose will be administered as a 90 -minute 
infusion after chemotherapy administration. For subsequent doses, trastuzumab will be 
administered as a 30 -90-minute IV infu sion. Trastuzumab may be administered after 
completion of chemotherapy administration. Two consecutive doses should be a minimum 
18 days apart.  
Chemotherapi[INVESTIGATOR_718687]  4 and per each individual agent â€™s 
prescribing information.  
The chosen chemotherapy (if administered IV) and randomized study drug must be 
administered within Â± 10 minutes of the indicated infusion duration.  
[IP_ADDRESS]  Premedications and Prophylaxis for Chemotherapy   
Standard premedications for the administration of the cytotoxic chemotherapy will be 
employed in the study. For chemotherapy, recommendations made in the locally approved 
label should be followed for each agent.  
[IP_ADDRESS]  Premedications for Margetux imab   
When margetuximab infusions coincide on the same day with cytotoxic chemotherapy 
administration, the premedications for the chemotherapy should be employed and should be 
sufficient for prophylaxis of margetuximab infusion reactions as well.  
Premedication is not required, but the following recommendations are made regarding 
premedications for margetuximab administration on those days upon which that 
administration is not precede d by a chemotherapeutic agent or if no premedication is 
employed for that chemotherapy. Premedication should be given within 30 minutes of 
margetuximab administration if it has not previously been administered prior to backbone 
Confidential Page 58 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 chemotherapy. These recommen dations should serve as guidelines and may be modified by 
[CONTACT_737].  
Prior to the infusion:  
â€¢ Acetaminophen 650 -1000 mg orally (PO) or ibuprofen 400 mg PO  
â€¢ Diphenhydramine [ADDRESS_980594]  
â€¢ Ranitidine [ADDRESS_980595]  
â€¢ Dexamethasone 10 mg IV or equivalent (for patients at high risk)  
 
[IP_ADDRESS]  Premedications for Trastuzumab   
There are no premedications specified for administration of trast uzumab (See most current 
Herceptin Prescribing Information). Dose modifications for toxicity are described in 
Section  [IP_ADDRESS].1 .  
6.3.4 Additional Instru ctions for Handling   
Margetuximab or trastuzumab should not be mixed or diluted with other drugs. Any partially 
used vials or diluted dosing solutions should be discarded using appropriate drug disposal 
procedures. Although trastuzumab may be supplied in a multi -use vial, each vial may only be 
used once during this study.  
6.4 Dispensing Study Drug   
Under no ci rcumstances is the investigator allowed to release the clinical study drug supplies 
for use by [CONTACT_451407] 1572 (or equivalent document) or 
administer study drug to a patient who is not enrolled in this study. Study drug must be  
dispensed at an institution specified on Form FDA 1572 (or equivalent document).  
6.5 Selection and Timing of Dose for Each Patient   
Patients will be randomized 1:1 to receive either ma rgetuximab or trastuzumab, both in 
combination with chemotherapy preselected by [CONTACT_093]. Randomization will be 
stratified by [CONTACT_612032] (â‰¤ 2, > 2), number of lines of therapy in the metastatic 
setting (â‰¤2, >2), and choice of chemot herapy (capecitabine, eribulin, gemcitabine, or 
vinorelbine). Study drug (margetuximab or trastuzumab) will be administered after 
chemotherapy drugs are administered on Day 1 of each 3 -week cycle.  
6.5.1 Selection and Timing of Infusion Sub -Study Patients   
Patients who participate in the infusion sub -study will not be stratified nor randomized. They 
will be enrolled to receive either monotherapy margetuximab or margetuximab in 
combination w ith protocol -specified ( Table  4) physician choice chemotherapy, at the 
Confidential Page 59 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 discretion of the investigator. Margetuximab will be administered on Day 1 of each  3-week 
cycle, after the chemotherapy if combination therapy is chosen.  
6.6 Potential Adverse Events and Supportive Care Measures   
6.6.1 Study Drugs (Margetuximab and Trastuzumab)   
Supportive care measures specific to trastuzumab and margetuximab are described below; 
recommended modifications for toxicity specific to these agents are provided in 
Section  6.1.1 . 
6.6.2 Infusion Related Reactions   
Infusion -related reactions including  
hypersensitivity/anaphylactic/anaphylactoid reactions may occur.  
Precautions for the management of these reactions should be observed  
during margetuximab and trastuzumab administration.  
Infusion reactions associated with margetuximab or trastuzumab admin istration should be 
managed according to the standard practice of medicine. General guidelines for the 
management of such reactions are provided in this section.  
Patients should be monitored closely for the development of infusion -related reactions during  
margetuximab or trastuzumab infusion. Medications and supportive measures for the 
treatment of severe hypersensitivity reactions should be available for immediate use for an 
infusion reaction and may include, but are not limited to: subcutaneous (SC) epin ephrine 
(0.3 to 0.5 mL of a 1:1000 solution), antihistamines (e.g., diphenhydramine 25 to 50 mg IV), 
corticosteroids (e.g., hydrocortisone 25 -100 mg IV push or equivalent), IV fluids, 
vasopressors, oxygen, bronchodilators, and antipyretics. Resuscitation e quipment and other 
supplies for the emergency management of an allergic/toxic reaction must also be available. 
The patient should be treated according to the best available local practices and procedures. 
All supportive measures consistent with optimal pat ient care will be provided throughout the 
study according to institutional standards.  
Should symptoms of fever or chills develop, it may be difficult to distinguish whether the 
cause of the symptoms is related to emerging infection or infusion reaction. As  such, patients 
should be evaluated carefully for the presence of infection, with the acquisition of cultures 
and/or implementation of empi[INVESTIGATOR_718688]. Please refer to Section  [IP_ADDRESS]  for guidance regarding the management of 
infusion reactions.  
Confidential Page 60 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 [IP_ADDRESS]  Grading of Infusion Reactions   
Infusion reactions will be categorized as follows:  
â€¢ Grade 1:  mild reaction; infusion interruption not indicated, intervention not 
indicated. Note: although interruption in infusion is not indicated, temporary rate 
reduction is indicated before resuming the original infusion rate, as tolerated by 
[CONTACT_102] (see Section  [IP_ADDRESS] ); 
â€¢ Grade 2:  therapy or infusion interruption indicated, but responds promptly to 
symptomatic treatment [e.g., antihistamines, non -steroidal anti -inflammatory 
drugs (NSAIDS), narcotics, IV fluids]; prophylactic medications indicated for 
ï‚£ 24 hours;  
â€¢ Grade 3:  prolonged (e.g., not rapi[INVESTIGATOR_718689]/or brief 
interruption of infusion); recurrence of symptoms following initial improvement; 
hospi[INVESTIGATOR_79806] (e.g., renal impairment, pulmonary 
infiltrates);  
â€¢ Grade 4:  l ife-threatening consequences; pressor or ventilatory support indicated;  
â€¢ Grade 5:  death.  
Guidelines regarding premedications for the prevention of infusion reactions are provided in 
Section [IP_ADDRESS] . Investigators are encouraged to intervene early and vigorously in the 
treatment of infusion reactions and cytokine release syndrome if they occur.  
[IP_ADDRESS]  Management of Observed Margetuximab or Trastuzumab 
Infusion Reactions   
The following are treatment guidelines (which may be modified as needed by [CONTACT_718741]) for margetuximab or trastuzumab 
infusion reactions:  
â€¢ Grade 1:  
o Slow the infusion rate by 50%  
o Monitor the patient for worsening of condition.  
o Continue rate at 50% reduction and increase dose rate to the original rate 
by [CONTACT_718742] 30 minutes, as tolerated.  
â€¢ Grade 2:  
o Stop the infusion.  
o Administer diphenhydramine hydrochloride 25 -50 mg IV , ibuprofen 400 
mg or institutional equivalent orally for fever, and oxygen and 
bronchodilators for mild bronchospasm.  
Confidential Page 61 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Resume the infusion at 50% of the prior rate once the infusion reactio n has 
resolved or decreased to Grade 1. The rate may then be escalated to the 
original rate after 30  minutes, as tolerated.  
o Monitor for worsening condition.  
o For patients with Grade 2 infusion reactions despi[INVESTIGATOR_250896], 
corticosteroids (hydrocortisone 100 mg IV or equivalent) should be 
considered for acute management of the event. Dexamethasone 10 mg IV 
should be added to the premedication regimen for sub sequent dosing of 
margetuximab or trastuzumab at the discretion of the investigator.  
â€¢ Grade 3:  
o STOP THE INFUSION AND DISCONNECT THE INFUSION TUBING 
FROM THE PATIENT.  
o TO AVOID EXACERBATION OF INFUSION REACTION: DO NOT 
FLUSH THE TUBING â€“ ASPI[INVESTIGATOR_718690].  
o Administer diphenhydramine hydrochloride 25 -50 mg IV , hydrocortisone 
100 mg IV (or equivalent), and other medications/treatment as medically 
indicated. Higher doses of corticosteroids (i.e. dexamethasone 10 mg IV) 
may also be consid ered for acute management.  
o IV fluids, supplemental oxygen and bronchodilators should be considered 
as appropriate.  
o If symptoms have resolved to baseline within 6 hours, a rechallenge may 
be considered at the next scheduled dose, with a 50% reduction of infusion 
rate. In addition, patients should be premedicated for this rechallenge and 
for any subsequent doses of marge tuximab or trastuzumab, per the 
premedication guidelines in Section  [IP_ADDRESS]  and Section [IP_ADDRESS] . Patients 
who have a Grade 3 infusion reaction that does not resolve within 6 hours 
despi[INVESTIGATOR_718691].  
o Patients who experience a second Grade 3 infusion reaction at the time of 
rechallenge (irrespective of duration), should not receive further 
margetuximab or trastuzumab.  
o Report as an immediately reportable event (IRE) within 24 hours.  
o Report the event as an SAE, if appropriate.  
â€¢ Grade 4:  
o STOP THE INFUSION AND DISCONNECT THE INFUSION TUBING 
FROM THE PATIENT.  
Confidential Page 62 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o TO AVOID EXACERBATION OF INFUSION REACTION OR CRS: 
DO NOT FLUSH THE TUBING â€“ ASPI[INVESTIGATOR_718692].  
o Administer diphenhydramine hydrochloride 50 mg IV, dexa methasone 10 
mg IV (or more as considered appropriate), and other 
medications/treatment as medically indicated (e.g., an IL -6 receptor 
inhibitor or IL -6 inhibitor, an IL -2 receptor inhibitor, and/or an anti -TNFï¡ 
antibody).  
o Give epi[INVESTIGATOR_718693].  
o Support ventilation and blood pressure as indicated.  
o Discontinue the patient from further margetuximab or trastuzumab. 
(Patients may remain on study and continue to receive backbone 
chemotherapy if otherwise eligible.)  
o Report as an IRE wit hin 24 hours.  
o Report the event as an SAE.  
â€¢ Grade 5:  
o Report as an IRE within [ADDRESS_980596] be recorded. The start of infusion is â€œ0â€ 
time.  
6.7 Method of Assigning Patients to Treatment Groups   
This is a randomized, comparator -control study comparing margetuximab plus chemotherapy 
to trastuzumab plus chemotherapy. Patients enrolled in the study will be stratified according 
to the number of metastatic sites (â‰¤2, >2), number of line s of therapy in the metastatic setting 
(â‰¤2, >2), and choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).  
Patients who meet eligibility criteria for enrollment will be randomized using IxRS within 
3 days of Study Day 1 (Cycle 1 Day  1). A central randomization scheme using permuted 
blocks will be prepared and patients will be randomized 1:1 to margetuximab plus 
chemotherapy or trastuzumab plus chemotherapy. To minimize bias, chemotherapy will be 
selected by [CONTACT_718743].  
Confidential Page 63 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 6.7.1 Assignments in the Infusion Sub -Study   
The sub -study will start with a safety run -in group.   
Stage A1  
A cohort of about 9 patients will receiv e margetuximab as a 120 -minute infusion time in 
Cycle  1. Of the subjects completing Cycle 1, 6 patients will go on to receive a 60 -minute 
infusion time in Cycle 2 and beyond. Patients will be allocated to the reduced infusion time 
in order of their complet ion of Cycle 1 of treatment. Any remaining subjects in the cohort 
will continue to receive 120 -minute infusions. If 2 or more patients in Stage A1 experience a 
Grade 3 or higher IRR during Cycle 2, the infusion acceleration will be abandoned and 
enrollment  into the sub -study will be stopped. If no more than 1 of the 6 patients in Cycle 2 
of Stage A1 experiences a Grade 3 or above IRR, an additional 9 patients will be enrolled to 
Stage A2.  
Stage A2  
As in Stage A1, about 9 patients will receive margetuximab infused at 120 minutes in 
Cycle  1. Six patients, in the order of their completion of Cycle 1, will go on to receive a 
reduced infusion time of 30 minutes in Cycle 2 and beyond. Any remaining subjec ts in the 
cohort will continue to receive 120 -minute infusions. If no more than 1 of the 6 patients in 
Stage A2 experiences a Grade 3 or higher IRR during Cycle 2, the sub -study will enroll about 
60 patients in Stage B to receive margetuximab infused at 12 0 minutes in Cycle 1 followed 
by 30 minutes in Cycle 2 and beyond. If 2 or more patients in Stage A2 experience a Grade 3 
or higher IRR during Cycle 2 (30 -minute infusion), patients in Stage B will be infused 
according to the method in Stage A1.   
Stage B  
Patients will be assigned to the shortest infusion schedule based on the stoppi[INVESTIGATOR_718694] A1 and A2. In the absence of Grade [ADDRESS_980597] to treatment assignment. Independent assessment of PFS will be 
blinded. The infusion sub -study is not blinded.   
Confidential Page 64 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980598] to 
treatment assignment until primary PFS analysis. Following independent blinded PFS 
assessments to support the pri mary endpoint, the Sponsor was unblinded.     
6.9 Concomitant Therapy   
All concomitant medications and blood products administered during the patient â€™s 
participation in the study until t he End of Treatment visit (or [ADDRESS_980599] dose of 
study drug, whichever occurs later) must be recorded in the patient â€™s source documents and 
eCRF.  
The following rules concerning concurrent treatment(s) will apply in this study:  
â€¢ Any anti -neoplas tic therapi[INVESTIGATOR_718695], including but not 
limited to chemotherapy or other small molecules, biologics, or hormonal or 
radiotherapy, are not allowed.  
â€¢ Palliative radiotherapy is only allowed during the study treatment period for the 
treatment of bone lesions present at baseline. Radiation therapy to a new lesion 
would, per RECIST ( Appendix 8 ), qualify as progressive disease and necessitate 
discon tinuation of therapy. RECIST target lesions cannot be in the radiation field.  
â€¢ Patients may not receive other investigational drugs during the period of study 
treatment.  
â€¢ Vaccinations (with the exception of the annual inactivated influenza vaccine) are 
prohibited during study treatment.  
Patients may receive the following concurrent therapy:  
â€¢ Antiemetics, antidiarrheals, anticholinergics, antispasmodics, antipyretics, 
antihistamines, analgesics, antibiotics and other antimicrobials, histamine receptor 
antagoni sts or proton pump inhibitors, and other medications intended to treat 
symptoms or signs of disease.  
â€¢ Bisphosphonates or RANKL inhibitors provided such agents are approved in the 
local jurisdiction and treatment with the agent is begun before the start of s tudy 
treatment.  
â€¢ Use of granulocyte colony stimulating factor, granulocyte -macrophage colony 
stimulating factor or other growth factors is allowed per local practice.  
â€¢ Transfusions such as red blood cells and platelets are permitted to treat symptoms 
or sign s of anemia or thrombocytopenia and should be documented on the 
concomitant medication form.  
Confidential Page 65 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 6.10 Restrictions   
6.10.1  Prior Therapy   
Prior therapy restrictions are described in the inclusion/exclusion criteria specified in 
Section  5, Selection and Withdrawal of Patients.  
6.10.[ADDRESS_980600] a fluid intake of ï‚³ 2 liters on days associated with PK sampling, and that ECGs will be 
obtained pre -meal.  
6.10.3  Patient Activ ity Restrictions   
There are no restrictions on patient activities and no requirement for patient confinement 
during the study.  
6.11 Treatment Compliance   
Study drugs and backbone chemotherapy of the investigator â€™s choice will be administered by 
[CONTACT_718744]. Records of dose 
calculation, administration, and dosing regimen will be accurately maintained by [CONTACT_718745][INVESTIGATOR_014]. A site study monitor, designated by [CONTACT_1034], will review dose 
calculation, study drug administration and regimen, as well as medication accountability, 
during in vestigator site visits and at the completion of the study.  
6.12 Packaging and Labeling   
Chemotherapi[INVESTIGATOR_718696] d. 
Margetuximab will be supplied in single -use vials. Normal saline in 250 -mL IV bags will be 
obtained from the institution â€™s usual commercial supplier for the dilution of margetuximab 
solution for administration. All investigational products will be label led according to local 
regulatory health authority requirements.  Please see the Pharmacy Manual for detailed 
information about the packaging of margetuximab.  
Trastuzumab (marketed as HERCEPTINÂ® by [CONTACT_8229], Inc., A Member of the [COMPANY_002] 
Group, [ADDRESS_980601], So uth San Francisco, CA [ZIP_CODE] -4990; Made in Switzerland by 
F. Hoffmann -La [COMPANY_002] Ltd, Basel) is available as follows:  
Confidential Page 66 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ 440 mg vial is supplied in a multi -use vial containing 440 mg trastuzumab as a 
lyophilized sterile powder, under vacuum. Each carton contains  one vial 
trastuzumab and one vial (20 mL) of Bacteriostatic Water for Injection, USP, 
containing 1.1% benzyl alcohol as a preservative.  
â€¢ 150 mg vial is supplied in a single -dose vial containing 150 mg trastuzumab as a 
white lyophilized powder for preparati on of a concentrated solution for infusion. 
Each carton contains one vial trastuzumab 150 mg.  
Trastuzumab (marketed as HERCEPTINÂ®) will be provided in the commercial packaging 
taken from commercial supply. Trastuzumab will be appropriately labeled and will comply 
with local legal requirements, as required. Please see the Pharmacy Manual for detailed 
information about the packaging and labeling of the trastuzumab.  
Prepared margetuximab/trastuzumab IV bags should be labeled for administration per the 
institution â€™s guidelines.  
6.[ADDRESS_980602] be stored at 2âˆ’8Â°C (36âˆ’46 Â°F) prior to reconstitution.  
Vials containing margetuximab must be stored under refrigeration at 2Â° to 8Â°C (36Â° to 46Â°F) 
and must not be frozen, and in an appropriate lo cked room accessible only to the pharmacy 
personnel or a duly designated person. Protect margetuximab from light during storage. Do 
not shake margetuximab vials. To ensure compliance, temperature logs will be maintained. 
The refrigerator must have a digita l min/max thermometer or a continuous recording device.  
Administration should begin immediately after preparation of the margetuximab solution and 
no later than 6 hours after preparation when stored at 2Â° to 8Â°C.  
Accurate accounting of all study medication  must be maintained. The Investigator agrees to 
keep an inventory of all study drugs received and used during the course of the study using 
the institution â€™s drug accountability logs or logs provided by [CONTACT_134187]. Drug disposition 
records must be kept in  compliance with applicable guidelines and regulations.  
A Pharmacy Manual will be provided to the investigator or designee. When the study is 
completed, copi[INVESTIGATOR_718697]. 
Original drug accounta bility records must be maintained with study -related documentation 
for inspection by [CONTACT_265640]. Additional details regarding storage, handling, and 
accountability can be found in the Pharmacy Manual.  
6.[ADDRESS_980603] be 
returned to MacroGenics or its representative, unless the site has received written 
Confidential Page 67 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980604] ensure 
arrangements are made for proper disposal and that appropriate records of disposal are 
documented and maintained and copi[INVESTIGATOR_480305].  
Confidential Page 68 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 7 STUDY PROCEDURES   
This section provides a general description of the procedures and assessments associated with 
this study. The Schedule of Events ( Appendix 1 ) details the schedule of assessments by 
[CONTACT_15449].  
7.1 Informed Consent   
The Investigator is responsible for ensuring that the patient or his/her legal representative 
provides informed consent prior to performing any study -related assessments, evaluations, or 
procedures. Informed consent for this study must be provided by [CONTACT_718746] (IR B)/Independent Ethics Committee (IEC) -approved informed consent 
document (Consent for Study Participation). A copy of the signed informed consent 
document must be provided to the patient and the original maintained according to 
institutional procedures. Th e patient â€™s medical records will include documentation of the 
informed consent process.  
7.[ADDRESS_980605] 60 days and any significant prior medical 
conditions (e.g., hospi[INVESTIGATOR_602], surgeries, prior cancer history) should be collected. Any 
untoward event that occurs during the Screening period (pri or to first dose of any study drug) 
should be recorded as concurrent medical history and not as an AE unless it is due to a 
protocol -related procedure. Any untoward event that occurs following the first dose of study 
drug (margetuximab or trastuzumab) shou ld be collected as an AE.  
7.3 Prior and Concomitant Medications   
All concomitant medications and blood products administered during the patient â€™s 
participation in the study until the En d of Treatment visit (or [ADDRESS_980606] dose of 
study drug, whichever occurs later) must be recorded in the source document and on the 
eCRF. To the extent possible, patients who receive anti -cancer agents, either approved or 
experimental, after rem oval from study treatment should have this information recorded in 
the eCRF, including the name [CONTACT_718775].  
Prior courses of chemotherapy will be documented in the medical records and on the eCRF.  
7.4 Physical Examination   
The investigator will perform physical examinations of all patients (see Appendix 1 ). 
Physical examinations will include height (screening only); weight; and examination of skin, 
HEENT (head, eyes, ears, nose, and throat), lymph nodes, heart, chest, lungs, abdomen, 
extremities, and the neurologic system. Interval physical exams (sympto m-directed) noting 
any changes from baseline will be recorded after the initial exam.  
Confidential Page 69 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Physical exams will be performed at Screening, Day 1 of each treatment cycle, and on at the 
End of Treatment visit. Weight will be measured during Screening, Cycle 1 Day 1, Day 1 of 
each subsequent Odd treatment cycle, and at the End of Treatment visit.  
7.5 Vital Signs   
Vital sign evaluations will include blood pressure, heart rate, respi[INVESTIGATOR_697], an d 
temperature. Vital signs will be collected as indicated in Schedule of Events ( Appendix 1 ).  
Vital signs will be performed at Screening. On the first  dose of study treatment (Cycle 1, 
Day 1), vital signs will be taken at the following time points:  
â€¢ Prior to initiation of margetuximab or trastuzumab infusion  
â€¢ at end of margetuximab or trastuzumab infusion, and  
â€¢ at 60 minutes (Â± 10 minutes) after infusion  with margetuximab or trastuzumab.  
For subsequent cycles, vital signs will be collected only at the start and end of margetuximab 
or trastuzumab infusion as indicated in Appendix [ADDRESS_980607] of care for patients who are receiving a HER2 -targeted 
agent  (margetuximab or trastuzumab) . Local labs with units and normal ranges will be 
reported only as AEs, if clinically significant, or within Serious Adverse Event reporting. 
Clinically significant labs, in the Investigator â€™s opi[INVESTIGATOR_1649], mean a disease and/or organ toxicity 
that is new, has worsened from baseline, or requires additional active management.   
MacroGenics or its designee will provide the following blood sampling supplies for central 
lab ADA testing only: polypropylene transport tubes, labels, and shippi[INVESTIGATOR_149222]. Serum 
tubes should be labeled with the Patient ID and date of sampling. The Investigator will 
maintain a log with the same  data.  
Confidential Page 70 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980608] be appropriately prepared, divided if appropriate, frozen, and shipped (while 
often retaining certain replicate samples at the site) according to the instructions in the 
Laboratory Manual.  
Please consult the Laboratory Manual for spec ific directions on the collection and processing 
of samples.  
7.[ADDRESS_980609], all patients will be requested to 
provide tissue samples for protocol -defined sensitivity analysis. Second, if a patient â€™s 
previous HER2 testing does not meet protocol requirements (i.e., not per formed at an 
accredited reference laboratory), or if previous results are not available, a sample is required 
for central HER2 testing to determine study eligibility. Samples can be from the patient â€™s 
original biopsy or resection or be obtained from subseq uent samples, but the most recently 
available specimen should be obtained. Samples can be from either primary or metastatic 
tissue. A testing report of a patient â€™s most recently available HER2+ specimen is acceptable 
to determine patient study eligibility provided the testing was performed at an accredited 
laboratory. Details of sample acquisition requirements are provided in the Laboratory 
Manual.  
7.[ADDRESS_980610] of care.  Findings will be reported only as AEs, if clinically 
significant  in the view of the Investigator , or within Serious Adverse Event reporting.  
7.8.2 Multigated Acquisition Ventriculography Scanning and 
Echocardiography   
MUGA scans or echocardiograms will be o btained and analyzed locally in all patients 
according to the Schedule of Events ( Appendix 1 ). The same modality should be used 
throughout the study f or any given patient. All MUGA scans or echocardiography performed 
will be evaluated for the change in LVEF from baseline.  
Confidential Page 71 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 7.9 Adverse Events   
7.9.1 Criteria for Evaluation   
â€¢ Safety assessment will be based on the evaluation of AEs from the time of 
initiation of any study therapy through the End of Treatment visit (or [ADDRESS_980611] dose of study drug, whichever  occurs later) and will be determined based 
on signs, symptoms, physical examination findings and/or laboratory test results 
from enrolled patients as appropriate. Local labs with units and normal ranges 
will be reported only as AEs, if clinically signific ant, or within Serious Adverse 
Event reporting. Clinically significant labs, in the Investigator â€™s opi[INVESTIGATOR_1649], mean a 
disease and/or organ toxicity that is new, has worsened from baseline, or requires 
additional active management.    
â€¢ All AEs (related to the pr otocol or not) will be collected from the time the patient 
receives the first dose of any study medication.  
â€¢ AEs reported between the time the patient signed the informed consent and the 
administration of the first dose of any study medication will be captu red as 
concurrent medical history unless due to a protocol -related procedure.  
â€¢ AE and SAE recording will continue until the End of Treatment visit is performed 
(or [ADDRESS_980612] dose of study drug, whichever is later).  
â€¢ SAEs considered related to study drug may be reported at any time, even after the 
patient â€™s final visit.  
â€¢ Progression of the underlying neoplasm resulting in hospi[INVESTIGATOR_30059] 
(e.g.,  patient hospi[INVESTIGATOR_80529], or dies from disease progression only, without any 
other SAE) will b e documented as an anti -tumor activity outcome and not as an 
SAE. If an SAE occurs in a patient and it is unclear whether the event is related to 
progressive disease, the SAE should be reported  
7.9.2 Definitions   
[IP_ADDRESS]  Adverse Event   
An AE is  any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does  not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal product, wheth er or not considered related to the medicinal product.  
An AE will also be considered to be any untoward effect of a study -related procedure, 
conducted after signed informed consent and prior to study drug administration.  
Confidential Page 72 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 [IP_ADDRESS]  Adverse Drug Reaction   
Adverse drug reaction (ADR) is a noxious and unintended response to the medicinal product 
related to any dose. As used herein, the phrase â€œresponse to a medicinal product â€ means that 
a causal r elationship between a medicinal product and an AE is at least a reasonable 
possibility (i.e., the relationship cannot be ruled out).  
[IP_ADDRESS]  Adverse Event of Special Interest   
An adverse ev ent of special interest (AESI) is an event of scientific and medical interest or 
concern to the Sponsor â€™s product or program, for which ongoing monitoring and rapid 
communication to the Sponsor of such events could be appropriate. An AESI may be a 
serious or non -serious AE, which may require further investigation to fully characterize and 
understand it.  
[IP_ADDRESS]  Treatment Emergent Adverse Event   
An event that is temporally associated with adm inistration of study product is defined as a 
treatment emergent adverse event (TEAE). Events meeting this definition will be those 
occurring during or after administration of the first dose of study drug. Events that existed 
before the first administration  of study drug and then increased in severity during or after the 
first administration of study product will also be considered treatment emergent. Such events 
will be captured on the eCRF as new events, with the onset date as the date of the increase in 
severity.  
[IP_ADDRESS]  Product Quality Issue   
Product quality issues are defined as abnormalities that may be introduced during the 
manufacturing/labelling, packaging, shippi[INVESTIGATOR_007], handling or stor age of the products. They may 
occur with or without clinical consequences.  
[IP_ADDRESS]  Serious Adverse Events   
An SAE is any untoward medical occurrence that results in any of the following ou tcomes:  
â€¢ Death  
â€¢ Life-threatening (immediate risk of death)  
â€¢ Inpatient hospi[INVESTIGATOR_1081] (even if the 
event is Grade 1) unless for an elective procedure unrelated to the study or 
underlying disease.  
â€¢ Persistent or signi ficant disability or incapacity (disability is defined as a 
substantial disruption of a person â€™s ability to conduct normal life functions).  
â€¢ Congenital anomaly/birth defect  
Confidential Page 73 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Important medical events that may not result in death, be life -threatening, or 
requi re hospi[INVESTIGATOR_37347], based upon appropriate 
medical judgment, they may jeopardize the patient and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical eve nts include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home; blood dyscrasias or 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of 
drug dependency or drug abuse.  
[IP_ADDRESS]  Immediately Reportable Ev ent (IRE)   
IREs are events that must be reported immediately to MacroGenics Product Safety, or 
assigned designee, within 24  hours of being identified. IREs include but are not limit ed to:  
â€¢ SAEs  
â€¢ Pregnancy in a study patient or partner of a study patient. (Note: If the female 
partner of a male patient becomes pregnant, the partner must be requested to 
complete a Pregnant Partner Consent Form so that pregnant partner, fetal and/or 
newbo rn information can be collected.) Upon confirmation of serum pregnancy 
testing, the patient will be followed for the outcome of pregnancy. All live 
newborns will be followed six months after the birth, and all necessary 
information will be collected to ass ess the effects of study drug on the newborn. If 
necessary, the follow -up period will be extended for the newborn.  
â€¢ AESI requiring immediate reporting include (see Section 7.9.3  below):  
o Grade 3 or greater infusion -related reactions or Cytokine Release 
Syndrome (see  Section  6.6.1 ) 
o Left ventricular dysfunction leading to dose delay or discontinuation (see 
Section  7.8) 
â€¢ Administration of a dose significantly greater than the planned dose of any study 
agent (margetuximab, trastuzumab, or chemotherapy) resulting in an event of 
clinical consequence.  
â€¢ Any suspected transmission of an infectious agent via study drug (marget uximab 
or trastuzumab)  
â€¢ Withdrawal of the patient from study drug (margetuximab or trastuzumab) 
administration for any reason, including AE, other than disease progression.  
â€¢ Any abnormal liver enzyme laboratory value meeting criteria for potential Hy â€™s 
Law, defined as AST and ALT values of â‰¥ 3.0 Ã— ULN with total bilirubin level of 
â‰¥ 2.0 Ã— ULN without an alternate etiology for the abnormal values.  
â€¢ Product Quality Issue with clinical consequences.  
In those cases, in which the IRE is considered related to study drug and the event of 
sufficient clinical concern to warrant study drug discontinuation, the study drug may be 
Confidential Page 74 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 discontinued and the patient will continue participation in the study for observational safety 
and analysis (except for cases where the patient i s withdrawn from the study by [CONTACT_1275]). At any time after completion of the study, if an investigator becomes aware of 
an SAE that is suspected related to study drug, the investigator should report the event to 
MacroGenics Product Safety immediate ly. 
A physician â€™s assessment of the event is expected to be completed in conjunction with 
reporting an IRE to MacroGenics Product Safety.  
7.9.[ADDRESS_980613]   
AESI will include the following:  
â€¢ All infusion -related reactions; only Grade 3 or greater will be reported as 
Immediate Reportable Events.  
â€¢ Left ventricular dysfunction requiring delay or cessation of margetuximab or 
trastuzumab administration  
7.9.[ADDRESS_980614] be immediately reported to the sponso r/designee as an IRE. The sponsor will 
collect the information and evaluate accordingly to protect the safety of the study patients.  
7.9.[ADDRESS_980615] be made according to the criteria described below.  
[IP_ADDRESS]  Assessment of Seriousn ess  
Event seriousness  will be determined according to the definition of an SAE in 
Section  [IP_ADDRESS] . Seriousness serves as a guide for defining regulatory reporting obligations 
for AEs.  
[IP_ADDRESS]  Assessment of Severity   
Event severity  will be assigned according to  the Investigator â€™s assessment using the Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (for described events and 
syndromes). For events not contained in CTCAE, the investigator may assign severity 
according to the following scale:  
â€¢ Grade 1= Mild  
â€¢ Grade 2 = Moderate AE  
Confidential Page 75 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Grade 3 = Severe AE  
â€¢ Grade 4 = Life -threatening or disabling AE  
â€¢ Grade 5 = Death related to AE  
Any event or laboratory value judged as Grade 4 severity should be separately evaluated to 
determine whether it also meets the SAE  criterion of â€œimmediately life threatening. â€ (See 
Section [IP_ADDRESS] ). 
Note: Severity is not synonymous with seriousness. The term â€œsevere â€ is often used to 
describe the intensity (severity) of a specific event. The event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as 
â€œserious, â€ which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a patient's life or functioning.  
[IP_ADDRESS]  Assessment of Causalit y  
The Investigator is required to provide an assessment of causality or relationship of AEs to 
the study drug (margetuximab or trastuzumab) based on 1) temporal relationship of the  event 
to the administration of study drug, 2) whether an alternative etiology has been identified, 
and 3) biological plausibility. If, in investigator â€™s opi[INVESTIGATOR_718698], the 
investigator is also required to make causality relationship with the chemotherapy based on 
the product label for that specific country/region. The causality assessment categories that 
will be used for this study are describe d below.  
Causality assessments that are considered not related  to study drug :  
None:  The event is related to an etiology other than the study drug (the alternative 
etiology should be documented in the patient â€™s medical record).  
Unlikely:  The event is unlik ely to be related to the study drug and likely to be related to 
factors other than study drug.  
If an SAE is considered "unlikely" or "unrelated" to study drug, the Investigator should offer 
his/her clinical opi[INVESTIGATOR_305638](s), agent(s), or proces s(es) were the likely causative 
mechanism for the event.  
Causality assessments that are considered related  to study drug:  
Possible:  There is an association between the event and the administration of the study 
drug and there is a plausible mechanism for the event to be related to study 
drug; but there may also be alternative etiology, such as characteristics of the 
patient â€™s clinical status or underlying disease.  
Probable:  There is an association between the event and the administration of study 
drug, a p lausible mechanism for the event to be related to the study drug and 
Confidential Page 76 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 the event could not be reasonably explained by [CONTACT_718747] â€™s clinical status or an alternative etiology is not apparent.  
Definite:  There is an association between  the event and the administration of study 
drug; a plausible mechanism for the event to be related to the study drug and 
causes other than the study drug has been ruled out and/or the event re -
appeared on re -exposure to the study drug.  
[IP_ADDRESS]  Assessment of Expect edness   
As part of the regulatory reporting requirements, the Sponsor must perform an assessment of 
expectedness (expected/unexpected from the perspective of previously observed, not on the 
basis of what might be anticipated from the pharmacological properties of a medicinal 
product) for AEs. AEs will be considered unexpected if the nature, seriousness, severity or 
outcome of the reaction(s) is not consistent with the reference information (e.g., the Adverse 
Drug Reaction section of the Investigator â€™s Brochure) for  the study product.  
7.9.[ADDRESS_980616] dose 
of study drug, whichever occurs later. If a patient experiences an AE after the informed 
consent document  is signed and prior to treatment with study drug, it should be captured as 
medical history; however, if the investigator believes the AE may have been caused by a 
protocol -related procedure it will be recorded as a protocol -related AE and entered onto the  
eCRF.  
To identify the occurrence of any new medical complaints or worsening of previous 
complaints, non -leading questioning should be posed to the patient.  
Events related to disease progression/worsening of underlying disease (including those with a 
fatal outcome) will be collected as efficacy endpoints, and not documented as AEs/SAEs. 
These events may not qualify for expedited reporting to regulatory agencies if consistent with 
expected rates of progression for the underlying disease. However, if an SAE o ccurs in a 
patient and it is unclear if the event is due to progressive disease, the SAE should be 
reported.  
If a patient reports signs and symptoms that represent a single medical syndrome, diagnosis, 
or concept, the syndrome/diagnosis/concept should be d ocumented (e.g., cough, runny nose, 
fever = upper respi[INVESTIGATOR_1092]) in the eCRF.  
The Investigator must follow all SAEs until resolution and record the date of resolution. 
Resolution of an event is defined as the return to pre -treatment status or  stabilization of the 
condition with the expectation that it will remain chronic.  
Confidential Page 77 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 [IP_ADDRESS]  Changes in Clinical Laboratory Parameters   
Safety laboratory assessments, whether performed locall y at the discretion of the investigator 
or as the result of central testing will be evaluated by [CONTACT_718748]. 
The Investigator is responsible for reviewing the results of all laboratory tests as they become 
available. Clinical ly important discrepancies between local and central testing results should 
be addressed as appropriate. Laboratory tests will be graded according to CTCAE v 4.03.  
Laboratory values that fall outside of a clinically accepted reference range or values that  
differ significantly from previous values must be evaluated by [CONTACT_718749]. The investigator may repeat the laboratory test or request additional tests to 
verify the results of the original laboratory tests. If the Investiga tor determines the laboratory 
value is an abnormal change from baseline and is of clinical significance for that patient, it is 
considered an AE.  
Generally, Grade 1 laboratory findings need not be reported as AEs unless clinically 
significant. The Investi gator will evaluate laboratory findings of â‰¥ Grade 2 or higher 
classification to determine their clinical significance and if an AE has occurred. Consistent 
with the CTCAE designation of Grade 3 events as severe or medically significant and 
Grade  4 events as life -threatening, Grade 3 and Grade 4 laboratory findings should be 
reported as AEs or SAEs, as appropriate. Grade 2 laboratory findings may be reported as AEs 
if, in the opi[INVESTIGATOR_689], the event exhibits clinical significance. If clinical ly 
relevant abnormal laboratory values are associated with clinical symptom(s), or consistent 
with a diagnosis, the diagnosis should be reported as the AE (e.g., hemoglobin 9 g/dL in an 
adult female = anemia). If these clinically relevant abnormal laborato ry values do not result 
in a diagnosis, the test result or finding should be reported as the AE assuming that it does 
not represent a laboratory error. Repeat testing may be indicated. Such laboratory values 
should generally be recorded as â€œincreased â€ or â€œdecreased â€ (e.g., change from baseline 
hemoglobin of 13 g/dL to 11g/dL= hemoglobin decreased). Investigators are required to 
report any abnormal liver enzyme laboratory values meeting the criteria for potential Hy â€™s 
Law as described in Section [IP_ADDRESS]  for immediately reportable event.)  
7.9.[ADDRESS_980617] be reported immediately  (within 
24 hours of identification ) to MacroGenics Product Safety or MacroGenics designee 
responsible for Product Safety (e.g., contract research organization [CRO]) by [CONTACT_718750](s)/forms. Throughout the study, the Investigator must ensu re 
documentation of all AEs in the eCRF in a timely manner  
In case of patient or patient partner pregnancy, the MacroGenics Pregnancy Exposure eCRF 
must also be completed per Study Procedures. The Investigator must attempt to follow the 
pregnancy to term o r termination in order to report on outcome and health status of mother 
and child.  
Confidential Page 78 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 7.9.8 Emergency Unblinding   
Not applicable.  
7.10 Efficacy, Pharmacokinetic, Pharmacodynamic Assessments   
7.10.1  Efficacy Assessments   
[IP_ADDRESS]  Radiologic Evaluation   
Tumor assessments will be obtained at Screening using CT (with contrast) and/or MRI scans 
of the chest, abdomen and pelvis at time intervals as specified in Appendix 1  (Schedule of 
Events). Assessment of skin lesions identified at screening may be made by [CONTACT_718751] a reference ruler or by [CONTACT_718715] 1.[ADDRESS_980618] 1.1 criteria. 
Investigators will assess tumor response(s) for determinat ion of suitability for continued 
therapy and the secondary endpoint of Investigator Assessed PFS. All patients who have CR, 
PR, SD, or non -evaluable as their local radiological assessment are eligible for further 
therapy. Non -radiological evidence of disea se progression should be clearly documented in 
the eCRF.  
With Protocol Amendment 4, central review of radiographic images is discontinued. 
Investigator -assessed PFS and ORR will continue to be measured according to the protocol 
schedule.   
All patients wi ll have a bone scan performed at baseline and then as clinically indicated 
during the study for the assessment of bone metastasis. Patients with bone only disease 
should be followed at regular intervals by [CONTACT_718752]. Patients with a history of treated brain metastasis who are otherwise eligible 
must have a baseline brain MRI or CT within 4 weeks prior to randomization and as 
clinically indicated thereafter.  
Tumor evaluations will be performed at base line (prior to treatment) and every [ADDRESS_980619] 24 weeks of treatment; thereafter, beginning with Cycle 9, tumor evaluations will be 
performed every [ADDRESS_980620] the date of the 
documented progression per that new tumor assessment schedule.  
It is recommended that any accumulation of fluid (pleural or pericardial effusion and/or 
ascites) that is new or increased in size from baseline, and, when appropriate, any new 
lesions noted by [CONTACT_485622], be assessed by [CONTACT_718753]. 
Confidential Page 79 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Progression can only be documented from new or increasing fluid collections if cytology 
confi rms that the fluid is malignant.  
[IP_ADDRESS]  Digital Imaging of Skin Lesions   
When applicable, digital images of skin lesions will be obtained on the same schedule for 
radiographic evaluations .  
[IP_ADDRESS]  Overall Survival   
Patients who are discontinued from study treatment will be followed up for their survival 
status at 3 -month intervals (Â± one week) until withdrawal of informed consent, loss to follow 
up, or the end of study is reached. Procedures for patients lost to follow -up are described in 
Section 5.4.2 .  
7.10.2  Immunogenicit y  
Immunogenicity evaluations will be performed only as indicated in the Schedule of Events 
(Appendix 1 ) for patients receiving margetuximab only. With Protocol Amendment 4, 
collection of samples for anti -drug antibody (ADA) assay will be decreased in frequency 
from once every 6 weeks (i.e., every 2 treatment cycles) to once every 12 weeks (i.e., every 4 
treatment cycles), consistent with radiographi c evaluation. ADA samples will continue to be 
collected at end of treatment and during follow -up.  
The generation of ADA directed against margetuximab will be assayed using enzyme -linked 
immunosorbent assay (ELISA). The proportion of patients who are negat ive for ADA at 
baseline and become positive in this assay will be reported, as will the proportion of patients 
who are negative at baseline and remain negative and those who have positive ADA at 
baseline that increases or decreases in titer over the course  of treatment. Samples with 
positive ADA will be evaluated for neutralizing activity. Immunogenicity samples from all 
patients may be retained for future evaluations of neutralizing antibodies as allowed per local 
requirements/regulations.  
Blood samples wi ll be collected from the arm contralateral to the site of IV infusion. If an 
indwelling catheter is used, the fluid in the catheter will be removed and discarded prior to 
the collection of blood sample for ADA assessment.  
Procedures for the acquisition, ha ndling and processing of ADA specimens are provided in 
the Laboratory Manual.  
7.10.3  Pharmacokinetics   
With Protocol Amendment 4, PK sample collection will be discontinued  for patients wh o are 
still receiving study treatment .   
Confidential Page 80 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 7.10.4  Biomarkers   
Specimens will be collected for the determination of Fc receptor genotype (CD16A, CD32A, 
and CD32B), as allowable per local requ irements. Procedures for the acquisition, handling 
and processing of biomarker specimens are provided in the Laboratory Manual.  
7.11 Health -Related Quality of Life   
HRQoL will be evalua ted using the EQ -5D-5L and NFBSI -16 (10, 16). The NFBSI -[ADDRESS_980621] 
cancer â€“related symptoms ( Appendix 5 ). The primary focus for analysis of NFBSI -16 
HRQoL scale will be on the FBSI -16 score. EQ -5D-5L (Appendix 6 ) and NFBSI -16 data 
will be collected at baseline (prior to therapy administration on Cycle 1 Day 1), Day 1 of 
each Odd cycle thereafter, and at the End of Treatment visit. Patients participating in the 
infusion sub -study are exempt from completing the HRQoL assessments.  
HRQoL data collection will continue until notification of discontinuation by [CONTACT_157248].  
7.12 Sample Retention and Further Testing   
Samples acquired for protocol specified assays retained for study purposes 
(analysis/re -analysis) may be retained up to [ADDRESS_980622] approval of a marketing 
application in an International Conference on Harmonisation (ICH) region and until there are 
no pendi ng or contemplated marketing applications in an ICH region or until at least [ADDRESS_980623]. If allowed per local regulation/requirements, and patients consent to the  use of their 
PK, ADA, and HER2 study samples for non -study research purposes, these samples may also 
be used for future research use (including assay development/optimization) and may be 
retained up to [ADDRESS_980624] bridging ELISAs will be carried out in the Sponsor â€™s designated central 
laboratory to characterize the immunogenicity of margetuximab. Analysis of PK data will be 
Confidential Page 81 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980625] software. Population PK  modeling will be performed and 
an appropriate model and model parameters will be described.  
Confidential Page 82 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980626] -of-care should be performed 
prior to obtaining informed consent from the patient. During the screen ing period, the 
Principal Investigator (PI) should review inclusion/exclusion criteria and verify that all 
assessments were performed within the protocol -specified windows and the patient is still 
eligible for the study. Only those patients who meet all in clusion/exclusion criteria specified 
in Section  5.1 and Section  5.2 will be entered into this study.  
8.1.1 Up to 4 Weeks Prior to Randomizat ion  
The following evaluations are to be performed within 28 days (4 weeks) prior to 
randomization in this study.  
â€¢ Perform radiographic tumor evaluations ( Section [IP_ADDRESS] ) and digital imaging of 
skin lesions  Section [IP_ADDRESS] : 
o CT (with contrast) or MRI of chest, abdomen, and pelvis â€“ all patients  
o Bone scan â€“ all patients  
o CT or MRI of brain â€“ patients with known, treated brain metastases or 
symptoms of brain metastases  
o Digital images of skin lesions â€“ all applicable patients . 
 
The above tumor assessments will be considered baseline  (Section 7.10.1 .1). Tumor 
assessments performed as standard of care prior to stud y registration may be considered 
baseline and need not be repeated if completed within 4 weeks prior to randomization.  
â€¢ Perform MUGA scan or echocardiogram determination of LVEF ( Section 7.8.2 ). 
A previous evaluation may be considered baseline if completed within 4 weeks 
prior to randomization.  
â€¢ Request archival pathological material from primary or metastatic site for central 
HER2 testing (formalin -fixed paraffin embedded [FPPE] tissue block or 
5 unstained slides). The most recent tumor biopsy from the patient should be 
obtained when available. If previous HER2 testing was performed at a reference 
laboratory and meets ASCO/CAP guidelines, the biopsy sp ecimen is required only 
for efficacy sensitivity analyses, and the results are not required prior to 
randomization. If HER2 test results are not available from previous testing, this 
specimen may be used for eligibility purposes.  
Confidential Page 83 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Procedures for the acquis ition, handling and processing of specimens for central 
HER2 testing are provided in the Laboratory Manual.  
â€¢ Obtain documentation of HER2 status from most recent result available.  
â€¢ Perform toxicity review and AE assessment (with grading based on CTCAE, 
Version 4.03) ( Section 7.9), and concomitant medications ( Section 7.3). 
 
8.1.2 Up to Two Weeks Prior to Randomization   
The following evaluations are to be performed within 14 days (2 weeks) pr ior to 
randomization. Results of central laboratory and ECG evaluations must be reviewed and 
patient eligibility confirmed prior to randomization to study drug.  
â€¢ Conduct medical history ( Section 7.2). 
â€¢ Conduct physical examination (PE), including height and weight ( Section 7.4). 
â€¢ Take vital signs ( Section 7.5). 
â€¢ Evaluate ECOG performance status ( Appendix 4 ). 
â€¢ Obtain ECG, standard 12 -lead (in triplicate) ( Section 7.8.1 ). 
â€¢ Obtain specimen for complete blood count (CBC) with differential and platelet 
count.  
â€¢ Obtain specimen for chemistry panel.  
â€¢ Perform serum ï¢-hCG pregnancy test for women of childbearing potential.  
â€¢ Perform toxicity review an d AE assessment (with grading based on CTCAE, 
Version  4.03) ( Section 7.9), and concomitant medications ( Section 7.3). 
 
8.[ADDRESS_980627] be randomized t hrough an IxRS and dosed within 72 hours of 
randomization, with dosing preferably on the same day as randomization. Prior to 
randomization, the PI [INVESTIGATOR_718699]/exclusion criteria and verify that all screening 
assessments were performed within th e protocol -specified screening windows and the patient 
is still eligible for the study. The date that informed consent is given is the first day of 
Screening.  
The following information should be provided during registration:  
â€¢ Patient Identification (ID) Nu mber  
â€¢ Date of signed informed consent  
â€¢ Number of lines of therapy in the metastatic setting (â‰¤2, >2)  
Confidential Page 84 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Number of metastatic sites (â‰¤ 2, > 2)  
â€¢ Choice of backbone chemotherapy (capecitabine, eribulin, gemcitabine, or 
vinorelbine).  
8.2.1 Registration for the Infusion Su b-Study   
â€¢ Patient Identification (ID) Number  
â€¢ Date of signed informed consent . 
8.3 Cycle 1   
8.3.1 Cycle 1 Day 1   
[IP_ADDRESS]  Prior to First Dose of Study Treatment on Cycle 1 Day 1   
For some assessments, if the corresponding screening assessment was performed within the 
specified number of days prior to initiating study treatment on Cycle 1 Day1, the assessment 
need not be repeated prior to dosing on Cycle 1 Day 1. When this is the ca se, details are 
provided below.  
â€¢ Clinical assessments:  
o Review medical history ( Section 7.2) 
o Conduct PE, including weight ( Section 7.4) 
o Administer the NFBSI -16 and EQ -5D-5L questionnaire ( Section  7.11; not 
required for infusion sub -study)  
o Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3). 
â€¢ Laboratory assessments for loca l laboratory testing:  
o Perform local urine or serum pregnancy test for women of childbearing 
potential. Pregnancy test must be negative to administer chemotherapy or 
study drug.  
o Local chemistry and hematology should be performed prior to dosing for 
all cycl es as needed if the results of central testing are not yet available.  
â€¢ Laboratory assessments for central laboratory testing:  
o Obtain specimen for CBC with differential and platelet count  
ï‚§ Not required if the Screening CBC with differential and platelet 
coun t (Section  8.1.2 ) was performed within 3 days of dosing with 
study treatment  
o Obtain specimen for chemistry panel  
Confidential Page 85 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Not required if the Screening chemistry panel ( Section 8.1.2 ) was 
performed within 3  days of dosing with study treatment  
o Obtain specimen for PT, aPTT  
o Obtain specimen for urinalysis  
o Obtain specimen for PK sampling (margetuximab arm only, Section  
7.10.3 ) 
o Obtain specimen for Fc Î³R genotypi[INVESTIGATOR_007] â€“ specimen must be obtained at the 
Cycle  1 Day 1 visit  
o Obtain specimen for ADA (margetuximab arm only, Section 7.10.2 ).  
 
[IP_ADDRESS]  During and Following Administration of Study Treatment   
The following evaluations should be performed only after ALL pre -treatment evaluations 
described in Section [IP_ADDRESS]  have been completed:  
â€¢ Administer chosen chemotherapy â€“ per specific chemotherapy regimen (see 
Table  4) according to institutional guidelines, including guidelines for 
premedications.  
â€¢ Prior to initiation of margetuximab or trastuzumab infusion:  
o Obtain ECG (standard 12 -lead in triplicate,  Section 7.8.1 )  
o Take vital signs ( Section 7.5) 
â€¢ Administer margetuximab or trastuzumab ( Section 6.3) 
â€¢ Following completion of margetuximab or trastuzumab infusion:  
o Obtain specimen for PK sampling  (margetuximab arm only, 
Section  7.10.3 )  
o Obtain ECG (standard 12 -lead in triplicate, Section 7.8.1 )  
o Take vital signs ( Section 7.5): 
ï‚§ At end of margetuximab or trastuzumab infusion,  
ï‚§ At 60 minutes after end of margetuximab or trastuzumab infusion . 
 
8.3.2 Cycle 1 Day 8   
If the patient is required to return to the study site on Cycle 1 Day 8 for chemotherapy 
administration, a toxicity review and AE assessment ( Section 7.9), and review of 
concomitant medications ( Section  7.3) should also be performed. Lo cal laboratory 
evaluations should be performed as needed according to local practice and institutional 
guidelines.  
Confidential Page 86 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 8.4 Study Evaluations for Even Cycles (e.g., Cycles 2, 4, 6, 8)   
Procedures required each visit during Even treatment cycles are described below (see also 
Schedule of Events in Appendix 1 ). All procedures should be performed on the scheduled 
study day with exception of MUGA/ECHO/radiology assessments, which may be performed 
within 14 days pre -dose (chemotherapy and study drug), unless otherwise specified. Day 8 
procedures are to be performed only if patients are requ ired to return to the study site for 
chemotherapy administration.  
8.4.1 Even Cycle Treatment Visits: Day 1   
[IP_ADDRESS]  Prior to Administration of Study Treatments   
â€¢ Clinical assessments:  
o Conduct PE ( Section 7.4)  
o Take vital signs ( Section 7.5)  
o Obtain ECG according to institutional standard of care, as clinical ly 
indicated   
o Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3).  
â€¢ Laboratory assessments f or local laboratory testing  
o Perform serum or urine pregnancy test for women of childbearing 
potential. Pregnancy test must be negative to administer chemotherapy or 
study drug.  
o Chemistry and/or hematology test(s) should be performed locally 
according to i nstitutional standard of care prior to dosing for all cycles as 
needed .  
[IP_ADDRESS]  Administration of Study Treatments   
â€¢ Administer chosen chemotherapy â€“ per specific chemotherapy regimen (see 
Table  4) 
â€¢ Administer margetuximab or trastuzumab . 
[IP_ADDRESS]  Following Administration of Study Treatments   
â€¢ Laboratory assessments for central laboratory testing  
o Obtain specimen for PK sampling (margetuximab arm only, 
Section  7.10.3 )  
ï‚§ Cycles 2 â€“ 6 only 
â€¢ Clinical assessments:  
Confidential Page 87 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Take vital signs ( Section 7.5)  
o Obtain ECG according to institutional standard of care as  clinically 
indicated .  
8.4.2 Even Cycle Treatment Visits: Day 8 (as needed)   
â€¢ Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3)  
â€¢ Administer chosen chemotherapy â€“ per specific chemotherapy regimen (see 
Table  4).  
 
8.5 Study Evaluations for Odd Cycles >1 (e.g., Cycles 3, 5, 7)   
Procedures required each visit during Odd treatment cycles are described below (see also 
Schedule of Event in Appendix 1 ). All procedures should be performed on the scheduled 
study day with exception of  central laboratory assessments, which may be performed within 
3 days pre -dose (chemotherapy and study drug) and MUGA/ECHO/radiology assessments, 
which may be performed within 14 days pre -dose (chemotherapy and study drug), unless 
otherwise specified. Day 8 procedures are to be performed only if patients are required to 
return to the study site for chemotherapy administration.  
8.5.1 Odd Cycle Treatment Visits: Day 1   
[IP_ADDRESS]  Prior to Administrati on of Study Treatments   
â€¢ Clinical assessments:  
o Conduct PE, including weight ( Section 7.4)  
o Take vital signs ( Section 7.5) 
o Obtain ECG according to institutional standard of care as clinically 
indicated   
o Obtain MUGA scan or echocardiogram for determination of LVEF 
(Section  7.8.2 ) â€“ within 7  days prior to Day 1 visit: Cy cle 3, Cycle 5, and 
every 4th cycle thereafter (e.g., Cycles 9, 13, 17) while on treatment  
o Administer the NFBSI -16 and EQ -5D-5L questionnaire ( Section  7.11; not 
required for infusion sub -study)  
o Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3). 
â€¢ Laboratory assessments for loca l laboratory testing  
o Perform serum or urine pregnancy test for women of childbearing 
potential. Pregnancy test must be negative to administer chemotherapy or 
study drug.  
Confidential Page 88 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Chemistry and/or hematology test(s) should be performed locally per 
institutional sta ndard of care prior to dosing for all cycles as needed.  
o Obtain specimen for ADA (margetuximab arm only, Section 7.10.2 )  
â€¢ Radiographic tumor evaluati ons and digital imaging of skin lesions â€“ within 14 
days prior to Day 1 visit:  
o Obtain CT and/or MRI scan(s) ( Section [IP_ADDRESS] ) 
o Obtain digital images of skin lesions (if applicable, Section [IP_ADDRESS] ). 
 
[IP_ADDRESS]  Administra tion of Study Treatments   
â€¢ Administer chosen chemotherapy â€“ per specific chemotherapy regimen (see 
Table  4) 
â€¢ Administer margetuximab or trastuzumab . 
 
[IP_ADDRESS]  Following Administration of Study Treatments   
â€¢ Clinical assessments:  
o Take vital signs ( Section 7.5) 
o Obtain ECG according to institutional standard of care as clinically 
indicated   
o Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3).  
 
8.5.2 Odd Cycle Treatment Visits: Day 8 (as needed)   
â€¢ Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3)  
â€¢ Administer chosen chemotherapy -per specific chemotherapy regimen (see 
Table  4). 
8.[ADDRESS_980628] dose of study drug. Procedures required for the 
End of Treatment Visit include the following (see also Schedule of Events in Appendix 1 ): 
â€¢ Clinical assessments:  
o Conduct PE, including weight ( Section 7.4)  
o Take vital signs ( Section 7.5)  
Confidential Page 89 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 o Evaluate ECOG performance status ( Appendix 4 ) 
o Obtain MUGA scan or echocardiogram for determi nation of LVEF 
(Section  7.8.2 ) 
o Administer the NFBSI -16 and EQ -5D-5L questionnaire ( Section 7.11; not 
required for infusion sub -study).   
o Perform toxicity review and AE assessment ( Section 7.9), and review 
concomitant medications ( Section 7.3).  
â€¢ Laboratory assessments:  
o Perform serum or urine pregnancy test locally for women of childbearing 
potential.  
o Obtain specimen for ADA (margetuximab arm only, Section 7.10.2 ).  
Safety Follow -up: Ongoing AEs at the time of study drug discontinuatio n will be followed to 
the End of Treatment visit or [ADDRESS_980629] dose of study drug, whichever occurs later. 
SAEs will be followed to resolution (see Section [IP_ADDRESS] ). 
8.[ADDRESS_980630]-Treatment Follow -up and Observation of Survival   
Follow -up information regarding disease and vital status (including dates of progression and 
death [including appropriate documentation such as a death certificate, if allowed by [CONTACT_13125]]), and additional cancer treatment(s) received will be requested by [CONTACT_151079] 
3-month intervals (Â± 1  week) after treatment discontinuation until de ath, withdrawal of 
consent, lost to follow -up, or the end of study ( Appendix 1 ). Procedures for patients lost to 
follow -up are described in Section 5.4.[ADDRESS_980631] to follow -up, withdrawal of 
informed consent, or death, radiologic tumor evaluations ( Section [IP_ADDRESS] ) and digital 
imaging of skin lesion s (if applicable, Section [IP_ADDRESS] ), should be performed every [ADDRESS_980632] dose of margetuximab. Details for acquisition, handling, and 
shippi[INVESTIGATOR_718700].  
Belgium only : monthly urine or serum pregnancy tests should be performed locally in women 
of childbearing potential for [ADDRESS_980633] -treatment follow -up period.  
Confidential Page 90 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980634] deviation (SD), median, 25th, and 75th quartile. Time -to-event endpoints will 
be summarized b y median durations, hazard ratios, and corresponding 95% confidence 
intervals (CIs).  
Unless otherwise noted, baseline values will be defined as the most recent value collected 
prior to the first dose of study drug.  
Data summaries and tabulations will be c onducted using SAS software Version 9.2 or higher. 
A detailed analysis plan (SAP) will be prepared and submitted to regulatory health 
authorities, as per local requirements, before study initiation.  
9.2 Independent Data Safety Monitoring Committee   
An independent Data Safety Monitoring Committee (DSMC) will oversee the ongoing 
monitoring and interpretation of the safety and efficacy data from this study. A DSMC charter 
will be created, r eviewed, and approved by [CONTACT_718754]. The 
independent DSMC will review safety data, with the first assessment to occur approximately 
[ADDRESS_980635] assessment to occur 30 days after enrollment of 
the 60th patient, or 90 days after the second DSMC assessment (i.e., following enrollment of 
the 30th patient), whichever is later. If no adverse safety signal is ide ntified, the DSMC will 
meet on a bi -annual basis thereafter. If, according to this schedule, a DSMC meeting is 
expected to occur near the time of a planned interim analysis (see  Section  9.9.1 ), the timing 
of the DSMC meeting will be adjusted to align with the interim analysis. More frequent 
assessments may be used if emergent safety data warrant. The DSMC will evaluate aggregate 
safety data comparing the two arms and also evaluate safety within each baseline 
chemotherapy to ensure patient safety. For these reviews, the committee will be provided 
with safety tables and data listings. When approximately [ADDRESS_980636] Safety  
group .  
Confidential Page 91 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980637] a 2 -month improvement in median PFS from 4 months to 6 months 
(haza rd ratio [HR]=0.67) in patients treated with margetuximab plus chemotherapy, a total of 
257 PFS events are required to provide 90% power at a 2 -sided alpha=0.05. The analysis of 
the primary PFS endpoint will occur when about [ADDRESS_980638] been randomized, whichever occurs later.  
The sample size is calculated to ensure 80% power for the analysis of OS. The median OS 
for patients treated with trastuzumab plus chemotherapy is estimated to be [ADDRESS_980639] an increase to a median OS of 16 months in patients treated with 
margetuximab plus chemotherapy (HR=0.75). Assuming that OS is exponentially distributed 
with median OS time of 12 months for the trastuzumab plus chemotherapy arm and 
16 months fo r the margetuximab plus chemotherapy arm, 2  interim analyses are performed 
as described in Section 9.9.1 , and a Lan -DeMets alpha spending function using an 
Oâ€™Brien -Fleming stoppi[INVESTIGATOR_718701], approximately 385  deaths will be required to 
provide 80% power to achieve statistical significance at overall type I error of 2 -sided 
alpha=0.05. It is anticipated that about 530 patients will be accrued to achieve this n umber of 
events. Patients will be enrolled over 24 months, and estimated to remain on study for an 
average of 16  months, for a total anticipated study duration of approximately 40 months.  
The planned sample size for the infusion sub -study is approximately  78 patients, 
approximately 18 patients for Stage A and about 60 patients for Stage B. The sample size of 
60 patients for Stage B of the infusion sub -study is derived to provide adequate assessment of 
primary safety endpoint for the sub -study.   
The overal l total number of patients enrolled for the entire study is expected to be 
approximately 608.  
9.3.1 Analysis Populations   
Three analysis populations are defined:  
â€¢ Intent -to-Treat Population â€“ all patients randomized. Patients will be analyzed 
according to the treatment (margetuximab or trastuzumab) assigned during 
randomization. This population will be used to summarize baseline data and 
evaluate PFS, OS, and HRQoL.   
Confidential Page 92 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Response Evaluable Population â€” all patients who are randomized who have 
measurable disease at baseline. This population will be used to evaluate ORR and 
CBR.  
â€¢ Safety Population â€“ all patients who are randomized and receive any amount of 
any study treatme nt. Patients will be analyzed according to the actual treatment 
received rather than the treatment group to which they were randomized. This 
population will be used for safety, PK, PD, and immunogenicity analyses.  
 
9.4 Demographics and Baseline Characteristics   
Patient disposition, demographics, baseline characteristics, disease history, medical history, 
concomitant medications, and study drug exposure data will be summarized using descr iptive 
statistics.  
9.5 Safety Endpoint(s) and Analyses   
9.5.1 Adverse Events   
AEs will be coded to the Medical Dicti onary for Regulatory Activities (MedDRA) dictionary. 
Only treatment -emergent AEs, as defined in Section 7.9.2 , will be summarized in tables. 
Events  prior to treatment (e.g., due to study -related procedure) will be listed in an appendix 
to the final study report.  
The following tables of AE data will be created to summarize the number and percent of 
patients who experience at least one event of each of the following types:  
â€¢ All AEs by [CONTACT_3229]  
â€¢ Drug -related AEs by [CONTACT_718755] (as a separate table)  
â€¢ All SAEs (this may be a listing if there are few events)  
â€¢ Drug -related SAEs by [CONTACT_718756] (as a separate table)  
â€¢ Fatal AEs (this may be  a listing if there are few events)  
â€¢ AEs that result in study drug discontinuation  
â€¢ AESI by [CONTACT_718756] (as a separate table)  
â€¢ AEs which lead to dose interruption by [CONTACT_718756] (as a separate table)  
â€¢ AEs that lead to withdrawal of study drug by [CONTACT_718757] (as a separate table)  
 
All of these tables will display the number and percent of patients that experience the given 
event and will display events by [CONTACT_1196] (SOC) and preferred term. Events will 
be displayed alphabetically for SOC and in  descending order of overall preferred term 
incidence within each SOC.  
Confidential Page 93 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980640] one event of each of the following types:  
â€¢ Any AE  
â€¢ Any drug -related AE  
â€¢ Any AE ï‚³Grade 3  
â€¢ Any drug -related AE ï‚³Grade 3  
â€¢ Any SAE  
â€¢ Any drug -related SAEs  
â€¢ AEs which lead to dose interruption  
â€¢ Any AE that results in study drug discontinuation  
â€¢ Any AEs that result in withdrawal from study drug  
â€¢ Any fatal AE  
â€¢ Any AESIs  
 
9.5.2 Laboratory Values   
Summaries of laboratory values will display descriptive statistics for numerically quantified 
labs. Summaries will be grouped by [CONTACT_16416] (e.g., hematology, blood chemistry, and 
urinalysis) and will be displayed by [CONTACT_451429].  
In cases where an abnormality resulted in a repeat laboratory test, the repeat value will be 
used for the summaries. A list of repeated laboratories including original values and repeat 
values w ill be included.  
Graphs of mean values over time may also be generated.  
9.5.[ADDRESS_980641] of 
care.   
Confidential Page 94 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 9.6 Efficacy Endpoints and Analyses   
Progression -free survival  â€“ defined as the time from randomization date to the date of first 
documented disease progression or death from any cause, whichever occurs first. For patients 
who are not known to be dead or progressed at time of dat a cut -off for PFS analysis, the PFS 
will be censored at the last tumor assessment.    
Incomplete or missing data can complicate interpretation of PFS. Appendix 3  describes the 
handling of these data for the PFS analysis.  
Overal l survival  â€“ defined as the time from randomization to the date of death (from any 
cause). For patients who are not known to be dead at the time of data cut -off for OS analysis, 
the OS will be censored at the time they are last known to be alive.  
Objective  response rate  â€“ the proportion of patients in the response evaluable population 
achieving a best response of CR or PR when such responses are confirmed at least [ADDRESS_980642]-baseline radiographic assessment will be considered as non -responders.  
Duration of response â€“ defined as the time from initial response to date of first documented 
disease progression or death from any cause, whichever occurs first. DoR will be analyzed 
for responding patients only. For responding patients who are not known to be dead or 
progressed at the time of data cut -off for DoR analysis, the DoR will be censored at the last 
tumor assessment.  
Clinical benefit rate â€“ the proportion of patient s in the response evaluable population 
achieving a best response of CR, PR, or SD of duration >6 months.  
HRQoL â€“ Patients will be administered the EQ -5D-5L and NFBSI -[ADDRESS_980643] been randomized, whichever occurs later. OS will be conducted at the 
time of PFS analysis and subsequently when 70% of the OS events and a final OS analysis 
when about [ADDRESS_980644] occurred.   
For both PFS and OS, Kaplan -Meier methods will be used to generate survival curves and 
estimate the median OS and PFS along with corresponding 95% CIs for each treatment 
group. A log -rank test str atified by [CONTACT_718758] -to-event endpoints between the two treatment groups. In addition, hazard 
ratios and 95% CIs will be assessed using stratified Cox proportional hazards models with 
treatmen t as the only covariate. Sensitivity analyses of PFS and OS will be performed; 
further details are provided in the SAP.  
Confidential Page 95 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 The following are pre -defined stratification factors:  
â€¢ Number of metastatic sites (0 -2, >2)  
â€¢ Number of lines of prior therapy in the metas tatic setting (â‰¤2, >2)  
â€¢ Choice of backbone chemotherapy (capecitabine, eribulin, gemcitabine, or 
vinorelbine)  
 
In addition, the hazard ratios and 95% CIs for PFS and OS in each subgroup of the above 
three stratification factors as well as the following sub groups will be assessed using 
unstratified Cox proportional hazards model with treatment as only covariate and presented 
by [CONTACT_508698]:  
â€¢ Prior use of T -DM1 (yes, no)  
â€¢ Region (North America, Europe, Other)  
â€¢ HER2 status (3+ or ISH amplified, Other)  
â€¢ Age (â‰¤60 and >60 years)  
â€¢ Race (White, Black, Asian, Other)  
â€¢ ECOG (0 and 1)  
â€¢ ER and PR status (ER+ and/or PR+, ER - and PR -, Unknown)  
â€¢ CD16A haplotypes (FF, FV , or VV)  
â€¢ CD32A haplotypes (HH, HR, or RR)  
â€¢ CD32B haplotypes (II, IT, or TT)  
 
[IP_ADDRESS]  Primary Endpoint for the Infusion Sub-Study   
The number of patients with Grade [ADDRESS_980645] significant p -value<0.05, then both 
hypotheses are rejected. Otherwise, this endpoint is retained and the second p -value is tested 
at p<0.025. If a p -value<0.025 (0.05/2) is obtained, this hypothesis is rejected. Otherwise, 
both hypo theses are retained.  
Investigator -assessed PFS will be analyzed using the same methods as described above for 
the primary endpoint of PFS.  
Confidential Page 96 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 Independent review -assessed ORR will be compared between groups using a 
Mantel -Haenszel statistic stratified by [CONTACT_718759].  
[IP_ADDRESS]  Secondary Endpoint for Infusion Sub -study   
The number of patients with any grade IRR will be assessed using descriptive statistics.   
9.6.[ADDRESS_980646] reports from patients will be obtained using the NFBSI -16 and EQ -5D-5L 
Questionnaires (10, 16). Responses Data will be collected at baseline, Day 1 of each Odd 
cycle, and at the End of Treatment visit. The primary patient -repor ted outcome (PRO) 
endpoint for analysis will be the NFBSI -16 total score, with secondary analysis of the 
subscales that add to the total (disease related symptoms, treatment side effects, and 
function/well -being. Analyses using mixed model repeated measure s using the baseline score 
and protocol defined stratification factors are planned as covariates. Subscale scores will be 
tabulated and summarized. Data from the EQ -5D-5L scale will be summarized by [CONTACT_15449]. 
To minimize missing data, sites will be inst ructed and patients educated on the importance of 
recording the direct patient experience in order to appreciate the positive and negative 
aspects of treating advanced breast cancer, and they will specifically be trained on best 
practices for patient enrol lment, adherence to endpoint data collection requirements, and 
methods to ensure complete data capture and management. Every effort will be made to 
collect survey data at all defined visits including at early withdrawal. Reasons for missing 
data will be su mmarized.  
Duration of response, where response is assessed by [CONTACT_718760], respectively, will be analyzed using Kaplan -Meier methods and compared between 
two treatment groups using a stratified log -rank test.  
Investigator assessed ORR will also be compared between two treatment groups using a 
Mantel -Haenszel statistic stratified by [CONTACT_718717].  
Clinical benefit rate, where response is assessed by [CONTACT_718760], res pectively, will also be compared between two treatment groups using a Mantel -
Haenszel statistic stratified by [CONTACT_718717].  
Change in tumor size over time will be summarized and the best percentage change from 
baseline will be pr esented by [CONTACT_15224]. Change calculations will be based on target 
lesions only.  
Confidential Page 97 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980647] ratios 
and 95% CIs as described in the subgroup portion of Section  9.6.[ADDRESS_980648] of margetuximab on OS. The details will be provi ded in the SAP.  
9.7 Pharmacokinetic and Exposure -Response Analyses   
Serum concentrations of margetuximab will be summarized by [CONTACT_718761]. Any population PK modeling will be performed by [CONTACT_507366]. An analysis plan will be created prior to analysis.  
Summary statistics will be tabulated for serum PK parameters by [CONTACT_718721]. 
Geometric means and percent coefficients of va riation will be reported for C max, AUC tau, 
AUC inf, and C trough; arithmetic means and standard deviations will be reported for T half, CL, 
and V ss; and medians, minimum, and maximum will be reported for T max.  
Exposure -response analyses will be conducted sep arately using key efficacy and safety 
parameters of interest. An analysis plan will be created prior to analysis.  
9.[ADDRESS_980649] positive ADA at baseline that increases or decreases in titer over the 
course of treatment wil l be summarized. Neutralizing activity will be determined for samples 
with positive ADA. The effects of ADA on key PK, efficacy, and safety parameters will be 
investigated.  
9.9 Timing of Analyses   
Patients in the infusion sub -study are not included in the interim analysis of OS, futility, and 
final analysis.  
9.9.1 Interim Analyses   
[IP_ADDRESS]  Interim Analyses for OS   
Two interim analyses of OS will be conducted for the randomized population. The first will 
occur at the time of the primary PFS analysis, when approximately [ADDRESS_980650] experienced clearly 
documented clinical disease progression. The second interim analysis will occur when 70% 
Confidential Page 98 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980651] occurred unless that threshold was met at the time of PFS 
analysis.  
The overall type 1 error rate is controlled at 2 -sided 0.05 using the sequential analysis of PFS 
followed by [CONTACT_718762] -DeMets alpha spending 
function with O â€™Brien -Fleming boundaries for the OS analyses. The efficacy boundaries 
based on this method will depend on the actual observed number of OS events at each 
analysis and hence will be calculated and provided  to DSMC once the actual number of OS 
events is known for each interim analysis. For example, if we observe 139 OS events (as 
expected per simulation) at the time of observing 257 PFS events for the primary PFS 
analysis, then the efficacy boundaries at eac h interim and final analysis are as follows 
(ADDPlan v6, with O â€™Brien -Fleming type alpha spending function and Schoenfeld formula 
for sample size calculation).    
Table 5 Planned Interim Analyses   
Analysis  Timing of Analysis  Observed number (% of 
information fraction) of 
OS Events at Each 
Analysis  Efficacy Boundary in 
Terms of Two -Sided 
Significance Level  
First Interim  Time of Primary PFS Analysis  139 (36%)  0.0004  
Second Interim  70% of Overall OS Events  270 (70%)  0.0146  
Final  100% of Overall OS Events  385 (100%)  0.0454  
 
[IP_ADDRESS]  Interim Futility Analysis for PFS   
When approximately [ADDRESS_980652] and patient safety as well as conditional power. The 
committee may recommend study termination if  the conditional power is low (as guidance, it 
is considered low if the conditional power is less than 20%), if there are safety issues, or if 
under the current conduct of the study, study objectives are unlikely to be achieved.  
9.9.[ADDRESS_980653] occurred.  
Confidential Page 99 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 10 QUALITY CONTROL AND ASSURANCE   
Quality review activities will be undertaken to ensure accurate, complete, and reliable data. 
MacroGenics, Inc., and/or its representatives will do the following:  
â€¢ Provide instructional material to the study sites, as appropriate.  
â€¢ Sponsor a start -up training session (Investigator Meeting or Study Initiation Visit) 
to instruct the Investigators  and study coordinators. This session will give 
instruction on the protocol, the completion of the CRFs, and study procedures.  
â€¢ Make periodic visits to the study site to monitor protocol compliance and general 
Good Clinical Practice (GCP) compliance.  
â€¢ Be ava ilable for consultation and stay in contact [CONTACT_65127] 
e-mail, telephone, and/or fax.  
â€¢ Review and evaluate eCRF data and use standard computer checks to detect and 
query errors in data collection.  
â€¢ Conduct a quality review of the database.  
 
10.1 Monitoring, Auditing and Inspections   
To ensure the safety of participants in the study, compliance with applicable regulations, and 
ensure accurate, complete, and reliab le data, the Investigator will keep records of laboratory 
tests, clinical notes, and patient medical records in the patient files as source documents for 
the study (refer to Section 11.6 for additional information on source documents).  
MacroGenics, Inc., or its designee will monitor the study on a regular basis throughout the 
study period according to the study monitoring plan. The Investigator will allocate adequate  
time for such monitoring activities. The study monitor periodically will conduct a 
cross -check of a sample of the patient data recorded on CRFs against source documents at 
the study site. The Investigator will also ensure that the monitor is given access to all the 
above noted study -related documents, source documents (regardless of media) and study -
related facilities (e.g., investigational pharmacy, etc.), and has adequate space to conduct the 
monitoring visit. Queries may be raised if any datum is unclea r or contradictory. The 
Investigator and site personnel must address all queries in a timely manner.  
Participation as an Investigator in this study implies acceptance of the potential for inspection 
by [CONTACT_12925]/Representatives, US or non -US government regulatory authorities, 
IRB/IEC and applicable compliance and quality assurance offices. The Investigator will 
permit study -related audits and inspections and will provide access to all study -related 
documents (e.g., source documents, regulatory  documents, data collection instruments, study 
data, etc.). The Investigator will ensure the capability for inspections of applicable 
study -related facilities (e.g., pharmacy, diagnostic laboratory, etc.).  
Confidential Page 100 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980654] be maintained. For data collection and data management 
purposes, patients are to be identified by a patient nu mber only. Documents that identify the 
patient beyond patient number will not be submitted to the sponsor (e.g., the signed informed 
consent document; patient initials) and must be maintained in strict confidence by [CONTACT_3786], except to the extent n ecessary to allow auditing by [CONTACT_50756], 
study monitor, or sponsor representatives.  
Site personnel record all data for each study patient through eCRFs using an Electronic Data 
Capture (EDC) system approved by [CONTACT_456]. Sites must compl ete the eCRFs in a timely 
manner and the Investigator must promptly review the completed eCRFs for each patient. As 
the person ultimately responsible for the accuracy of all eCRF data, the Investigator must 
e-sign the Investigator's Statement in each patie nt's eCRF. The EDC system automatically 
generates queries resulting from the computer checks embedded into the system, so as to 
ensure accuracy, quality, consistency, and completeness of the database. Manual queries 
resulting from review by [CONTACT_53194], medic al coders, and other Data Management staff are also 
posted from within the EDC system, where they are tracked. Sites resolve the queries and 
correct the entered data when necessary. Every change to data is captured in the EDC system 
audit trail. Upon compl etion of the study, each site will be provided with a compact disk 
containing the eCRFs for each of their patients.  
Confidential Page 101 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980655] or Inde pendent Ethics Committee 
Approval   
The Investigator should provide the Sponsor with a statement of compliance from the 
IRB/IEC indicating compliance with the applicable regulations in the region and ICH. Any 
documents that the IRB/IEC may need to fulfill its responsibilities, such as the protocol and 
any amendments, IB, and information concerning patient recruitment, payment or 
compensation procedures, or information from the sponsor  will be submitted to the IRB/IEC. 
The IRB/IEC â€™s written unconditional approval of the study protocol and the informed 
consent forms (ICFs) will be in the possession of the Investigator and the Sponsor before the 
study drug is initiated at the Investigator â€™s site. The Investigator will transmit the IRB/IEC â€™s 
unconditional approval statement to the Sponsor. This approval must include the date of 
review, and refer to the study by [CONTACT_451433]/or study number and version number and 
refer to the ICFs by v ersion number or date. If the IRB/IEC or institution uses its own unique 
number for the protocol instead of the Sponsor â€™s number, that unique number should be 
noted on the approval statement. If approval of the ICFs is stamped on the forms (instead of 
docu mented in the IRB/IEC approval statement) the date of approval and/or expi[INVESTIGATOR_718702].  
Protocol modifications or changes may not be initiated without approval from the Sponsor 
and prior written IRB/IEC approval (when required), except when nece ssary to eliminate 
immediate hazards to the patients. Such modifications will be submitted to the IRB/IEC; 
written verification that the modification was submitted should be obtained.  
The Investigator must, where required by [CONTACT_427], submit to th e IRB/IEC:  
â€¢ The protocol and the IB and any amendments or updates.  
â€¢ The informed consent form(s) and any amendments or changes.  
â€¢ Any documents given to patients or potential patients (e.g., recruitment materials, 
diary cards) and the plan for distribution/use . 
â€¢ Revisions of other documents originally submitted for review or for notification.  
â€¢ Serious and/or unexpected AEs occurring during the study.  
â€¢ New information that may adversely affect the safety of patients or conduct of the 
study.  
â€¢ At minimum, an annual up date and/or request for re -approval of study, unless 
otherwise specified by [CONTACT_1744]/IEC.  
â€¢ Protocol violations or deviations  
â€¢ Notification when the study has been completed.  
â€¢ Proof of indemnity/liability insurance.  
Confidential Page 102 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 â€¢ Other documents required by [CONTACT_1201]/IEC  
 
11.[ADDRESS_980656] of the Study   
The investigational study will be conducted under a US Investigational New Drug (IND) 
application according to the Protection of Human Subjects [LOCATION_002] Code of Federal 
Regulations, Title 21 (21 CFR 50), Institutional Review Boards (21 CFR 56), Obliga tions of 
Clinical Investigators (21 CFR 312.60 âˆ’ 312.69), the current ICH Guideline for Good 
Clinical Practice (ICH E6), and in accordance with ethical principles that have their origin in 
the Declaration of Helsinki, and all other applicable local regulat ions and/or guidelines.  
The protocol and the informed consent document will be reviewed and approved by [CONTACT_5040]/IEC of each participating center before study initiation. Serious adverse events, 
regardless of causality, will be reported to the Sponsor/desig nee and to the IRB/IEC, if 
required by [CONTACT_427]. The Investigator will keep the IRB/IEC informed regarding the 
progress of the study.  
11.[ADDRESS_980657] be approved by [CONTACT_1201]/IEC. The 
Investigator will provide the Sponsor with a copy of the  IRB/IEC -approved consent forms 
and a copy of the IRB/IEC â€™s written approval before the start of the study.  
Consent forms must be written (and appropriately translated in the patient â€™s native language 
or language in which the patient has fluency) so as to  be understood by [CONTACT_718763]. Informed consent will be documented by [CONTACT_2224] a written consent form approved 
by [CONTACT_1201]/IEC. The form must be signed and dated by [CONTACT_102], and by [CONTACT_718764].  
All versions of each patient â€™s signed ICF must be kept on file by [CONTACT_718765]/or authorized MacroGenics monitoring and 
regulatory compliance persons. The patient should receive a copy of the  signed and dated 
written ICF and any other written information provided to the patients.  
Confidential Page 103 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 11.4 Patient Confidentiality   
To maintain confidentiality of patients, all laboratory specimens,  evaluation forms, reports, 
and other records will be identified by a coded number. Clinical information will not be 
released without written permission of the patient, except as necessary for monitoring by 
[CONTACT_64379], the Sponsor of the clinical study, or the Sponsor â€™s 
representative. The Investigator must also comply with all local applicable privacy 
regulations [e.g., US Health Insurance Portability and Accountability Act of 1996 (HIPAA)], 
on protection of individuals with regard  to personal data.  
11.[ADDRESS_980658] recorded, which may include, but are not limited to, the patient â€™s 
medical file, original laboratory reports, histology, and pathology reports (as applicable). The 
Investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information will be entered onto CRFs designed to capture all observations 
and other data pertinent to the clinical investigation. Data should be recorded on source 
documents and entered onto CRFs. Electronic CRFs should be filled out completely by [CONTACT_74320]/her designee. Prior to CRF database lock, the Investigator will verify the 
completeness and accuracy of the data and indicate that he/she has done so by [CONTACT_718766]. The Investigator will retain  a copy of all source 
documents.  
11.6 Access to Source Documentation   
The Investigator and study center will permit the Sponsor, its representatives, IRB, and all 
relevant regulatory age ncies access to all original source data and documents regardless of 
media, for study monitoring audits and inspections.  
The Investigator may be subjected to a field audit by [CONTACT_134187], Inc. (or designee), and/or 
regulatory inspectors in order to validat e the participation of patients in the study and to 
verify the data reported on the CRFs on file at MacroGenics, Inc. MacroGenics should be 
notified immediately of any audits scheduled by [CONTACT_188553]. Copi[INVESTIGATOR_718703], findings and/or  correspondence from regulatory authorities for audits conducted on a 
MacroGenics -sponsored study should be promptly forwarded to MacroGenics.  
11.7 Retention of Data   
Per ICH guidelines,  all essential documents, including CRFs, source documents (regardless 
of media), signed ICFs, and laboratory test results, should be retained by [CONTACT_718767] [ADDRESS_980659]. There may be other circumstances for which MacroGenic s, Inc., is 
required to maintain study records for longer periods (e.g., applicable local regulations); 
Confidential Page 104 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980660] obtain written 
permission from MacroGenics, Inc., prior to destruction of study documents.  
11.8 Financial Disclosure   
The Investigator and Sub -Investigators will be required  to disclose any applicable financial 
arrangement as defined in US regulation (i.e. 21 CFR 54). The following information will be 
collected: any significant payments of other sorts from MacroGenics, Inc., or any alliance 
partner, such as a grant to fund on going research, compensation in the form of equipment, 
retainer for ongoing consultation or honoraria; any proprietary interest in margetuximab; and 
any significant equity interest in MacroGenics, Inc., as defined in 21 CFR 54. Investigators 
are obliged to  update the Sponsor with any changes in reported information up to 1 year 
following the end of the study (as defined in Section  4.3.2 ) 
In considera tion of participation in the study, MacroGenics, Inc., will pay the Investigator or 
nominated payee the sums set out in the payment schedule attached to the Investigator 
agreement.  
Financial disclosure information will be documented in writing and signed and dated by [CONTACT_3786]. This information will be collected prior to that investigator taking part in the 
research.  
11.9 Publication and Disclosure Policy   
Data collected in this c linical study belong to the study Sponsor which will formulate a 
policy on the use of study data. This policy will be codified in the Clinical Trial Agreement. 
This includes authorship issues: scheduling and prioritizing analyses for reports, publications,  
and presentations; and developi[INVESTIGATOR_007] a review and approval process.  
MacroGenics intends to publish the results of this study in an international peer -reviewed 
journal following completion of all primary endpoints. Interim results may be published prior 
to co mpletion if warranted. If appropriate, results may be presented at scientific conferences 
prior to publication. MacroGenics will adhere to all relevant regulatory guidelines and best 
practices during preparation of any manuscripts or other scientific prese ntations.  
11.10  Discontinuation of the Study or Study Sites   
11.10.1  Discontinuation of Study Sites   
Participation may b e discontinued if MacroGenics, Inc., the Investigator, a regulatory 
authority, or the IRB of the study sites deems it necessary for any reason.   
Confidential Page 105 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 11.10.2  Discontinuation of the Study   
The study may be discontinued by a regulatory authority or at the discretion of the Sponsor. 
The study may be terminated if there is evidence of futility, an unacceptable safety signal, or 
failure to achieve a primary endpoint. Patients who are enrolled in  the study and continue to 
receive benefit from treatment as defined in the protocol at the time of study termination may 
continue to receive treatment as described until a reason to discontinue treatment is indicated.  
The Investigator maintains the right  to discontinue his/her participation in the study should 
his/her clinical judgment so dictate. The Investigator will notify the IRB/IEC of any study 
discontinuation. Study records must be retained as noted above.  
11.11  Identification of the Coordinating Princip al Investigator   
A Coordinating PI [INVESTIGATOR_718704].  
As part of his or her responsibilities, the Coordinating PI [INVESTIGATOR_718705]. Agreement with the final Clinical Study Report will be documented by [CONTACT_718768].  
Confidential Page 106 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 107 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 108 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 109 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 110 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 111 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 112 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 113 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 114 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 
Confidential Page 115 of 142

Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980661] cancer: the HERNATA study . J 
Clin Oncol, 2011. 29(3): p. [ADDRESS_980662] cancer . N. Engl. J. Med, 2012. 
366(2): p. [ADDRESS_980663] cancer . J. Clin. Oncol, 
2010.  28(7): p. [ADDRESS_980664] cancer (ABC2) . Breast, 
2014. 23(5): p. [ADDRESS_980665], D H enner, WL Wong, et al. , 
Humanization of an anti -p185HER2 antibody for human cancer therapy . Proc Natl 
Acad Sci U S A, 1992. 89(10): p. 4285 -9. 
6. Cortes J, J O'Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, et al. , 
Eribulin monotherapy versus trea tment of physician's choice in patients with 
metastatic breast cancer (EMBRACE): a phase 3 open -label randomised study . 
Lancet, 2011. 377(9769): p. [ADDRESS_980666] cancer (Review) . The Cocharane Library, 2013. 2013(Issue 12).  
8. Dzimitrowicz H, M Berger, C Vargo, A Hood, O Abdelghany, AS Raghavendra, 
et al. , T-DM1 Activity in Metastatic Human Epi[INVESTIGATOR_300786] F actor Receptor [ADDRESS_980667], et al., New 
response evaluation criteria in solid tumours:  revised RECIST guideline (version 1.1), 
in Eur J Cancer . 2009. p. [ADDRESS_980668] cancer: development and initial validation 
of the National Co mprehensive Cancer Network -Functional Assessment of Cancer 
Therapy -Breast Cancer Symptom Index (NFBSI -16). Value. Health, 2012. 15(1): p. 
183-190. 
11. Genentech , Herceptin Prescribing Information . Genentech, 2014.  
12. Geyer CE, J Forster, D Lindquist, S Ch an, CG Romieu, T Pi[INVESTIGATOR_118487], et al. , 
Lapatinib plus capecitabine for HER2 -positive advanced breast cancer . N Engl J 
Med, 2006. 355(26): p. [ADDRESS_980669] cancer (NeoSphere): a 
Confidential Page 116 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 randomised multicentre, open -label, phase 2 trial . Lancet Oncol, 2012. 13(1): p. [ADDRESS_980670] cancer: American Society of Clinical Oncology clinical 
practice guideline . J. Clin. Oncol, 2014. 32(19): p. 2078 -2099.  
15. GLOBOCAN . GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and 
Prevalence Worldwide in 2012. GLOBOCAN 2012 2012; Available from: 
http://globocan.iarc.fr/Pages/fact_sheets_ cancer.aspx . 
16. Herdman M, C Gudex, A Lloyd, M Janssen, P Kind, D Parkin, et al. , 
Development and preliminary testing of the new five -level version of EQ -5D (EQ -
5D-5L). Qual. Life Res, 2011. 20(10): p. 1727 -1736.  
17. Krop IE, SB Kim, A Gonzalez -Martin, PM  Lorusso, JM Ferrero, M Smitt, et al. , 
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2 -
positive advanced breast cancer (TH3RESA): a randomised, open -label, phase 3 trial . 
Lancet Oncol, 2014. 15(7): p. 689 -699. 
18. Musolino A, N Naldi, B Bortesi, D Pezzuolo, M Capelletti, G Missale, et al. , 
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of 
trastuzumab -based therapy in patients with HER -2/neu -positive metastatic breast 
cancer . J Clin Oncol, 2008. 26(11): p. 1789 -1796.  
19. NCCN . Clinical Practice Guidelines in Oncology: Breast Cancer. 2014 2014; 
Available from: NCCN.org.  
20. Nordstrom JL, S Gorlatov, W Zhang, Y Yang, L Huang, S Burke, et al. , Anti -
tumor activity and toxicokineti cs analysis of MGAH22, an anti -HER2 monoclonal 
antibody with enhanced Fc -gamma receptor binding properties . Breast. Cancer Res, 
2011. 13(6): p. R123.  
21. Pi[INVESTIGATOR_94899] -Gebhart MJ, M Procter, B Leyland -Jones, A Goldhirsch, M Untch, I 
Smith, et al. , Trastuzumab af ter adjuvant chemotherapy in HER2 -positive breast 
cancer . N Engl J Med, 2005. 353(16): p. 1659 -1672.  
22. Pi[INVESTIGATOR_53643] X, A Manikhas, B Zurawski, E Chmielowska, B Karaszewska, R Allerton, 
et al. , CEREBEL (EGF111438): A Phase III, Randomized, Open -Label Study of 
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With 
Human Epi[INVESTIGATOR_14907] [ADDRESS_980671] Cancer . J. 
Clin. Oncol, 2015.  
23. Society AC , Cancer Facts & Figures . Atlanta: American Cancer Society, [ADDRESS_980672] cancer in CLEOPATRA: a randomized, double -blind, 
placebo -controlled phase III study . Oncologist, 2013. 18(3): p. [ADDRESS_980673] cancer . N Engl J Med, 2012. 367(19): 
p. [ADDRESS_980674] cancer: a german breast group 26/breast international group 
03-05 study . J Clin Oncol, 2009. 27(12):  p. 1999 -2006.  
Confidential Page 117 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04 Amendment 4, 0 8 June 2020  
 
 27. Wilks S, S Puhalla, J O'Shaughnessy, L Schwartzberg, E Berrak, J Song, et al. , 
Phase 2, multicenter, single -arm study of eribulin mesylate with trastuzumab as first -
line therapy for locally recurrent or metastatic HER2 -positive breast ca ncer. Clin. 
Breast Cancer, 2014. 14(6): p. [ADDRESS_980675] Cancer, 2009. 9(3): p. 178 -183. 
 
 
 
 
 
Confidential Page 118 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 4. Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and temperature) are to be collected as follows:  at Screening; Cy cle 1 Day 1 - before margetuximab or 
trastuzumab infusion, at end of margetuximab or trastuzumab infusion, and at 60 minutes after end of trastuzumab or margetuxi mab infusion; all subsequent 
Cycles  â€“ before and at end of margetuximab or trastuzumab infusions; and at the E nd of Treatment visit.  
5. With Protocol Amendment 4, ECGs will no longer be collected and analyzed centrally. Instead, ECGs will be collected and interpreted locally according to 
institutional standard of care.  
6. MUGA or echo to be performed at Screening; Cycle  3 Day 1; Cycle 5 Day 1, and on Day 1 of each 4th cycle thereafter (e.g., Cycles 9, 13, 17) while on treatment; 
and at the End of Treatment visit. Cycle [ADDRESS_980676] be obtained within 14 days prior to randomization for women of childbearing potential.  
10. With Protocol Amendment 4, blood and urine samples will no longer be collected  and ana lyzed centrally . Instead, blood  and/or urine  samples for safety will be 
collected according to institutional standard of care for patients who are receiving a HER2 -targeted agent (margetuximab or trastuzumab).   
11. With Protocol Amendment 4, all PK sample coll ection will be discontinued for patients who are still receiving study treatment at the time of the amendment.  
12. With Protocol Amendment 4, collection of samples for ADA assay will be decreased in frequency from once every 6 weeks (every 2 treatment cycles)  to once every 
12 weeks (every 4 treatment cycles), consistent with radiographic imaging. ADA samples will continue to be collected at end of treatment and during follow -up at [ADDRESS_980677] dose of margetuximab. ADA samples for t he infusion sub -study will be obtained according to the same schedule as the 
margetuximab arm.  
13. Tumor evaluations (radiology and digital imaging of skin lesions) to be performed at Screening and Day [ADDRESS_980678] 24 weeks of study 
treatment. Following 24 weeks on study treatment, tumor evaluations will be performed every 4 cycles (beginning with Cycle 9)  while on treatment or every [ADDRESS_980679] to follow -up, withdraw of informed consent, 
death, or end of study. For all patients: CT (with contrast) or MRI of chest, abdomen, and pelvis for all evaluations; bone s can at screening and as clinically 
indicated thereafter. For  patients with known, treated brain metastases and/or signs or symptoms of brain metastasis: CT or MRI of brain at Screening o nly and as 
clinically indicated thereafter. Tumor evaluations may be performed up to 14 days prior to the scheduled study visit.  
14. Information collected to include disease and vital status (including dates of progression and death, if appropriate) and addit ional cancer treatment(s) received 
following the End of Treatment visit.  
15. Patients to receive one of 4 backbone chemotherapy options  (capecitabine, eribulin, gemcitabine, or vinorelbine) to be selected by [CONTACT_093] (see Section 6.1 
and Table  4.)  Selected chemotherapy must be allowed for use per local regulations. The Day [ADDRESS_980680]-treatment Follow -up to occur at 3 -month intervals Â±  [ADDRESS_980681] occur  within 72 hours of Cycle 1 Day 1 , with dosing preferably on the same day as randomization.  
19. Day 8 evaluations to be performed only if patients are required to return to the study site for administration of backbone ch emotherapy.  
20. For Belgium sites only: mon thly urine or serum pregnancy tests should be performed locally in women of childbearing potential during the post -treatment follow -up 
period.  
21. Tumor assessments performed as standard of care may be considered baseline and need not be repeated if completed  within 4 weeks prior to randomization.  
22. HRQoL assessments are not required for patients assigned to the infusion sub -study.  
 
Confidential Page 121 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Appendix 2  Principal Investigator â€™s Agreement   
Study Title:  A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs 
Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ 
Metasta tic Breast Cancer Who Have Received Prior Anti -HER2 Therapi[INVESTIGATOR_718659]:  CP-MGAH22 -[ADDRESS_980682] fully discussed the objectives of this trial and the contents of this protocol with  the 
Sponsor â€™s representative.  
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution of the ethical review of the study, 
without written authorization from Mac roGenics, Inc. It is, however, permissible to provide 
information to a patient in order to obtain consent.  
I agree to conduct this trial according to this protocol and to comply with its requirements, 
subject  to ethical and safety considerations and guide lines, and to conduct the trial in 
accordance with ICH guidelines on GCP and with the applicable regulatory requirements.  
I understand that the Sponsor may decide to suspend or prematurely terminate the trial at any 
time for whatever reason; such a decisi on will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the trial, I will communicate my 
intention immediately in writing to the Sponsor.  
 
 
Signed:    Date:    
 
PI [CONTACT_5627] (printed):  ________________________________ ________________________  
PI [CONTACT_23682]:  ________________________________ ____________________________  
PI [CONTACT_2761]:  ________________________________ ______________________________  
PI [CONTACT_65086]:  ________________________________ ________________________  
 
Confidential Page 122 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980683] tumor  assessment prior 
to missed assessments  Censored  
 
Confidential Page 123 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Appendix 4  Eastern Cooperative Oncology Group (ECOG) 
Performance Status   
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity, but ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light house work or office work)  
2 Ambulatory and capable of all self -care, but unable to carry out any work activities. Up and 
about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry -on any self -care. Totally confined to bed or chair . 
5 Dead  
 
Confidential Page 124 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Appendix 5  NCCN/FACT Breast Symptom Index -16 (FBSI -16)  
 
 
Confidential Page 125 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 
Confidential Page 126 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
  
Confidential Page 127 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Appendix 6  EQ-5D-5L  
 
Confidential Page 128 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
  
Confidential Page 129 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
  
Confidential Page 130 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980684] 1.1 Guidelines   
(Adapted from Eisenhauer et al. 2009  (9)) 
MEASURABILITY OF TUM OR AT BASELINE  
Definitions  
At baseline, tumor lesions/lymph nodes will be categorized measurable or non -measurable as 
follows:  
Measurable  
Tumor lesions :  Must be accurately measured in at least one dimension ( longest  diameter in 
the plane of measurement is to be recorded) with a minimum  size of:  
â€¢ [ADDRESS_980685] scan (CT scan slice thickness no greater than 5 mm).  
â€¢ 10 mm caliper measurement by [CONTACT_12148] (lesions which cannot be 
accurately measured with calipers should be recorded as non -measurable).  
â€¢ [ADDRESS_980686] X -ray. 
 
Malignant lymph nodes : To be considered pathologically enlarged and measurable, a lymph 
node must be â‰¥ [ADDRESS_980687] scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow -up, only the short  axis 
will be measured and followed. See also notes below on â€˜Baseline documentation of target 
and non -target lesions â€™ for information on lymph node measurement.   
Non-measurable  
All other lesions, including small lesions (longest diameter < 10mm or pathological lymph 
nodes with â‰¥10 to <15 mm short axis) as well as truly non -measurable lesions. Lesions 
considered truly non -measurable include: leptomeningeal disease, ascites, pleural or 
pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
abdominal masses/abdominal organomegaly identified by [CONTACT_718769].  
Confidential Page 132 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Special considerations regarding lesion measurability  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment:  
Bone lesions:  
â€¢ Bone scan, PET scan or plain films are not co nsidered adequate imaging 
techniques to measure bone lesions. However, these techniques can be used to 
confirm the presence or disappearance of bone lesions.  
â€¢ Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components, that can be evaluated by [CONTACT_677163].  
â€¢ Blastic bone lesions are non -measurable.  
 
Cystic lesions:  
â€¢ Lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non -measurable) since 
they are, by [CONTACT_108], simple cysts.  
â€¢ â€˜Cystic lesions â€™ thought to represent cystic metastas es can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions.  
 
Lesions with prior local treatme nt: 
â€¢ Tumor lesions situated in a previously irradiated area, or in an area subjected to 
other loco -regional therapy, are not considered measurable unless there has been 
demonstrated progression in the lesion prior to study enrollment.  
 
SPECIFICATIONS BY [CONTACT_718770] S 
Measurement of lesions  
All measurements should be recorded in metric notation, using calipers if clinically assessed. 
All baseline evaluations should be performed as close as possible to the treatment start and 
never more than 4 weeks  before the beginning of the treatment.  
Method of assessment  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging based evaluation 
Confidential Page 133 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 should always be  done rather than clinical examination unless the lesions(s) being followed 
cannot be imaged but are assessable by [CONTACT_461].  
Clinical lesions: Clinical lesions will only be considered measurable when they are 
superficial and â‰¥10 mm diameter as assesse d using calipers (e.g. skin nodules). For the case 
of skin lesions, documentation by [CONTACT_3606] a ruler to estimate the size of 
the lesion is suggested. As noted above, when lesions can be evaluated by [CONTACT_718771] , imaging evaluation should be undertaken since it is more objective 
and may also be reviewed at the end of the study.  
Chest X -ray: Chest CT is preferred over chest X -ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X -ray, particularly in identifying new 
lesions. However, lesions on chest X -ray may be considered measurable if they are clearl y 
defined and surrounded by [CONTACT_6776].  
CT, MRI:  CT is the best currently available and reproducible method to measure lesions 
selected for response assessment. This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is [ADDRESS_980688] 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice 
the slice thickness. MRI is also acceptable in certain situations (e.g. for body scans).  
Ultrasound:  Ultraso und is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to 
the next. If new lesions are identified by [CONTACT_12153], confirmation 
by [CONTACT_12154]. If there is concern about radiation exposure at CT, MRI may be 
used instead of CT in selected instances.  
Endoscopy, laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  
Tumor markers:  Tumor markers alone  cannot be used to assess objective  tumor response.  
TUMO R RESPONSE EV ALUATIO N 
Assessment of overall tumor burden and measurable disease  
To assess objective response or future progression, it is necessary to estimate the overall 
tumor burden at baseline  and use this as a comparator for subsequent measurements. 
Measurable disease is defined by [CONTACT_12155] (as detailed 
above).  
Baseline documentation of â€˜target â€™ and â€˜non-target â€™ lesions  
Where more than one measurable lesion is present at baseline all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved 
Confidential Page 134 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980689] only one or two organ sites in volved, a 
maximum of two and four lesions respectively will be recorded). Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all 
involved organs, but in addition should be those that lend themselves to reproducible 
repeated measurements . It may be the case that, on occasion, the largest lesion does not lend 
itself to reproducible measurement in which circumstance the next largest lesions which can 
be measured reproducibly should be selected .  
Lymph nodes  merit special mention since they are normal anatomical structures which may 
be visible by [CONTACT_33490]. As noted above, pathological nodes 
which are defined as measurable and may be identified as target lesions must meet criterion 
of a short axis of â‰¥ [ADDRESS_980690] in which the image is obtained (for CT scan this is almost always the axial plane; 
for MRI the plane of acquisition may be axial, sagittal or coronal). The smaller of these 
measures is the short axis. Fo r example, an abdominal node which is reported as being 20 
mm x30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this 
example, 20 mm should be recorded as the node measurement. All other pathological nodes 
(those with short axis â‰¥10 mm but < 15 mm) should be considered non -target lesions. Nodes 
that have a short axis < 10 mm are considered non -pathological and should not be recorded 
or followed.  
A sum of the diameters  (longest for non -nodal lesions, short axis for nodal lesio ns) for all 
target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes 
are to be included in the sum, then as noted above, only the short  axis is added into the sum. 
The baseline sum diameters will be used as reference to further characterize any objective 
tumor regression in the measurable dimension of the disease.  
All other lesions (or sites of disease) including pathological lymph nodes should be identified 
as non-target lesions  and should also be recorded at baseline. M easurements are not required 
and these lesions should be followed as â€˜present, â€™ â€˜absent, â€™ or in rare cases â€˜unequivocal 
progression. In addition, it is possible to record multiple non -target lesions involving the 
same organ as a single item on the case rec ord form (e.g. â€˜multiple enlarged pelvic lymph 
nodes â€™ or â€˜multiple liver metastases â€™). 
Response criteria  
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions.  
Evaluation of target lesions  
Compl ete Response (CR) : Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <  10 mm.  
Confidential Page 135 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 Partial Response (PR) : at least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters.  
Progressive Disease (PD) : at least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study  (this includes the baseline sum if that is the 
smallest on study). In ad dition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. ( Note:  the appearance of one or more new lesions is 
also considered progression).  
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.  
Special notes on the assessment of target lesions  
Lymph nodes.  Lymph nodes identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to below 10 mm on study. This means that when 
lymph nodes  are included as target lesions, the â€˜sumâ€™ of lesions may not be zero even if 
complete response criteria are met, since a normal lymph node is defined as having a short 
axis of <[ADDRESS_980691] achieve a short axis <10 mm.  For 
PR, SD and PD, the actual short axis measurement of the nodes is to be included in the sum 
of target lesions.  
Target lesions that become â€˜too small to measure, â€™ While on study, all lesions (nodal and non -
nodal) recorded at baseline should have their a ctual measurements recorded at each 
subsequent evaluation, even when very small (e.g. 2 mm). However, sometimes lesions or 
lymph nodes which are recorded as target lesions at baseline become so faint on CT scan that 
the radiologist may not feel comfortable  assigning an exact measure and may report them as 
being â€˜too small to measure. â€™ When this occurs it is important that a value be recorded on the 
case report form. If it is the opi[INVESTIGATOR_26191], 
the measurem ent should be recorded as 0 mm. If the lesion is believed to be present and is 
faintly seen but too small to measure, a default value of 5 mm should be assigned ( Note:  It is 
less likely that this rule will be used for lymph nodes since they usually have a definable size 
when normal and are frequently surrounded by [CONTACT_12156]; however, if 
a lymph node is believed to be present and is faintly seen but too small to measure, a default 
value of 5 mm should be assigned in this circumstance  as well). This default value is derived 
from the [ADDRESS_980692] slice thickness (but should not be changed with varying CT slice 
thickness). The measurement of these lesions is potentially non -reproducible, therefore 
providing this default value will prevent fal se responses or progressions based upon 
measurement error. However, if the radiologist is able to provide an actual measure, that 
should be recorded, even if it is below 5 mm.  
Lesions that split or coalesce on treatment. When non -nodal lesions â€˜fragment, â€™ the longest 
diameters of the fragmented portions should be added together to calculate the target lesion 
sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid 
in obtaining maximal diameter measurements of each individua l lesions. If the lesions have 
Confidential Page 136 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980693] diameter for the â€˜coalesced lesion. â€™ 
Evaluation of non -target lesions  
This section prov ides the definitions of the criteria used to determine the tumor response for 
the group of non -target lesions. While some non -target lesions may actually be measurable, 
they need not be measured and instead should be assessed only qualitatively  at the time  
points specified in the protocol.  
Complete Response (CR):  Disappearance of all non -target lesions. All lymph nodes must be 
non-pathological in size (<10mm short axis).  
Non-CR/Non -PD: Persistence of one or more non -target lesions(s).  
Progressive Disease (P D): Unequivocal progression  (see comments below) of existing non -
target lesions. ( Note:  the appearance of one or more new lesions is also considered 
progression).  
Special notes on assessment of progression of non -target disease  
The concept of progression of non -target disease requires additional explanation as follows:  
When a patient also has measurable disease . In this setting, to achieve â€˜unequivocal 
progression; on the basis of the non -target disease, there must be an overall level of 
substantial worsen ing in non -target disease such that, even in presence of SD or PR in target 
disease, the overall tumor burden has increased sufficiently to merit discontinuation of 
therapy. A modest â€˜increase â€™ in the size of one or more non -target lesions is usually not 
sufficient to quality for unequivocal progression status. The designation of overall 
progression solely  on the basis of change in non -target disease in the face of SD or PR of 
target disease will therefore be extremely rare.  
When the patient has only non -measurable disease.  The same general concepts apply here as 
noted above, however , in this instance there is no measurable disease assessment to factor 
into the interpretation of an increase in non -measurable disease burden. Because worsening 
in non -target di sease cannot be easily quantified (by [CONTACT_108]: if all lesions are truly non -
measurable) a useful test that can be applied when assessing patients for unequivocal 
progression is to consider if the increase in overall disease burden based on the change in  
non-measurable disease is comparable in magnitude to the increase that would be required to 
declare PD for measurable disease: i.e. an increase in tumor burden representing an 
additional 73% increase in â€˜volume â€™ (which is equivalent to a 20% increase diam eter in a 
measurable lesion). Examples include an increase in a pleural effusion from â€˜trace â€™ to â€˜large, â€™ 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as â€˜sufficient to require a change in therapy. â€™ If â€˜unequivocal progression â€™ is seen, 
the patient should be considered to have had overall PD at that point. While it would be ideal 
to have objective criteria to apply to non -measurable disease, the very nature of that disease 
makes it impossible to do so; t herefore, the increase must be substantial.  
Confidential Page 137 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 New Lesions  
The appearance of new malignant lesions denotes disease progression. There are no specific 
criteria for the identification of new radiographic lesions; however, the finding of a new 
lesion should be u nequivocal: i.e. not attributable to differences in scanning technique, 
change in imaging modality or findings thought to represent something other than tumor (for 
example, some â€˜newâ€™ bone lesions may be simply healing or flare of pre -existing lesions). 
This is particularly important when the patient â€™s baseline lesions show partial or complete 
response. For example, necrosis of a liver lesion may be reported on a CT scan report as a 
â€˜newâ€™ cystic lesion, which it is not.  
A lesion identified on a follow -up st udy in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. An example of this 
is the patient who has visceral disease at baseline and while on study has a CT or MRI brain 
ordered which r eveals metastases. The patient â€™s brain metastases are considered to be 
evidence of PD even if he/she did not have brain imaging at baseline.  
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation wil l clarify if it represents truly new disease. If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of the 
initial scan.  
EV ALUATION OF BEST O VERALL RESPONSE  
The best overall response is the best respo nse recorded from the start of the study treatment 
until the end of treatment taking into account any requirement for confirmation. The patient â€™s 
best overall response assignment will depend on the findings of both target and non -target 
disease and will al so take into consideration the appearance of new lesions.  
Time point response  
It is assumed that at each protocol specified time point, a response assessment occurs. Table 
A-[ADDRESS_980694] measurable disease at baseline.  
Missing assessments and inevaluable designation  
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable (NE) at that time point. If only a subset of lesion measurements is made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can b e made that the contribution of the individual missing lesion(s) would not 
change the assigned time point response. This would be most likely to happen in the case of 
PD. For example, if a patient had a baseline sum of [ADDRESS_980695] achieved PD status, regardless of the contribution of the missing lesion.  
Confidential Page 138 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980696] overall response: all time points  
The best overall response  is determined once  all the data for the patient is known.  
Table A -1 Time Point Response: Patients with Target (+/ - Non-Target) 
Disease  
Target lesions  Non-target lesions  New lesions  Overall response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable.  
 
Best response determination in trials where confirmation of complete or partial response IS 
required:  Complete or partial responses may be claimed only if the objective response is 
confirmed on a follow -up scan obtained no less than [ADDRESS_980697] overall response can be 
interpreted as in Table A -2. 
 
Confidential Page 139 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -[ADDRESS_980698] overall response  
CR CR CR 
CR PR SD, PD or PRa 
CR SD SD  
CR PD SD  
CR NE SD  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD duration met, 
otherwise, PD  
PR NE SD provided minimum criteria for SD duration met, 
otherwise, NE  
NE NE NE 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable.  
a If a CR is truly  met at first time point, then any disease seen at a subsequent time point, even disease 
meeting PR criteria relative to baseline, makes the disease PD  at that point (since disease must have 
reappeared after CR). Best response would depend on whether minimum duration for SD was met. 
However, sometimes â€˜CRâ€™ may be claimed when subsequent scans suggest small lesions were likely still 
present and in fact th e patient had PR, not CR at the first time point. Under these circumstances, the 
original CR should be changed to PR and the best response is PR.  
 
Special notes on response assessment  
When nodal disease is included in the sum of target lesions and the nod es decrease to 
â€˜normal â€™ size (<10 mm), they may still have a measurement reported on scans. This 
measurement should be recorded even though the nodes are normal in order not to overstate 
progression should it be based on increase in size of the nodes. As n oted earlier, this means 
that patients with CR may not have a total sum of â€˜zeroâ€™ on the case report form (CRF).  
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
â€˜symptomatic deterioration â€. Every effort should be made to document objective  progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stoppi[INVESTIGATOR_12003]. The objective response status of 
such patients is to be determined by [CONTACT_718772] -target disease as shown in 
Table A -1 and Table A -2. 
For equivocal findings of progression (e.g. very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
Confidential Page 140 of 142
Margetuximab  MacroGenics, Inc.  
Clinical Trial Protocol: CP -MGAH22 -04  Amendment 4, 0 8 June 2020  
 
 
 assessment. If at the next scheduled assessment, progress ion is confirmed, the date of 
progression should be the earlier date when progression was suspected.  
CONFIRMATION/DURATIO N OF RESPONSE  
Confirmation  
Objective responses should be confirmed by [CONTACT_76964]/or MRI scans obtained no less than [ADDRESS_980699] met 
for CR/PR (whi chever is first recorded) until the first date that recurrent or progressive 
disease is objectively documented (taking as reference for progressive disease the smallest 
measurements recorded on study). The duration of overall complete response is measured 
from the time measurement criteria are first met for CR until the first date that recurrent 
disease is objectively documented.  
Duration of stable disease  
Stable disease is measured from the start of the treatment until the criteria for progression are 
met, taking as reference the smallest sum on study  (if the baseline sum is the smallest, this is 
the reference for calculation of PD .  
 
 
 
 
 
Confidential Page 141 of 142
CP-MGAH22-04 Protocol Amendment 4 (08-Jun-2020)
This is the electronic signature [CONTACT_718776].
User Task: eSignatories Approval
esearch Approval (Intended or Designee)
08-Jun-2020 18:35:43 GMT[PHONE_006]
User Task: eSignatories Approval
Data Management/Statistics Approval
(Intended or Designee)
08-Jun-2020 18:40:46 GMT[PHONE_006]
Confidential Page 142 of 142
